EVER 2012 NICE

PROGRAMME BOOK PROGRAMME www.ever.be SCIENCE FOR SIGHT OCTOBER 10-13

21 CME credits

EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH Innovative. Dedicated. Worldwide.

For more than 30 years URSAPHARM has been developing innovative phar- maceutical concepts, converting these into successful pharmaceutical and medicinal products for the ophthalmology and general medicine sectors – for the well-being of patients throughout the world.

www.ursapharm.de

URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129 Saarbrücken, Germany, www.ursapharm.de science intherecentyears. vision in career international their developing winners prize previous the of some seen have implemented. I successfully scientifi the guarantees Nice in meeting our join to agreed We will keep the prizes for young scientists that we have we presentations.that scientists fiyoung for re prizes rapid the keep will and We sessions poster with extensive meeting EVER 2012 the in implemented be also will data. aim their This present to level residency or PhD the at scientists younger for opportunity the provide to of society our goal major a always was It congress. the of excellence that speakers of list atmosphere.The EVER beyond splendid the and in Europe from experts with ideas of intense an exchange for allow again will It years. previous these of success the on based research eye in developments future discuss Theto platform a provide will Nice in congress EVER into reducedblindnessandvisionloss. as the improvement in diagnosis and treatment will translate well as disease ocular of mechanisms basic into insight the is particularly true for Ophthalmology and Visual Science and brought significant advances in many areas of Medicine. This Nice,France.in century meeting 21st TheEVER 2012 the to you welcome to pleasure great my is it President EVER As Dear EVERmembers, EVER President2012 Leopold SCHMETTERER c

Universities. With all this we must not forget that Research that forget not our must we at this Universities.all With restrictions budget of because meeting the join to scientists diffithe more for also cult but organizers the for diffi more cult it makes This crisis. economic fi and nancial the of problems the with faced is EVER societies, other As EVER President2012 SCHMETTERER Leopold venue inNice. conference new our at days enjoyable spend all will we that congress. We will keep this spirit for 2012 and I am convinced program,the with associated activities social the to also but What makes EVER unique is not only related to the scientific such efforts. to way promising obtain research money and EVER is a a good starting point for undoubtedly is Consortia form To funded. European work our get to efforts our increase and this communicate to forget not crisis.should Wethe of out ways the of one is Science Biomedical in Development and WORD FROM THEPRESIDENT 1 EVER 2012 Programme book EVER 2012 Programme book 2 Sponsors ...... Congress Time Schedule ...... Presenting authorsbycountry ...... Presenting fi rst authors ...... Saturday, October13 ...... Friday, October12 ...... Thursday, October11 Opening Ceremony ...... Courses ...... Courses overview ...... 10 ...... October Wednesday, Exhibition ...... Floor plan ...... About theProgramme Book ...... Programme Committee2012 ...... Partnership Grants ...... General Information ...... Board Members2012 ...... About EVER ...... President the from Word Evening session: EVERGeneral Assembly andPrizeGiving ...... Second afternoonsession ...... 3 ...... session Poster First afternoonsession ...... Lunchtime session: CISBayer ...... Second morningsession ...... Ambati Jayakrishna Lecture: Keynote First morningsession ...... Early morningsession: BreakfastCISCroma ...... Second afternoonsession ...... 2 ...... session Poster Ophthalmic ResearchLecture: GeorgeL. Spaeth ...... Business Meetings of the scientifi c sessions ...... First afternoonsession ...... Lunchtime session: CIS Allergan ...... Second morningsession ...... Allikmets Rando lecture: Keynote First morningsession ...... Early morningsession: BreakfastCIS Alcon ...... Evening session ...... 1 ...... session Poster Second afternoonsession ...... First afternoonsession ...... EVI Award Lecture ...... Lunchtime session: CIS Théa ...... Second morningsession ...... Miller Joan Lecture: Keynote First morningsession ...... 11 ...... 23 ...... 19 ...... back cover ...... back ...... 18 ...... 12 ...... 5 ...... 22 ...... 53 ...... 111 ...... 83 ...... 8 ...... 125 ...... 58 ...... 31 ...... 44 ...... 34 ...... 45 ...... 132 ...... 107 ...... 96 ...... 74 ...... 66 ...... 1 ...... 6 ...... 131 ...... 116 ...... 88 ...... 48 ...... 40 ...... 39 ...... 17 ...... 100 ...... 70 ...... 43 ...... 105 ...... 16 ...... 73 ...... 69 ...... 63 ...... 99 ...... 79 TABLE OFCONTENT ...... 93 ...... 65 ...... 95 ...... 21 ...... 81 ...... 119 ...... 33 ...... 3 EVER 2012 Programme book

Membership other for annual congress. its umbrella during meet an to societies provides ophthalmological It sciences. visual and ophthalmology of subspecialties scientifi all covers European which largest the is EVER the of information. and and research eye vision by means of meetings, publications and exchange the encourage concerning knowledge of to dissemination are association non-profi a is EVER, Research, Eye and Vision for Association European The Participants: memberofCONCORDIA • e-alerts • quarterlyE-Newsletter • freeelectronic subscriptiontotheEVERjournal, • 25travelgrants forbestpaperstoattendtheEVER • votingrights fortheelectionofBoardMembers • EACCME granted21EuropeanCMEcredits(ECMEC) • participating intheEBOreviewcourses • organizing SpecialInterestSymposia(SIS)and • reducedregistration feeforEVERannualmeeting • submission ofabstractstoEVERannualmeeting • The benefits ofEVERmembershipare: that bestrepresentshisorherprimaryareaofinterest. Scientifi11 the of Sections one c select must member Every and startsonJanuary 1. be submitted at any time, membership is on calendar year basis Applicationsformembership available- onwww.ever.be may- in orwithaninterestophthalmicandvisionresearch. Membershipisopen toindividuals ofany nationality, engaging 27% Acta Ophthalmologica(IF2.629) annual meeting (except members-in-trainingandemeritusmembers) for theEVERannualmeetings recognized bythe American Medical Association- courses duringtheEVERannualmeeting 73% Research only: 27% Clinical withorwithoutresearch: 73% t raiain Te is f the of aims The organisation. t c organization c Elections Epidemiology(MBGE) Pharmacology(PBP) Paediatric/History (NSPH) Optics, Vision Sciences(EOVS) MEMBERS ACCORDING TO SCIENTIFICSECTIONS h saue ad ylw ae vial o te website: the on available www.ever.be »aboutstatutes. are by-laws and statutes The full all members. to open end. are General an Secretary to new a coming for Elections is General Secretary the of term The Retina/ Vitreous • LensandCataract • EVER forelectionsin2013: of Board the in representatives their of succession the for Thecandidates 2 least at nominate will sections 2 following is available onpage79. Meetings Business Friday,on 15:50.- 15:10 12,from October 2012 The agenda their hold will sections scientifiThec Assembly onSaturdayOctober13, 2012. on General the at announced be will elections Thethe of result close will 2012 Voting October 12, midnight. elected voting. be will electronic Glaucoma through and Surface sections scientifi Ocular c the / of Cornea representatives new year This 10% 14% 16% 21% 3% 3% 4% 6% 7% 8% 9% Molecular Biology/Genetics/ Anatomy/Cell Biology(ACB) Physiology/Biochemistry/ Neuro-ophthalmology/ Strabismology/ Immunology/Microbiology (IM) Electrophysiology, Physiological Lens andCataract(LC) Pathology/Oncology (PO) Glaucoma (G) Cornea/Ocular Surface(COS) Retina/Vitreous (RV) ABOUT EVER 5 EVER 2012 Programme book EVER 2012 Programme book 6 BOARD MEMBERS 2012 IT andwebsitesupport byRESILION • SCHMETTERER Leopold • VERLAECKT Marlene • HERBORT Carl Secretary • VOTRUBA Marcela President ExecutiveOfficer Vice President Programme • KESTELYN Philippe General • BODAGHI Bahram • VAN EYCKEN Lies Elect • ZEYEN Thierry PresidentElect Secretary Executive Assistant Vice-President fax +3216234097 tel +3216233849 [email protected] Belgium 3000 Leuven, Kapucijnenvoer 33, • GICQUEL Jean-Jacques • MARTIN Lene Treasurer Past President

OFFICE EXECUTIVE COMMITTEE • KAWASAKI Aki • ZEYEN Thierry CellBiology • KNOP Nadja • ASOKLIS Rimvydas • Retina/ Vitreous POURNARAS Constantin History Paediatric / Strabismology/ Anatomy / EastEurope Neuro- Glaucoma ophthalmology /

REGIONAL REPRESENTATIVE Microbiology • Immunology/ DICK Andrew OcularSurface • KESTELYN Philippe • WEGENER Alfred Oncology • DESJARDINS Laurence Cornea/ LensandCataract Pathology / BOARD MEMBERS 2012 • PALLIKARIS Ioannis Greece, Crete Epidemiology Genetics/ Biology/ • LEROY Bart Vision Sciences Optics, Physiological • SPILEERS Werner Pharmacology Biochemistry/ • GARHÖFER Gerhard Molecular Electrophysiology, Physiology/

LOCAL REPRESENTATIVE SECTION CHAIRS 7 EVER 2012 Programme book EVER 2012 Programme book 8 Cancellation policy Montenegro, Moldova, Macedonia, Libya, Iran, Morocco, Ouzbekistan, Pakistan, Serbia, Georgia,Tunesia, Ukraine Egypt, and Congo, Bosnia Belarus, Herzegovina,Armenia, Algeria, Albania, only: countries listed these of Citizens * Registration feeson-site Registration Venue INFORMATIONGENERAL o-ebr80645* 800 310 * 210* 200* 400 270 250 Congress Dinner Congress Dinner Eye-Care / Technician (nonMD) 390* Non-member-in-training 455 Non-member Member-in-training EVER member/SIS-invitedspeaker cancellations orno-shows. to later prior for granted be not writing will Refunds 2012.21, September in received cancellation for granted be will fee registration advance the of 75% to up – Refunds to need Eye-Care/Technician,you an as register you if • to need you member-in-training, a as register you if • being or becoming an EVER member – or having an ab- • Please notethat: On-site registration starts on Wednesday, October 10, 09:00. presenter -mustregisterandpaytheregistrationfee. member,EVER an speaker,invited or person accompanying scientifithe not attending or Everyone whether - sessions c October 13at19:30. Wednesday, October 10 at 12:00 on and concludes starts on Saturday, congress EVER the of scientifiThe programme c in Nice, France EVER 2012willbeheldatthe Acropolis ConventionCenter visitthewebsiteon of yourDepartment Head the by signed document a with status your prove Head ofyourDepartment the by signed document a with traineeship your prove stract accepted – does not imply that you are registered (in training) (member /non-member) www.nice-acropolis.com U EUR EUR 0 60 90 60 90 Housing / Travel Website Tourist information Weather organisation. At thiswebsite, youcan h tawy ie oncs ot f h htl wt the with hotels the of most connects line tramway The Acropolis, at7kmfromthecitycentre. The Nice Côte d’Azur Airport is located 15 minutes from the tion inseveralcategoriesofhotels. accommoda- for rates special negotiated has Cynergies Global printCMEcertificate aftereachcongressyouattended • castyourvoteforofficers • access Acta Ophthalmologica, theEVERjournal • accessgeneralinformationaboutEVER • lookforotherEVERmembers • payon-lineandobtainanoverviewofpastpayments • obtainup-to-dateinformationaboutthescientific • The EVER website Pins, MonteCarlo, Cannesandtoother towns. Day excursions are available from Nice to Antibes, Juan-les- and othertouristattractions. landmarks city famous museums, interesting promenade, seaside lovely beaches, beautiful its its are Among attractions world.many the around from visitors attracts Nice sunny,climate,a temperate by d’Azur.Blessed Alpes-Côte The city of Nice is located on the French Riviera in Provence- in winteranditssunshine. climate mild its for renowned is mountains.It its by winds main the from protected is sea,it the onto opening city an Mediterrane- A microclimate. exceptional an enjoys Nice Acropolis ConventionCenter. status (session, hour, place)ofyourpresentation programme andtheEVER2012meetingview www.ever.be has a central role in the EVER EVERforever EVER General Assembly andPrizeGiving Business Meetings Publication oftheabstracts Photographs Internet access Coffee Congress Dinner Welcome Reception Agenda seepage119 Saturday, 18:00-19:30inroomUranie Agenda seepage79 RV Uranie ...... • Gallieni1&2 MBGE/PBP ...... • IM/NSHP ...... Thalie • G Clio ...... • EOVS/LC Gallieni3 ...... • Erato COS ...... • ACB/PO Gallieni4 ...... • Friday, 15:10-15:50 EVER BusinessMeetingsofthescientific sections journal. Access formembers-onlythroughEVERhomepage. published are congress on-line in a special issue 2012 of Acta Ophthalmologica, EVER the EVER the of abstracts The Wi-Fi internetaccessisavailable intheConvention Center. soft and coffee the drinks offeredduringthebreaks. are fee registration the in Included • Space islimited. Congress Dinnerfortrainees: 60EUR Congress Dinnerformembersornon-members: 90EUR Registration fortheCongressDinnerisrequired. in Acropolis ConventionCenter • The Welcome Receptionisopenforallparticipants Friday20:30inHotelNEGRESCO Wednesday 19:00-21:00 videos ofthepresentationsinalllecturehalls. It isstrictlyforbiddentotake photographsor CME -ContinuedMedicalEducationcredits No-shows Withdrawals EVER 2012congress App foriPhone /iPad Poster Prizes Liability M cei cri ae cn e rne fo te EVER the from printed website afterthecongress. be can certificates credit CME on Oct10-13inNice, France. 21 European CME credits (ECMEC) to granted the EVER 2012 congress has EACCME UEMS, the of Institution Education TheEuropean Medical Continuing for Council Accreditation sent totheEVERoffice inwriting. presenting from prohibited papers at EVER be for the next two years if a will valid reason is not accepted, been has poster or paper fi whose author, any rst that note Please withdrawal totheEVEROffice beforeSeptember21, 2012. reasons of notice written a send for should paper. they Alternatively, EVER the present author another have to the attend Secretary Programme of permission the to request may control, their unable beyond authors First No prizewillbegivenafterthecongress. sure toattend. prize giving ceremony on Saturday October 13.the Please make by followed and Assembly General the in announced be will and moderators the by chosen be will winners The SL, Spain. be will prize poster EOVS additional best One section. the each for in awarded poster be will EUR 200 of prize poster A arrangements withrespecttohealthandtravelinsurance. own their make should ParticipantsMeeting. the from ing aris- directly or during, either persons accompanying and acci- personal participants of property private to damage dents,or of loss for liability accept cannot organisers The generously sponsored by the by sponsored generously Efi Alta AppStore GENERAL INFORMATIONGENERAL cacia Tecnologia,

9 EVER 2012 Programme book

Travel grants forbestpaper • LC • IM • G • EOVS • • RV • PO • PBP • NSPH • MBGE • COS • ACB • 11 EVERsections: the from each, EUR 500 of grant travel a received have pleasedannounceareWetofollowingthe that members 11 a French study and anti-parasitictreatmentintoxoplasmicuveitis anti-inflof target possible a as IL-17A ammatory - 2843 2651 - Aquaporins inglaucomaeyes mouse modelof Wolfram syndrome a Wfs1 in impairment visual of Characterization - 4285 3664 - Relevance of complement factor H polymorphisms 3282 -Proteomicanalysisofuvealmelanoma in thereductionofintraocularpressure 4263 - Ghrelin’s expression in the eye and its implication of by advanced glycationend-productsinadultratretinas induced effect degeneration neuronal regenerative on and neurotrophin-4 Neuroprotective - 4475 and anteriorsegmentdysgenesisinmice microphalmia causes peroxidasin in mutation A - 2464 endophthalmitis of incidence the reduces surgery cataract of end the at injection cefuroxime Intracameral - 3483 thelitis endo- HSV-1viral targeting limits Meganuclease - 2631 in ARPE-19 cells clearance autophagy effectively induces AICAR - 4481 age-related maculardegeneration in the response to intravitreal bevacizumab in exudative - Thuy Linh TRAN -Denmark -GermainBARREAU -France - Arnaud SAUER -France - Agnes BOLTZ - Austria -Pathma RAMASAMY-Ireland

- Amandio ROCHADESOUSA -Portugal -BenoitCHAPELLIERFrance -KaiKAARNIRANTA -Finland -CécileDELETTREFrance EVER -GuzelBIKBOVA -Japan -Xiaohe YAN -Germany invivo ,

Anniversary Travel Grants The Finnish Ophthalmological Society 100th Alta Efi tae gat f .0 ER o h floig rus of groups following the authors to EUR announce 1.000 to of grant pleased is travel a Society Ophthalmological Finnish The Stamatina KABANAROU -Greece • grant of400EURforthebestpaperinEOVS section travel a announce to pleased Efi is TecnologíaAlta cacia • 2842 - Infl ammasome activation by oxidative stress in stress oxidative Inflby - activation 2842 ammasome • inflPolyphenolicreduce - compounds F079 • in ammation bomlte i ptet udron ln tr des- ferrioxamine treatment term long undergoing patients in abnormalities 2422 - Colour contrast sensitivity and electrophysiological KAARNIRANTA K–Kuopio A, SALMINEN K, KINNUNEN N, LAAKSO A,KAUPPINEN ARPE-19 cells KAUPPINEN A–Kuopio HäNLER M, SUURONEN T, SALMINEN A, KAARNIRANTA K, ARPE-19 cells cacia Tecnología SL, Spain, travel grant

GRANTS

11 EVER 2012 Programme book 12 EVER 2012 Programme book In CONCORDIApro VISU in CONCORDIA proVISU ww ww eb ophthalmology anditsscientific foundations(thesocietiesarelistedinalphabeticalorder): The followingsocietiescollaboratewithEVERtounifyEuropeanophthalmologybypromotingqualityeducationin ww w w ww. oo- ww. ww. oon sso eeu eev n ev u v li i v e ppo nne is r s .b b .o .e io o e o e u rrg n g . oor g currently has members from over 50 countries and is represented by 11 scientifi11 by represented the is of and sections.One countries c 50 over from members has currently sciences.EVER visual the and ophthalmology of areas all covers which Europe in association research ophthalmological leading the is EVER information. of exchange and meetings,publications of means by vision and eye the concerning knowledge of dissemination the and research encourage to aim We SOE 2013Congress, June8-11, Copenhagen, Denmark societies andsupranationalorganisationsbothwithinEurope and beyond. central a become subspecialty with to collaboration fostering by and is education through ophthalmology European mission in point its Today, European Societies. between National co-operation their stimulate between to and and ophthalmologists Europe in ophthalmology promote to aims SOE in Copenhagen, DenmarkonJune7-8. place take will and Surgery Refractive and Conjunctiva Cornea, on be will course 2013 EUPO The different placesinEurope. in held are courses rotation.EUPO residency their during knowledge theoretical of overview an get to residents allow to period year 4 a over covered is curriculum ophthalmology the of Most 1988. since Europe in training in residents for course subspecialty structured annual the of organiser the is EUPO EBO 2013, Paris, May10-11, 2013 review coursesopentoalldelegatesduringtheEVERcongress, seepages23, 25, 26and50. of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organised exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses in the countries of the European Union by ensuring that the training is raised to the best possible level. The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology In 2010, theEVERFoundation was createdtoraisemoneypromote thesegoals, www.ever-f.eu. and encouragesthemtoconveneannuallywithEVER. societies other with closely climate.collaborates autumn EVER agreeable its and access its for chosen main activities of EVER is the organizing of a high quality research meeting every October at a location

ww ww ww ww e ww w w www u w ww. w w. .w ww. w ww. w ffr ww. so ww. iil i o kkp o s eey a - p cce ie ev o y e r e ro v vvo .c n -s o v. c ic s l . . c o ooi i o oor .o r. n m o rg r nne e ff. g rg g . e g oor o t rrg g g are organizedbyEVICR.net, seepages15, 48, 58, 66, 70and74. EVER 2012, in Nice, France, on 11th and 12th of October 2012. Four sessions of the EVER 2012 program of new drugs and medical devices. The 7th EVICR.net Members Meeting will be held in conjunction with Study GroupiscollaboratingwithEVERsince2004. Seepages107and117. ment and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro develop- the foster to artifiaims and Group implants.corneas International corneal This synthetic cial The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, part initssessions, seepages102, 109and118. them.about knowledge and taketumours to eye delegates of EVER treatment all the encourages OOG improving of aim the with studies,activities control other quality and and meetings studies and center scientifishare multi- to organise information,databases c internet-based Europe,develop in oncology ophthalmic 1998.of since practice EVER the with improve convened to has are It OOG Thethe of aims scientifi independent an is OOG Therapy inOphthalmology), casereportsandseries, letterstotheeditoranddoctoraltheses. articles,and original reviews,(Diagnosis experimental essays and editorials,photo clinical educational Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes and Visionoffi for the Association European is scientifithe Ophthalmologica cial of Acta publication c throughout theworld. The EuropeanChapterofISCEVhasmetwithEVERsince1 venuesdifferent at annually held issymposium majorprofessionalpersonnel. otherIts optometrists and electrophysiology.basic and clinical physicians, are who members 400 Therescientists,about are engineers, fi the in workers amongst communication and co-operation promote to 1958 in founded was ISCEV their researchworktoaninternationaljuryduringtheEVERcongresssince2 grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding the for platform development a of translational research is and a It useful SOPs.Industry resource in harmonized order to to promote the development according Research Clinical for Directives International and European the quality,following of standards highest the with ophthalmology in perform research clinical to dedicated Sites, Research Clinical Ophthalmological European of network a is EVICR.net and anEVERsymposiumheldin ARVO since2005, seepage75. ophthalmology.EVER and and ARVO are vision collaborating in many fiin knowledge elds, of including an dissemination ARVO and symposium held every publication,year in EVER training, research, assist North in EVER of counterpart the senses many In America,of purposes the ARVOand encourage to are realise collaborative studies. SOIEiscollaboratingwithEVER si contributingbyor publicationsto thisinfi eld andpromoteto contacts between clinical centres orderin to progress of each member in this field, to promote education in bythe fiorganising or sponsoringeld of ophthalmo-Immuno-Infectiologysymposia or courses and to share mutual experiences in Theorderassociationformaimsantoare toophthalmologists of contribute otherand doctors toscientists or the havinginterestan c okru dvtd o ai ad lncl ptamc oncology. ophthalmic clinical and basic to devoted workgroup c nce 2008. Seepage100. LONG-TERM PARTNERS 002, seepages37and42. 998, seepage40.

eld of eld

13 EVER 2012 Programme book

16 EVER 2012 Programme book Section programme secretaries PROGRAMME COMMITTEE MEETING2012 Programme secretary, Marcela VOTRUBA V eiaVteu CatherineCREUZOT-GARCHER KarinLÖFFLER AndrzejGRZYBOWSKI RalphMICHAEL SayehPOURJAVAN NevilleOSBORNE PiergiorgioNERI MarzenaGAJECKA Jean-Jacques GICQUEL Ulla AAPOLA Retina/Vitreous Pathology/Oncology RV Physiology/Biochemistry/Pharmacology HistoryofOphthalmology PO PBP Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ MiguelCASTELO-BRANCOO NSPH MolecularBiology/Genetics/Epidemiology LensandCataract MBGE Immunology/Microbiology LC Glaucoma IM Electrophysiology, Physiological Optics,G Vision Sciences Cornea/OcularSurface EOVS Anatomy/CellBiology COS ACB Programme Committeemeeting,June2012 Scientifi This programme bookisorganised chronologically rf V = Retina/Vitreous Pathology/Oncology = RV Physiology/Biochemistry/Pharmacology = PO Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/HistoryofOphthalmology = PBP MolecularBiology/Genetics/ Epidemiology LensandCataract = NSPH Immunology/Microbiology MBGE = = Glaucoma LC = IM = Electrophysiology, Physiological Optics, Vision Sciences G Cornea/OcularSurface = EOVS Anatomy/CellBiology = COS = ACB CIS =CommercialInterestSymposium SIS =SpecialInterestSymposium FP =Free Paper session

= RapidFire presentation = Alta Eficacia Tecnología SL, Spain, travelgrantrecipient =EVERtravelgrantrecipient Conflict ofinterestdisclosed c sections Joint Meeting(JM) Free Papers (FP) Special InterestSymposium(SIS) Four digitnumbersrefertooralpresentations Day | Timeslot |HallOrderinsession X The sessionsare colour-coded Course General Assembly &BusinessMeeting Keynote Lecture Commercial InterestSymposium(CIS) ABOUT THE PROGRAMME BOOK One letterandthreedigitnumbersrefertoposters Day |Orderinthepostersession X Social Poster Session Workshop (WS) { 17 EVER 2012 Programme book 18 EVER 2012 Programme book GALLIENI 1&2 FLOOR PLAN GALLIENI 3 GALLIENI 4

AGORA 2 RHODES LEVEL 2 Mykonos Restaurant 6 5 4 3 2 1 Poster area Exhibition ePosters Housing Speakers room Registration

AGORA 3 LES MUSES LEVEL 3 EUTERPE 4 2 5 TERRACE 6 1 URANIE THALIE ERATO CLIO 3 Wisepress (7) Théa (1) Metrovision (10) Karger (5) ISOPT iSTAR Medical(9) Imedos Systems(2) Horus Pharma(4) Bausch +Lomb(11) ARVO (6) Allergan (8) Alimera Sciences(3) Alimera Sciences Imedos Systems Bausch +Lomb iSTAR Medical Horus Pharma Metrovision Wisepress Allergan Karger ISOPT ARVO Théa

EUTERPE REGISTRATION AREA TERRACE 11 10 2 1 9 8 7 6 5 4 3 EXHIBITION

CLIO THALIE ERATO URANIE 19 EVER 2012 Programme book

22 EVER 2012 Programme book COURSES OVERVIEW The 15 courses throughout the EVER 2012 congress: 2012 EVER the throughout courses 15 The 15. IM: Surgery of infl15. ammatory eyes ...... Saturday, October13, 16:20 - 17:50 ACB: MGD-Pathophysiology,14. diagnosisandclinicaltreatment ...... Saturday, October13, 08:15-09:45 13. PO: Managementofpigmentedfunduslesions 13...... NSPH: 12.The ocularmotilityexaminationandcommondisordersof ...... G: 11.A glaucomatoolkitforbeginners ...... COS: Cornealinfectiousdiseasesupdate 10...... COS: Endothelialkeratoplasty: thehiddenface ...... 9. ACB: Experimentalmodelsforeyeresearch ...... 8. IM: EBOcourse: Intraocular Infl ammationandInfection(Part II) ...... 7. 16:45 - 14:30 10, October Wednesday, PO: Eyelidtumours ...... 6. RV: EBOcourse: Retinaldetachment: fi rsttodescribeandthentreat 5...... COS: Commoncornealprocedures ...... 4. COS: Challengesofherpeticeyedisease ...... 3. ACB: Morphologicaltechniquesineyeresearch ...... 2. IM: EBOreviewcourse: Intraocular infl ammationandInfection(Part I) ...... 1. 14:15 - 12:00 10, October Wednesday, ...... 25 ...... 118 ...... 28 ...... 27 ...... 24 ...... 24 ...... 27 ...... 26 ...... 23 ...... 29 ...... 26 ...... 98 ...... 25 ...... 23 ...... 28 34 1524 13:45 1522 13:00 12:30 1516 1515 13:55 13:35 1513 13:00 1512 12:40 12:20 application andtheirresultsaswellpotentiallimitations. requirements,p methodological their their with together techniques morphological basic introduce to intends course Thepresent is partlylostinophthalmologicalresearchdepartments. focus of interest in eye research, basic information on morphological techniques as well as their performance and interpretatio increasing have techniques eye.biochemical the Since of structures tissue and cell actual the in changes pathological their or molecular-biolo high-tech advanced techniques though are increasingly applied in order to Even answer very conditions.specifi pathological certain c questions it is indispensable for specifiunder example to localize func of changes as c well as tissues of differe cellular and architecture normal the of evaluation the for research eye in standard gold a are techniques Morphological 20 1511 12:00 31 1523 13:15 1521 12:00 1514 13:15 the participationofaudience. Itwillbeintermediateandaimedatpathologiesthatarefrequent. practicalsituation.each during generaldi discussed interactiveallowing be be Thewill will choroid.points course Important Diagnostic tests will be discussed and imaging techniques will revisit the pathophysiology of different entities involving the Course 2 Course 1 ACB IM Erich KNOP, NadjaKNOP Morphological techniquesineyeresearch Bahram BODAGHI, CarlPHERBORT EBO course: Intraocular infl Theintraocularof topics major review to is course this of aim infl infection.and ammation of composed paper A il e ecie ad ifrn casfictos il e rsne. lncl hrceitc wl b highlighted. be will characteristics Clinical presented. be classifi will different cations and described be will features.uveitis different of understanding Thethe pathophysiology for presentations general consecutive 6 by multiple choice questions will evaluate the basic knowledge of the participants initially. The test will be followed THURET G–SaintEtienne Morphological techniquesforendothelialcellanalysisofcornealgrafts AKHTAR S–Riyadh Immuno electronmicroscopy–tracking thesub-cellularlocalization ofantigensinhighresolution Break KNOP E, KNOPN–Berlin considerations andresults Immunohistochemical identifi cation of tissue antigens–principalmethologicalrequirements, KNOP N, KNOPE–Berlin tissue investigation Preparation, fi xation, embedding, sectioningandstaining–basicrequirementsofmorphological HERBORT CP–Lausanne Imaging inuveitis: techniquesandindications PLEYER U–Berlin Laboratory work-up andspecializedinvestigations KHAIRALLAH M, KAHLOUNR–Monastir Symptoms andsignsofposterioruveitis Break NERI P, ARAPI I, CAPUANO V, PIRANI V–Ancona Symptoms andsignsofanterioruveitis ANDROUDI S–Thessaloniki Classifi cation ofuveitis DICK A–Bristol Pathophysiology ofuveitis ammation andInfection(Part I) 12:00 -14:15 tional proteins retina and the WEDNESDAY scussion and scussion Euterpe ly been the been ly n of results Uranie ntiation ractical

gical

Intermediate Beginners 23 EVER 2012 Programme book 24 EVER 2012 Programme book Intermediate Intermediate 12:00 -14:15 WEDNESDAY 34 1545 13:40 1543 13:00 1542 12:40 12:20 1534 13:35 1532 13:00 12:30 ophthalmogists intraining aswellforthemoreexperiencedophthalmologistswhowants toincreasetheirskills. The goal of this course is to offer a practical and comprehensive update on common corneal surgical procedures. It should be of 20 1531 12:00 experience in the diagnosis, management, controversies in treatment and complications of the various manifestations of herpetic t is course often “missed”.the is blindness, yet,of it to Theand aim lead may which disease,of recurrent complications a is examination.clinical the on mainly based is diagnosis its and eye the of structures all involve may infection herpetic Ocular keratitis,(conjunctivitis,uveiti scleritis, pathology ocular of cause frequent relatively a are infections virus herpes Human 32 1544 13:20 1541 12:00 1533 13:05 COS Course 3 COS Course 4 Petja VASSILEVA Challenges ofherpeticeyedisease Jean-Jacques GICQUEL, HarminderSDUA Common cornealprocedures YEUNG A–Nottingham Indications andlimitationsofamnioticmembrane transplantation MENCUCCI R–Florence Corneal collagencrosslinking: traditional vstransepithelial Break NUBILE M–Chieti Anterior andposteriorlamellarkeratoplasty GICQUEL JJ–Poitiers Modern pterygiumsurgery DUA H–Nottingham Limbal stemcelltransplantation techniques DEKARIS I, RATKOVIC M, PAUK M, DRACA N–Zagreb Treatment: surgicalmethods HERGELDZHIEVA T–Sofi a Treatment: medicaltherapy Break BODAGHI B–Paris Diagnosis VASSILEVA P–Sofi a Herpetic eyedisease s, opic neuritis). opic s, Ocular herpes Ocular o present our present o eye infection. interest for Thalie Erato 34 1564 13:45 1562 13:00 12:30 1555 13:40 1553 13:00 1552 12:40 12:20 32 1554 13:20 1551 12:00 31 1563 13:15 1561 12:00 Basic informationondiagnosis, pathologyandsurgeryofeyelidtumours PO Course 6 Course 5 RV Frédéric MOURIAUX, KarinLOEFFLER Eyelid tumours Catherine CREUZOT, ConstantinPOURNARAS EBO course: Retinaldetachment: fi uhr wl peet ifrn faue t cnie i a eia dtcmn (aey er oain vitreous location, tear (namely detachment retinal a in consider to features different present will Authors novmn, rlfrtv vtertnpty pir o ramn.W wl te fcs n h dfeet a to way different the on surgically removesubretinalfl focus then uid. Finallywewillreportonpotentialpostoperative complications. will We treatment. to prior vitreoretinopathy) proliferative involvement, BRISCOE D–Afula Bases ofsurgeryforeyelidreconstruction MOURIAUX F–Caen Margins ornotmargins Break LOEFFLER K–Bonn Bases ofpathologicaldiagnosiseyelidtumours LASUDRY J–Brussels Eyelid tumours: The relativevalue ofclinicalsigns CREUZOT C–Dijon How topreventpostoperative complication? JONAS JB–Mannheim How topreventproliferative vitreoretinopathy? Break POURNARAS CJ–Geneva How toremovesubretinalfl uid? BERROD JP–Nancy To analysetheroleofvitreousinaretinaldetachment KOROBELNIK JF–Bordeaux How tolocaliseretinaltears? rst to describe and then to treat 12:00 -14:15 Gallieni 1&2 WEDNESDAY

Clio

Beginners Beginners 25 EVER 2012 Programme book 26

EVER 2012 Programme book Intermediate Intermediate 14:30 -16:45 WEDNESDAY 61 1624 16:15 1622 15:30 15:00 1615 1614 16:10 15:50 1612 15:10 14:50 43 1611 14:30 54 1623 15:45 1621 14:30 and retinaldiseases. Lecturerswillgivedetailedpractical adviceandinstructionsoftheirtechniquesincoursematerial. on selected experimental methods of eye research. This year the course will focus on the techniques used in ocular infl ammation information practical give investigated.to are designed diseases is of Thecourse modalities diagnostic and therapeutic new or pat research.the eye translationalwhen and used basic widely Theyof are part essential an are disease of models Experimental 1613 15:30 IM Course 7 ACB Course 8 Bahram BODAGHI, CarlPHERBORT EBO course: Intraocular Infl Hannu UUSITALO, Ulla AAPOLA Experimental modelsforeyeresearch Thefi or basic different in presentations case and quiz a by followed be will uveitis of generalaspects on part rst entities thatarefrequentlyobservedinroutine. audience.the of present participation and the intermediate and generalinteractivebe discussion allowing will It more challenging situations. Important points will be discussed during each practical situation. The course will be UUSITALO-JÄRVINEN H–Tampere Oxygen inducedretinopathy(OIR)mousemodel BEUERMAN R, YUAN ZH–Singapore Experimental modelsofintraocular infl ammation Break ZACK DJ–Baltimore Methods tostudyneuroprotection KALESNYKAS G–Kuopio Experimental glaucomamodels BODAGHI B–Paris Paediatric uveitis MARKOMICHELAKIS N–Athens White dotsyndromes ABU EL ASRAR A–Riyadh Behçet disease, sarcoidosis, VKH Break WILLERMAIN F–Brussels B27-associated uveitis KESTELYN P–Ghent Infectious uveitis ammation andInfection(Part II) Euterpe and advice and , glaucoma Uranie hogenesis 61 1644 16:15 1642 15:30 15:00 1635 16:10 1633 15:30 1632 15:10 14:50 corneal infections. of options treatment and diagnosis for methods histopathologic and clinical the in developments recent of overview an you give f techniques diagnostic rapidinfections in the last years.in improvements Treatmentbeen has also improved,have diagnosis. but Thereremains a possible diffithe to cult problem,clinician especially for the Acanthamoeba. alerting In thi in important is these of each of steroids.setting topical clinical Theof use uncontrolled the with keratoplastyand penetrating keratotomyor types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged 55 1634 15:50 1631 14:30 scientifi c research. discusse and surgeons experienced of reports issues,personal remaining EK’s of review broad a offers evaluated.course The and assessed, further be to need still outcomes clinical and procedures curve,surgical learning demanding a demonstrating Besides Endothelial keratoplasty (EK) has become a major surgical procedure in corneal practice. Various techniques have been developed 15:45 1641 14:30 COS Course 10 Course 9 COS

1643 Jean-Jacques GICQUEL, HarminderSDUA Corneal infectiousdiseasesupdate Jean-Louis BOURGES, JoaquimMURTA Endothelial keratoplasty: thehiddenface DUA H–Nottingham Infectious crystallinekeratopathy anditsmanagement BREMOND-GIGNAC D–Amiens Infectious keratitis inchildren Break LABETOULLE M–LeKremlinBicêtre Herpes andzosterkeratitis GICQUEL JJ–Poitiers Corneal bacterialinfections GICQUEL JJ–Poitiers Rho KinaseInhibitors: theendofendothelialkeratoplasty? GAIN P–Saint-Etienne, Rouen THURET G, HEZ, CAMPOLMIN, HA THI BM, PISELLIS, DUMOLLARD JM, PEOC’HM, MURAINEM, TOUBEAU D, Endothelial cellviabilityofendotheliallenticules Break BAIKOFF G–Marseille FEMTO-DSEK: isendothelialcutpossible? BOURGES JL–Paris Femtolaser assistedpreparation andqualityofendothelialbutton MURTA J, ROSA A, QUADRADO M, BRITO S, CARDOSO A–Coimbra results Femtosecond laserandmicrokeratome preparation ofultrathin (UT)DSAEKGrafts, thesixmonthsclinical 14:30 -16:45 such as radial s course, we’ll WEDNESDAY as important worldwide. infections Thalie improved Erato s related s or such or

these

Intermediate Advanced 27 EVER 2012 Programme book 28

EVER 2012 Programme book Intermediate Beginners 14:30 -16:45 WEDNESDAY 15:30 15:00 1654 16:15 1652 15:30 15:00 in aformatthatincludesbothformalteachingandinteractive casediscussionwithexperiencedexperts. The aim of this course is to give the attendee a useful and practical approach to the patient with diplopia or disturbance of o differe the to important diagnosis orwillhighlightaparticularlyurgentthatshouldnotbemissed. is that evaluation the specifiof a aspect emphasize c will case Each management. and diagnosis on sion Thereafter,generateto op lectures preceding the in given information the use will who audience the to presented be will cases common supranuclear disorders, suchasskew deviationandinternuclearophthalmoplegia, inaseriesofdidacticlectures. a 6 fiand abnormal 3,4 versus nerves cranial normal onstrateof disorders and anatomy the review will addition,.we In ndings clinic.u eye general be a will Videosof setting the within systems motor ocular different the testing for approach systematic provide to intends .course Thisexamination ophthalmologic the of part important an is motility ocular of assessment careful A this course with very simple and clear recommendations. They would like to provide you with a ready-to-use clinical tool kit fo tests.those order lead Fourto will teachers, have experts you glaucoma when all mandatory is tests structural and functional glaucomas.well.for as signs glaucomas the of management the keyand a diagnosis is the Gonioscopy in understand step better A fito lamp slit c your useful use nd better will probably you course examinations.this basic After with management glaucoma own t practice.possible clinical really daily is in It interested mostly are who glaucoma in beginners for designed is Thiscourse 43 1651 14:30 55 1663 15:50 1661 14:30 1653 15:45 G Course 11 NSPH Course 12

1662 Alain BRON A glaucomatoolkitforbeginners Aki KAWASAKI ocular motility The ocularmotilityexaminationandcommondisorders of BORRUAT FX–Lausanne Supranuclear eyemovementdisorders Break KAWASAKI A–Lausanne Cranial nerves3,4 and6: frombrainstem toorbit BORRUAT FX–Lausanne A step-by-stepapproachtoexaminingeyemovements SUNARIC MEGEVAND G–Geneva How toevaluate structureinglaucomas? ZEYEN T–Leuven Visual fi eld examinationindailypractice Break HOMMER A–Vienna How tobecomefamiliarwithgonioscopy? BRON A–Dijon Do notforgetyourslitlamp Gallieni 1&2 o improve your improve o cular motility r glaucomas. sed to dem- to sed you during you en discus- en s well as well s a clear,a Clio ing of ing linical ntial 62 1676 1675 16:25 16:05 1673 15:30 1672 15:10 14:50 Focus will then be made on malignant uveal melanoma including clinical aspects with the prognostic factors and treatment option treatment and factors prognostic the with Radiotherapy techniquesandsurgicalwillbedevelopedindetail. aspects clinical including melanoma uveal malignant on made be then will Focus audience togetpreciseguidelinesforthemanagementofchoroidalnaevi. will lesions such of up follow the of description the and naevi suspicious and naevi benign between diagnosis Thedifferential The pathologyofalltheselesionswillbedescribed. Congenital pigmentedlesionsofthefundusarerare andcansometimesbeconfusedwithnaevusormelanoma. The coursewillcoverbenignandmalignant, congenitalandacquiredpigmentedlesionsofthefundus. 43 1671 14:30 54 1674 15:45 Course 13 PO Laurence DESJARDINS, BertilDAMATO Management ofpigmentedfunduslesions DAMATO B–Liverpool Malignant melanomaoftheuvea: surgicaltechniques DESJARDINS L–Paris Malignant melanomaoftheuvea: radiotherapy techniques MIDENA E–Padova Malignant melanomaoftheuvea: diagnosis, characterization andprognosis Break KIVELÄ T–Helsinki Suspicious choroidalnaevi COUPLAND SE–Liverpool Pathology ofpigmentedfunduslesions BECHRAKIS NE–Innsbruck Congenital pigmentedlesions 14:30 -16:45 Gallieni 4 WEDNESDAY allow the allow

s. Intermediate 29 EVER 2012 Programme book

EVER/ACTA Lecture by thecityofNicein Acropolis Convention Center Heritage Lecture Heritage 19:00 -21:00 Welcome Reception, Sponsored Ophthalmologic EVER lecture EVER IntroductionbyMarcela VOTRUBA Thierry ZEYEN-Leuven IntroductionbyEinarSTEFANSSON AndersHEIJL-Malmö Award giving perimetersinglaucomamanagement IntroductionbyLeopoldSCHMETTERER LeneMARTIN -Past-President European WELCOME 17:50 18 18:10 17:15 17:00 : 50 Ophthalmology: aphilatelicview The changingrolesofperimetryand Visual fields forEver-andmore Welcome bythePresidentEVER2012 Welcome addressbythecityofNice Leopold SCHMETTERER-President2012 OPENING CEREMONY

Uranie WEDNESDAY Uranie Uranie Uranie Uranie

31 EVER 2012 Programme book

34 EVER 2012 Programme book 08:15 - 09:45 FIRST MORNINGSESSION FIRST 08:15 -09:45 THURSDAY 92 2237 09:21 2236 09:15 2235 09:03 2233 08:51 2232 08:39 08:27 2224 09:21 2222 08:59 08:37 2214 09:27 2213 09:09 2212 08:51 08:33 81 2211 08:15 81 2231 08:15 2221 08:15 I Anteriorsegmentcomplicationsinvitreoretinal surgery - RV SIS POcularsurface andcornealbioengineering COS FP Doctor, Idon’tlike brightlights EOVS SIS

2234 2223 Nikolaos E. BECHRAKIS, HeinrichHEIMANN Jean-Jacques GICQUEL, MarioNUBILE Graham HOLDER why theyoccurandhowtodealwiththem rf rf THURET G, GAINP–Saint-Etienne ESPINASSE M, CINOTTI E, PERROT JL, LABEILLEB, CAMBAZARDF, DUMOLLARDJM, PEOC’HM, CAMPOLMIN, THURET G–Saint-Etienne HA THI BM, HEZ, CAMPOLMIN, PISELLIS, GAINP, PEOC’HM, DUMOLLARDJM, ACQUART S, GARRAUD O, PETROVSKI G–Debrecen, Oslo ALBERT R, VERÉB Z, CSOMÓSK, MOEMC, JOHNSENEO, NICOLAISSEN B, RAJNAVÖLGYI É, FESUSL, BERTA A, material-free medium Cultivation andcharacterization ofcorneallimbalepithelialstemcellsonlenscapsuleinanimal JAGER MJ–Leiden VAN ESSEN TH, SPARKS SJ, LINCC, HUSSAIN AK, COMMANDEURS, HORNGJL, LUYTENGPM, GHALBZOURI AEI, The fi sh scale-derivedBiocorneaasascaffold forhumancornealcells FIGUEIRA L, MATOS J, SERRAO P, FALCAO-REIS F, MOURAD–Porto Concentration gradient ofendogenousnoradrenaline fromperipherytocentreintherabbit cornea O’FLYNN L, TREACY O, RYAN A, MORCOSM, NOSOV M, RITTER T–Galway Donor bonemarrowderiveddendriticcellspromotecornealallograft survival intherat RAFAT M, KOH LB, ISLAMMM, LIEDBERGBO, GRIFFITHM–Linköping Highly elasticepoxy cross-linked collagenhydrogelsforcornealtissueengineering HOLDER GE–London The roleofelectrophysiology KAWASAKI A–Lausanne Photophobia inneuro-ophthalmologicalconditions LEROY BP–Ghent Photophobia ininheritedretinaldisease SPILEERS W–Leuven The fi rst consultation All speakers: Tips fortheanteriorsegmentsurgeonfromvitreoretinalperspective BLATSIOS G–Innsbruck How toachieveoptimalvisualizationinvitreoretinalsurgery HEIMANN H–Liverpool Anterior segmentproblemswithvitreoussubstitutes BECHRAKIS NE–Innsbruck The iris-diaphragm invitreoretinalsurgery TADAYONI R–Paris Dealing withcataracts invitreoretinalsurgery spectroscopy ofcorneaandskininnephropathic cystinosis Coupling innovative imaging: invivomultilaserconfocalmicroscopyandex Raman endothelial stemcells Identifi cation oflabel-retainingendothelialcellsin adulthumancorneas: anewcluefortheexistenceof Euterpe Uranie Erato IS ONN ESO 08:15 -09:45 MORNINGSESSION FIRST 93 2269 09:35 2267 09:25 2266 09:15 2265 09:05 08:55 2264 2263 08:45 2262 08:35 08:25 2253 2252 09:15 08:45 2246 2245 09:30 2244 09:15 2243 09:00 2242 08:45 08:30 81 2241 08:15 81 2261 08:15 2251 08:15 I Glaucoma: Lookingbeyondanocular disease G SIS Ocularpharmacologyanddrugdelivery SIS MEuropean EyeBank Association COS JM PBP

2268 Kaya NENGIN Francine BEHAR-COHEN Iva DEKARIS, Vincent BORDERIE HERMEL M, SALLAS, BAUER L, HAMSLEYN, STEINFELDP, WALTER P–Aachen Serum-free corneaculturewithhydroxyethyl starchasadeswellingagent PAREKH M–Zelarino–Venice and researchtesting A newandquantitativemethodtoevaluate theoverall qualityofcornealtissuesforclinicalapplications JIRSOVA K–Prague Light microscopyofthecornealpathologiesthatwemeetinourdailypractice asaneyebanker JULIENNE R, ALDOSSARY M, NEFZAOUI C, HEZ, HA THI BM, CAMPOLMIN, THURET G, GAINP–Saint-Etienne Worldwide EyeBanking(WEB)project: internationalsurveyofdemandand supply Saint-Etienne, Saint-Denis THURET G, HEZ, BERNARD A, CAMPOLMIN, HA THI BM, PEOC’HM, DUMOLLARDJM, DELESALLEN, GAINP– European studyonreliabilityassessmentofendothelialcellcountineye banks: theEuro-Keratotest study DUMOLLARD JM, PEOC’HM, THURET G–Saint-Etienne, Rouen CAMPOLMI N, HEZ, GAINP, MURAINEM, TOUBEAU D, PIPPARELLI A, ACQUART S, GARRAUD O, PISELLIS, thickness corneas Pan-endothelial viabilityassessmentwiththetripleHEC staining oforganculturedprecutDSAEKvsfull FUCHSLUGER T–Düsseldorf Biomaterials forocularsurfacereconstruction BORDERIE V–Paris Stem cellcultureforlimbaldefi ciency DEKARIS I, DRACA N, RATKOVIC M, PAUK M–Zagreb Use ofbevacizumab (anti-VEGFtreatment)inhigh-riskcornealgrafts ENGIN K–Istanbul Damage integrityfromeyetovisualcortex KOCABORA S–Istanbul Vascular issuesinglaucoma TEKELI OYA–Ankara Genetic basisofglaucomas BEHAR-COHEN F–Paris Electroporation foroculardrugdelivery OLSEN T–Århus Suprachoroidal delivery: newdirectionsandchallenges HUMAYUN M–Los Angeles Mini-pump revisitedforoculardrugdelivery HERRERO-VANRELL R–Madrid therapeutic effect Intraocular administration ofbiodegradable microspherestoincreasedrugbioavailability andextend GURNY R–Geneva New formulationsfortopicaldrugadministration URTTI A–Helsinki Potential roleoftransporters inocularpharmacokinetics Gallieni 1&2 THURSDAY Thalie Clio 35 EVER 2012 Programme book

IS ONN ESO 08:15 -09:45 MORNINGSESSION FIRST 92 2277 09:21 09:09 2275 08:57 2273 08:45 2272 08:39 08:27 81 2271 08:15 MFRO-BelgianFundforResearch inOphthalmology1 JM PAdvancesindiagnosisandmanagementofuveitis FP IM

Marie -José TASSIGNON, PhilippeKESTELYN 2276 2274 Piergiorgio NERI, CarlosPAVESIO rf rf KNOLL A, LUTZ T, GRULICH-HENN J, MACKENSEN F–Heidelberg Zürich, Münster MACKENSEN F, BECKERMD, JAKOB E, DOBNERBC, HEINZC, LORENZHM, HEILIGENHAUS A, MAXR–Heidelberg, Adalimumab inactiveuveitisrefractoty tostandardtreatment(ADUR) Final resultsofaninvestigatorinitiated, multicenterrandomised controlledtrialoftheeffi cacy of DAMATO EM, DICK A, LEERJW, SHARMASM–Bristol, Baltimore a surveillancestudy Long termeffi therapy inthetreatmentofnon-infectiousuveitis– cacy andtolerability ofanti-TNF BODAGHI B, LUMINATE INVESTIGATOR GROUP–Paris, NewJersey Voclosporin: neweranalysesofarandomized, controlledtrialfornoninfectiousuveitis JEEVA I, HARDISTY A, KOLB S, HOOLEJ, LONG V, WOOD M–Leeds HERBORT CP, PAPADIA M–Lausanne, Genova green angiography Appraisal ofchoroiditisinbirdshotretinochoroiditisisessentialandonlypossibleusingindocyanine MANTOVANI A, STAURENGHI G, HERBORT CP–Milano, Lausanne Novel interpretationoffundusautofl uorescence (FAF) fi ndings inchoriocapillaritis Tocilizumab foranterioruveitisandjuvenileidopathicarthritis–acasereport Paediatric rheumatologyclinicoutcomeatLeeds Teaching Hospitals, UK Gallieni 4 Gallieni 3 THURSDAY 37 EVER 2012 Programme book

EODMRIGSSIN 09:50-10:35 SECOND MORNINGSESSION 10:30 10:00 09:50 ent Newtreatments foragerelated maculardegeneration Keynote

2311 Award oftheEVER certifi cate ofhonour MILLER JW–Boston New treatmentsforagerelatedmaculardegeneration Introduction byConstantinPOURNARAS KEYNOTE LECTURE KEYNOTE Joan MILLER New treatments foragerelated maculardegeneration THURSDAY Uranie 39 EVER 2012 Programme book 40 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 THURSDAY 21 2436 2435 12:15 12:00 2433 11:45 2432 11:30 11:15 2425 2424 12:12 2423 11:54 11:36 11:18 2415 2414 12:12 2413 11:54 2412 11:36 11:18 10 2411 11:00 10 2431 11:00 2421 11:00 I Peelings inmacularsurgery RV SIS MISCEV EOVS JM I Wavefront aberrometry andqualityofvision COS SIS

2434 2422 Catherine CREUZOT, Ramin TADAYONI Jean-Jacques GICQUEL, PierreJeanPISELLA Graham HOLDER How todetachvitreousinmaculardiseases COCHENER B, LAMARDM, FERRAGUT S, IORGOVAN D, FATTAKHOVA Y, DEBOUGRENETLA TOCNAYE JL–Brest Quality ofvisionand3D PISELLA PJ–Tours Impact ofhigher-order aberrations onaccommodationinphakicpresbyopic patients VAN DEN BERG TJTP–Amsterdam Should youdecidetoperformcataract surgeryonyourpatients, basedonlyonstraylight? GICQUEL JJ, PISELLAPJ–Poitiers, Tours Shack-Hartmann aberrometryvsOQAS: thequarrelofancientsandmoderns? VANDERMEER G, NOCHEZ Y, GICQUELJJ, LEGRASR, PISELLAPJ–Tours, Poitiers, Orsay Spherical aberration andbinocularity CHATEAU N–Orsay An updateonthevisionsimulator LEROY BP, DEZAEYTIJDJ, DELOOZED, DELANGHEJ, KESTELYN P–Ghent Mechanisms &recoveryofvitamin A defi ciency FISHER A, ELEUTERI A, TEYMOURI R, HAGAN RP–Liverpool an Internetopensourceimplementation Recovery oftheERGfromverylowSNRrecordingsusingarobustfrequencydomainapproach: HOLDER GE, FUJINAMIK, ROBSON AG, WEBSTER AR, MICHAELIDESM–London Genotype-phenotype correlationsinStargardtdisease/ABCA4-relatedretinopathy KABANAROU SA, ROBSON AG, HOGGCR, EGANC, HOLDERGE–Athens, London desferrioxamine treatment Colour contrast sensitivityandelectrophysiologicalabnormalitiesinpatientsundergoinglongterm ZUEVA M, KOLCHIN A, KISELEVA T, LESENKO M, TSAPENKO I, RYABINA M–Moscow The fl icker ERGandretinalbloodfl ow relationshipindiabeticpatientswithout retinopathy GAUDRIC A–Paris What topeelinmacularsurgery? CREUZOT C–Dijon ILM peelinginmacularsurgery: benefi ts TADAYONI R–Paris ILM peelinginmacularsurgery: side-effect HARITOGLOU C–München How tostainILMinmacularsurgery GANDORFER A–München Euterpe Uranie Erato EODMRIGSSIN 11:00 -12:30 SECOND MORNINGSESSION 20 2458 2457 12:06 12:00 2455 11:54 11:48 11:36 2453 2452 11:24 11:12 2446 2445 12:15 2444 12:00 2443 11:45 2442 11:30 11:15 10 2441 11:00 10 2451 11:00 PImaging1/ Treatment inglaucoma G FP Newadvancesinmanagingscleritisandperipheral SIS IM

2456 2454 ulcerative keratitis Jost BJONAS, Anton HOMMER Piergiorgio NERI, CarlosPAVESIO rf rf rf rf VAN DE VEIRE S, WEBERS C, BECKERS H–Maastricht GAGLIANO C, LONGO A, UVA MG, REIBALDIM, AMATO R, RUSSO V, BIONDIP, AVITABILE T–Catania, Foggia SCHULZ S, ZINSERG–Heidelberg HOLZER S, PEREIRAI, KISSB, VASS C–Wien Zaragoza ARA GABARREM, SATUE PALACIAN M, BAMBOM, FERRANDEZ ARENAS B, GIL-ARRIBASL, FERRERAS AMEZ A– polarimetry withenhancedcornealcompensationinglaucomatouseyes Reproducibility andrepeatabilityofretinalnervefi ber layerparameters measuredbyscanninglaser FRANCOZ A, NICOT F, CATTANEO A, CREUZOT-GARCHER C, AHO S, BRON A–Dijon optical coherencetomography Choroidal thicknessinglaucomapatientsandsuspectsmeasuredbyspectral domain SHIN HY, PARK HY, JUNGKI, PARK CK–Seoul layer thicknessmeasuredbythecirrusspectral domainopticalcoherencetomograph The relationshipbetweenstandardautomatedperimetryandretinalganglioncell–innerplexiform BRON A, FRANCOZ A, NICOT F, KOEHRER P, AHO S, CREUZOT-GARCHER C–Dijon Heidelberg Retina Tomograph? Is spectral domain opticalcoherencetomography usefulinimprovingthecontourlinewith NERI P, CAPUANO V, ARAPI I, PIRANI V–Ancona PUK fromdiagnosistotreatment CASSOUX N–Paris Conditions mimickingscleritis LEE R–Bristol Scleritis andsystemicdiseases WATSON P–Cambridge Infectious scleritis HERBORT CP–Lausanne Imaging andscleritis PAVESIO C–London Scleritis: general concepts Clinical trialfortheevaluation ofneuroprotectiveeffectspalmitoylethanolamide: Visual Field and profi le shape Manual placementofSD-OCTperipapillarycirclescan: possibleinfl uence onRNFLT classifi cation Defects inmacular-retinal layeranalysisofglaucomapatientscomparedtonormativedatabase Case fromhellinnarrowangleglaucomapatient and Pattern-ERG THURSDAY Thalie Clio 41 EVER 2012 Programme book 42 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 THURSDAY 21 2475 2474 12:12 11:54 2472 11:36 11:18 2467 2466 12:00 2465 11:54 11:48 11:36 2463 2462 11:24 11:12 10 2461 11:00 MFRO-BelgianFundforResearch inOphthalmology2 JM 2471 11:00 PGeneticsandepidemiology MBGE FP I Lidmargin, meibomianglandsanddryeye ACB SIS Philippe KESTELYN, Marie-José TASSIGNON 2473 2464 Marzena GAJECKA, Graeme CMBLACK Erich KNOP, NadjaKNOP rf rf rf Bilateral progressivecoats-typeexudativeretinopathyinUshersyndrometypeIIIAfrom RABENSTEINER DF, HORWATH-WINTER J, BOLDINI, WOLTSCHE N, SCHMUTO–Graz Meibography followupstudiesindryeyepatients HALLER-SCHOBER EM, SCHMUTO–Graz HORWATH-WINTER J, RABENSTEINERDF, SCHWANTZER G, BOLDINI, FISCHLM, WACHSWENDER C, The lidmarginandDemodex SULLIVAN DA, SCHMIDT T, KNOPE, KNOPN, SULLIVAN BD–Boston, MA, Calgary, Alberta, Berlin, SanDiego, CA Lubricin: translating anideaintoacure NEPP J–Vienna Non invasive tearfi lm break-uptimeandblinking KNOP E, KORB DR, BLACKIE CA, KNOPN–Berlin, Boston, MA The Lid Wiper –aspecializedstructureattheinnereyelidmarginfordistributionoftearfi lm SOKOLAKIS TH, TSIRONI E, DARDIOTIS E, CHATZOULIS E, ZINZARASE–Athens, Larissa LUKASIK U, KOSIOR-JARECKA E, WROBEL-DUDZINSKA D, KUSMIREKK, KOCKI J, ZARNOWSKI T–Lublin AMELOOT F, AGRINIER N, MAALOUF T, ANGIOI K–Nancy YAN X, GRAW J–Munich-Neuherberg A mutationinperoxidasin causesmicrophalmiaandanteriorsegmentdysgenesisinmice KARA JOSÉN, COLLABORATIVE GROUPN–Ribeirao Preto, SaoPaulo, Natal, EighteenCities VERONESE RODRIGUESML, ARRUDA MELLOPA, COSTA PASSOS AD, REYDEFARIA MA, SOUZACARVALHO R, Ocular morbidityBrazilian study: causesofvisualimpairment LOSONCZY G, BALOGHI, VAJAS A, BERTA A–Debrecen pathogenesis inHungarianpatients The effectofaGas6c.834+7G>apolymorphismandtheinteraction ofknownriskfactorson AMD KIVELÄ T, TÄLL M, LINDAHLP, IMMONENI, LOUKOVAARA S, SANKILAEM–Helsinki c.528T>G Clarin1(CLRN1)mutation the plasminogenactivator inhibitor1and2genes Diabetic retinopathyinGreekCaucasiantype2diabeticpatients, relationship withpolymorphismin and primaryopenangleglaucoma Polymorphism ofendothelialnitricoxide synthase T786C inpatientswithnormaltensionglaucoma Activity andepidemiologyofarecently-openedophthalmicemergencycenterinanUniversityHospital Gallieni 1&2 Gallieni 4 Gallieni 3 UCTM ESO 12:35 -13:35 SESSION LUNCHTIME Moderator: HarminderSDUA 30 2523 13:35 2522 13:05 12:50 23 2521 12:35 End ofsession DUA H–Nottingham Ocular surfaceinsurgery COCHENER B, MURAINEM–Brest, Rouen A newmatrixtherapy agentinthetreatmentofcornealulcersresistanttoconventionaltreatments LEONARDI A, LAZZARINID, PILIEGOF, FREGONA I–Padova, Roma Clinical resultsontheeffi cacy of Thealoz vsautologousseruminmoderate toseveredryeye LUNCHTIME CIS LUNCHTIME What’s newinocularsurface? Euterpe THURSDAY 43 EVER 2012 Programme book 44 EVER 2012 Programme book IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST THURSDAY 14:10 14:40 14:20 14:15 2621 13:40 13:35 MEVI Award Lectures JM Carl ZeissEuropean Young Investigator Award 2012onOphthalmicResearch European Vision Award 2012 Thomas WHEELER -SCHILLING Award ceremony Carl ZeissEuropean Young Investigator Award 2012- Award Lecture Introduction by Thomas H. Wheeler-Schilling Award ceremony SCHAEFFEL F–Tübingen From chickens tohumans-learningaboutthepuzzlesofmyopia Introduction by Thomas H. Wheeler-Schilling EVI AWARD LECTURE Frank SCHAEFFEL Euterpe Euterpe IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 44 2637 2636 14:41 2635 14:35 2634 14:23 2633 14:11 2632 13:59 13:47 14:10 2617 2616 14:41 2615 14:35 2614 14:23 2613 14:11 2612 13:59 13:47 33 2611 13:35 13:35 14:40 14:20 14:15 2621 13:40 13:35 MEVI Award Lectures JM Imaging1 FP PInfl COS FP RV 2631 Carl ZeissEuropean Young Investigator Award 2012onOphthalmicResearch European Vision Award 2012 Carl ARNDT, ConstantinPOURNARAS, CatherineCREUZOT Eric GABISON, Gilles THURET rf rf rf rf ammatory ocularsurface FUCHSLUGER T–Düsseldorf BEN MHAMEDM, PEREIRAD, DOAN S, COCHEREAU I, GABISON E–Paris BASLI E, LAROCHE L, LAURENT M, DESPIAU MC, BORDERIE V–Paris The effectsofautologous serumeyedropsinthetreatmentofocularsurfacediseases: aretrospectivestudy MARSOVSZKY L, RESCHM, NEMETHJ, KOVACS L, TOLDI G, MEDGYESIE, BALOG A–Budapest, Szeged evaluation ofdryeyeinrheumatoidarthritis In vivoconfocalmicroscopicexaminationofcornealLangerhanscelldensity, distributionand LEAL C, LEROUXK, RAHMI A, SèVEP, DENISP, KODJIKIAN L–Lyon Scleritis, clinicalfeatures, etiologicaldiagnosisandtreatment: areviewof32cases JAUHONEN HM, VIIRI J, KAARNIRANTA K, LAIHIAJK, LEINOL–Kuopio, Turku Cis-urocanic acidinhibitsconjunctivitisandblepharitisinrat modelofacuteeyeirritation CHAPELLIER B, LABETOULLE M, GAILLEDRAT M, GABISONE–Paris, LeKremlinBicêtre Meganuclease targetingHSV-1 limits viral endothelitis invivo Award ceremony Carl ZeissEuropean Young Investigator Award 2012- Award Lecture Introduction by Thomas H. Wheeler-Schilling Award ceremony SCHAEFFEL F–Tübingen From chickens tohumans-learningaboutthepuzzlesofmyopia Introduction by Thomas H. Wheeler-Schilling JONAS JB, WEI W, XUL, SHAO L, DUK, WANG S, CHENC, XUJ, WANG Y, ZHOUJ, YOU Q–Mannheim, Beijing BAMBO M, FERRANDEZB, GARCIA-MARTIN E, GIL-ARRIBASL, ARA M, SATUE M–Zaragoza SUZANI M, MOORE AT–London Coats disease: fl uorescein angiography guidedmanagement GARCIA FERNÁNDEZM, CASTRONAVARRO J–Oviedo Natural evolutionofidiopathiclamellarmacularholes(LMH)andpseudoholes(MPH) TILLEUL J, QUERQUESG, CANOUI-POITRINE F, LEVEZIELN, SOUIEDEH–Créteil study ofexudativeamdpatients Assessment ofthespectralis spectral domainoctsegmentationsoftware inaretrospectivecohort ZERBIB J, MASSAMBAN, QUERQUESG, BLANCO-GARAVITO R, SROURM, BONNETC, SOUIEDEH–Creteil High-resolution spectral domainopticalcoherencetomography fi ndings inreticularpatterndystrohy BERNARDES R, SANTOS T–Coimbra Optical coherencetomography: signalsignatureonneuronalageingandblood-retinalbarrierstatus Subfoveal choriodalthickness: theBeijingEyeStudy Infl uence ofcataract inreproducibilityofOpticalCoherence Tomography measurements Comparison ofviral vectorsforgenetransfer to cornealendothelialcells Severe corticoresistantMoorenUlcers: managementwithRituximab andperipheral lamellargraft Euterpe THURSDAY Uranie Erato 45 EVER 2012 Programme book 46 EVER 2012 Programme book IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST THURSDAY 44 2664 2663 14:41 2662 14:19 13:57 2656 14:35 14:23 2654 2653 14:11 2652 13:59 13:47 2647 2646 14:41 2645 14:35 2644 14:23 2643 14:11 2642 13:59 13:47 33 2641 13:35 33 2661 13:35 13:35 PNewfrontiers inocularInfectology IM FP I Next-generation sequencinginretinal genetics MBGE SIS Diagnosis inglaucoma G FP

2655 2651 Uwe PLEYER, RegisKOWALSKI Andrew MCNAUGHT, Thierry ZEYEN Bart LEROY, Graeme CMBLACK rf rf Ocular toxoplasmosis: patientageandotherriskfactorsforaseverecourseofdisease DOWNES S, NEMETH AH–Oxford Using it: NGS intheinheritedretinaldegeneration clinic NEMETH AH, DOWNESS–Oxford Delivering it: Stargardtdisease BLACK GCM–Manchester Delivering it: retinitispigmentosa HALL G–Manchester Who wants it? MAY F, GIRAUD JM, FENOLLANDJ, ELCHEHABH, SENDOND, FRANCOZM, RENARDJP–Paris Evaluation ofthe fl icker defi ned formtestversusmatrix, innormalandglaucomaeyes SPAETH G, RICHMANJ–Philadelphia SPARCS: anewmethodofevaluating contrast sensitivityinpatientswithglaucoma NASR MB, KOUKOULA SC, TRANOS PG, LABIRISG, KOZOBOLIS VP–Thessaloniki, Alexandroupolis exfoliation syndrome, exfoliativeglaucomaandprimaryopen-angle Evaluation ofretrobulbar hemodynamicsandaqueoushumorlevelsofEndothelin-1in STEIN A, LYUBIMOV G, MOISEEVA I, IOMDINAE, NAZARENKO L–Moscow Analysis ofeyehydrodynamicsonthebasistestswithamechanicalloadapplied JANSONIUS NM, RAMDAS WD, WOLFS RCW, HOFMAN A, DEJONGPTVM, VINGERLING J–Groningen, Rotterdam Ocular perfusionpressure–ariskfactorforopen-angleglaucomaorstatisticalartifact? TRAN TL, BEK T, HAMANNS, HEEGAARDS–Copenhagen, Aarhus Aquaporins inglaucomaeyes CHIQUET C, LABETOULLE M, GERMIR, BERNHEIMD, MORAND P, ROMANETJP–Grenoble, Paris OBWALLER A, POLAT ZA, WALOCHNIK J, VURAL A, DURSUM A, ARICI MK–Vienna, Sivas ROBERT PY, SABATIER A, GARNIERF, PLOY MC–Limoges 16S RNAPCRinthediagnosisofbacterialkeratitis andendophthalmitis KOWALSKI R, ABDEL AZIZ S, ROMANOWSKIE, SHANKSRM–Pittsburgh Evaluation ofacomplete-killassayforanti-acanthamoebasolutions BOUCHENAKI N, KUZNETCOVA T, SAUTY A, HERBORT CP–Lausanne, Morges associated uveitis Positive interferon-gammareleaseassay(IGRA)testinacaseofnon-tuberculousmycobacterium FEL A, ROZENBERGF, TOUITOU V, LEHOANGP, BODAGHI B–Paris Etiologic diversityinpatientspresentingwithatypicalandsevereanterioruveitis PLEYER U, MäNZM, FELSG, METZNERS, HAZIROLAND, JOHNSENJ–Berlin using quantitativereal-timePCR Time profi le ofviral DNAinaqueoushumorofpatientstreatedfor VZV acuteretinalnecrosis Acanthamoeba keratitis. Resultsfromin-vivotoxicological andeffi cacy studies Miltefosine andpolyhexamethylenebiguanide, anewdrugcombinationforthetreatmentof Gallieni 1&2 Thalie Clio IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 43 2686 2685 14:35 2684 14:23 2683 14:11 2682 13:59 13:47 2673 14:35 14:05 33 2681 13:35 13:35 PLessonsfrom humanandanimalstudies ACB FP Proceedings infunctionalandstructural imaging SIS PBP 2672 2671 Erich KNOP, GiedriusKALESNYKAS Gerhard GARHOFER, SveinnHARDARSON rf HUSEVA YA, DENISOV SD–Minsk HONG S–Seoul pulp stemcells Retinal ganglioncelldifferentiationandprotectionusingneuronallydifferentiatedhumandental MORGAN IAN–Canberra Retinal pathways involvedinthecontrolofeyegrowthandmyopia ABU EL ASRAR A, MOHAMMADG, NAWAZ MI, SIDDIQUEIM, KANGAVE D, OPDENAKKERG–Riyadh, Leuven Expression oflysophosphatidicacid, autotaxinandacylglycerolkinase WILLERMAIN F, DELPORTE C–Bruxelles MOTULSKY E, SALIKD, JANSSENSX, PIONB, DUFRANER, CHAPUTF, BOLAKYN, GREGOIREF, CASPERSL, PERRETJ, Aquaporin-1 expressioninmembranes fromproliferative vitreoretinopathyandinepiretinalmembranes San Diego, Boston KNOP E, KNOPN, SCHMIDT T, MORRISONS, SULLIVAN BD, RAHIMIDARABADR, SULLIVAN DA–Berlin, Calgary, Expression ofLubricinmRNAandproteininhumanocularsurfacetissues SCHMETTERER L–Vienna New developmentsinopticalcoherencetomography HARDARSON S–Reykjavik Retinal oximetry technology SCHWEITZER D–Jena Investigation ofintra-cellular metabolismbytime-resolvedautofl uorescence Intermembranaceous spacesofhumanopticnerveintracanal part Gallieni 3 Gallieni 4 THURSDAY 47 EVER 2012 Programme book 48 EVER 2012 Programme book 51 64 SECOND AFTERNOON SESSION 15:15 -16:45 THURSDAY 60 2726 16:15 2725 16:05 2724 15:55 2723 15:45 2722 15:35 15:25 2717 2716 16:21 2715 16:15 16:03 2713 15:51 2712 15:39 15:27 51 2711 15:15 51 2721 15:15 PImaging2 RV FP MEVICR.net: Clinicaltrialsinglaucoma, anteriorsegmentand JM

2714 Michel PAQUES, HeinrichHEIMANN Esther HOFFMANN, Jorge ALIO SANZ, JoaquimMURTA ocular surface rf rf Foveal changesduringocularmovementsinnormaleyes. A prospectivestudy.Kinetics ofposterior Open discussion ROZEMA J–Antwerp Gullstrand (ECR-CCRS-2010-01) LORENZ K–Mainz The STRONGstudy RICH C–Fort Worth Perspectives fornewtreatmentsat Alcon -part1 MURTA J–Coimbra Femtosecond laserandmicrokeratome preparation ofultrathin (UT)DSAEKgrafts ALIO SANZJ–Alicante Trends inanteriorsegmentsurgery: whatiscoming? HOFFMANN E–Mainz Therapeutic targetsinglaucoma GONZALEZ C–Toulouse HALDAR S, DAVIES N–London Paris, Inzai, Chiba, Tokyo GOCHO-NAKASHIMA K, AUDO I, MOHAND-SAIDS, KAMEYA S, YAMAKI K, TAKAHASHI H, SAHELJA, PAQUES M– Follow-up studyofMEWDSusingadaptiveopticsretinalimaging YONEYA S, BABAM, SUZUKIM, KURODAH–Moroyama, Iruma, Saitama a preliminaryreport Observation offundususinganovelhigh-speedandhighresolutionopticalcoherenttomography: RODRIGUES P, GUIMARAESP, BERNARDESR, SERRANHOP–Coimbra Vascular networkofthehumanmaculafromOCT GUIMARAES P, RODRIGUESP, BERNARDESR, SERRANHOP–Coimbra 3D bloodvesselssegmentationfromopticalcoherencetomography THEOCHARIS IP–Athens pole duringocularmovementsinvarious diseases:avideomorphingtechnique neovascular AMD treated byseriesof3RanibizumabIVTprotocol, 4yearsfollow-up Atrophic areasand/withneovascular AMD. Characteristics, evolutionofatrophiclesionsassociatedto Assessment ofdifferentmethodsforinter-individual registration ofOCTtopography forstatisticalanalysis Euterpe Uranie EODATRONSSIN 15:15 -16:45 SECOND AFTERNOONSESSION 62 2754 2753 16:21 2752 15:59 15:37 2745 2744 16:27 16:09 2742 15:51 15:33 2734 2733 16:21 2732 15:59 15:37 51 2741 15:15 15:15 51 2751 15:15 IM SIS Opticneuropathies mistaken foropticneuritis SIS I Dealingwithadvancedglaucoma G SIS NSPH 2743 2731 Thomas FUCHSLUGER, UwePLEYER Progress incornealtransplantation: immunologyandinfl Antonella BOSCHI, Aki KAWASAKI Ejaz ANSARI ANSARI E–Maidstone Counselling thepatientwithadvanced disease HOLDER GE–London Differential diagnosisofadvanced glaucoma BRON A–Dijon Treatment optionsinadvanced disease ZEYEN T–Leuven Defi nition andinvestigativetechniquesinadvanced glaucoma FUCHSLUGER T–Düsseldorf Immune modulatoryeffectsofgenetherapy tocornealgrafts RITTER T, TREACY O, O’FLYNN L, WILK M, MORCOSM, RYAN A, NOSOV M–Galway Novel therapeutic strategies fortheinductionoftolerance incornealtransplantation DICK A–Bristol non-infectious intraocular infl ammation Current conceptsandfuturedirectionsinthepathogenesistreatmentofinfectious PLEYER U–Berlin Graft rejectionin keratoplasty -isthereaplacefortopicalimmunemodulation? GRUENERT A–Düsseldorf Graft rejectioninkeratoplasty -whatarethebenefi ts ofsystemicimmunemodulation? BOSCHI A–Brussels Retinopathies VIGHETTO A–Lyon Optic neuropathyinDevic’s disease: adiagnosticchallenge BORRUAT FX–Lausanne Infl ammatory opticneuropathies KAWASAKI A–Lausanne Compressive lesions ammation THURSDAY Thalie Erato Clio 49 EVER 2012 Programme book 50 EVER 2012 Programme book 51 64 SECOND AFTERNOON SESSION 15:15 -16:45 THURSDAY 63 2777 2776 16:37 2775 16:30 2774 16:15 2773 16:00 2772 15:45 15:30 2763 2762 16:20 15:55 53 2761 15:30 15:15 51 2771 15:15 I Retinalbarriers ACB SIS SEBO: What caneducationorganisations doforyoung WS Hannu UUSITALO, KaiKAARNIRANTA Peter RINGERS, Marko HAWLINA ophthalmologists? MUSELIER A–Dijon I havepassedtheexam GRIGORIU D–Bucharest I havegotagrant MATHYSEN D–Antwerp Evaluation remains akey point BARISANI-ASENBAUER T–Vienna UEMS-EACCME’s newcriteriafor theaccreditationofLiveEducationalEvents(LEEs) CREUZOT C–Dijon Surgical skillsamongEuropeanstudents TASSIGNON MJ–Antwerp Inventorisation ofEuropeaneducationprograms ACLIMANDOS W–London EBO exam: howtosucceed? UUSITALO-JÄRVINEN H–Tampere R-Ras inretinalangiogenesis BEUERMAN R, CHEWJ, WEON SR, BARATHI VA–Singapore Protective roleofsteroidsonmouseprimaryRPEcellsunderhypoxic stress PETRASH M–Aurora, Colorado Natural compoundsasleadtherapeutic agentsagainstdiabeticeyedisease Retinal barriersinhealthanddisease-introductionbyHannuUusitalo/KaiKaarniranta Gallieni 1&2 Gallieni 4 EODATRONSSIN 15:15 -16:45 SECOND AFTERNOONSESSION 61 2787 2786 16:15 2785 16:09 2784 16:03 2783 15:51 2782 15:39 15:27 51 2781 15:15 PGenetics, GenotypesandPhenotypes FP MBGE Marcela VOTRUBA, BartLEROY rf rf rf GARCIA FERNÁNDEZM, CASTRONAVARRO J, BAJOFUENTE A–Oviedo KAROLAK JA, NOWAK DM, MOLINARI A, PITARQUE JA, BEJJANIBA, GAJECKAM–Poznan, Quito, Spokane OLDAK M, FEDEROWICZ A, SZULBORSKIK, WIERZBOWSKA J, KOSINSKA J, PIOSKIR, SZAFLIKJP, SZAFLIKJ–Warsaw LARSEN M, LAENERSG, REYNIERP, MILEAD–Angers, Lille, Rouen, Montpellier, Copenhagen LERUEZ S, BONNEAU D, AMATI-BONNEAU P, DEFOORT-DHELLEMMES S, CROCHETM, DROUIN V, BLANCHETC, JUULG, OPA1-related sensorineural hearingloss NOWAK DM–Poznan, Quito, Spokane, Warsaw GAJECKA M, KAROLAKJA, MOLINARI A, PITARQUE JA, BEJJANIBA, POLAKOWSKI P, SZAFLIKJ, SZAFLIKJP, Complexity ofgeneticsinkeratoconus HAMEL C–Montpellier BOCQUET B, MARZOUKAN, HEBRARDM, MANESG, SENECHAL A, BAUDOIN C, MARQUETTE V, MEUNIERI, Search fortheidentifi cation ofnewgenescausingautosomalrecessiveretinitispigmentosa HAMEL C–Montpellier, Lille MANES G, DHAENENSCM, BOCQUETB, MARQUETTE V, BAUDOIN C, RICHARD AC, HEBRARDM, MEUNIERI, pigmentosa A strategy formoleculardiagnosisandsearchnewgenes/lociinautosomaldominantretinitis RDH12 mutationandearly-onsetretinaldegeneration Analysis oflincRNAat13q32keratoconus locus Detection ofanovelprematurestopcodonintheOPA1 geneinautosomaldominantopticatrophy Gallieni 3 THURSDAY 51 EVER 2012 Programme book

OTRSSIN1 16:45 -18:00 SESSION1 POSTER Graeme BLACK, MarzenaGAJECKA Moderators: Molecular Biology/GeneticsEpidemiology 07NHSgenemutationsinnonsyndromiccataract T007 UnusualphenotypeinafamilywiththeR124Cmutation T006 The BrittleCorneaSyndrome: Studyofafamilywithfi ve T005 T004 T003 PirfenidoneinhibitstheinductionofCOX-2stimulatedby T002 Relationships betweenestradiol, progesterone, and T001 T014 T013 Vascular endothelialgrowthfactor A geneticpolymorphisms T012 Non-syndromicretinitispigmentosa: Phenotype-genotype T011 T010 Progressionofgeographic atrophyandpolymorphismsof T009 T008 rf rf rf rf rf and AMD in Tunisians correlation intwelve Tunisian families Age-Related MacularDegeneration genes CFH, BF, C3, FHR1-3, FRH3and ARMS2/HTRA in the TGFBI gene affected siblings IL-1 normal humanpregnancy plasminogen activator inhibitorlongitudinallyduring WROBEL-DUDZINSKA D, CHODOROWSKAG, ZARNOWSKI T–Lublin LUKASIK U, KOSIOR-JARECKA E, BARTOSINSKA J, KOCKI J, glaucoma patients nitric oxide synthasepolymorphismin normaltension Nailfold capillaroscopicexamination and T786C endothelial KUSMIREK K, KOCKI J, ZARNOWSKI T–Lublin LUKASIK U, KOSIOR-JARECKA E, WROBEL-DUDZINSKA D, EL MATRI L, HABIBII, CHEBIL A, SFAR I, KORT F, GORGI Y–Tunis SCHORDERET D–Tunis, Lausanne EL MATRI L, CHEBIL A, FALFOUL Y, LARGUECHEL, MUNIERF, ZINZARAS E–Athens, Larissa SOKOLAKIS TH, TSIRONI E, DARDIOTIS E, CHATZOULIS E, SPANISH MULTICENTER GROUPON AMD S–Pamplona MORENO-ORDUñA M, FERNANDEZ-GARCIA V, GARCIA-LAYANA A, RECALDE S, FERNANDEZ-ROBREDOP, CAIREJ, GARCIA-GARCIAL, Oviedo GARCIA FERNÁNDEZM, CASTRONAVARRO J, BAJOFUENTE A– PISELLA PJ–TOURS, Strasbourg HABAY T, LAUMONIER F, LALAE, SPEEG-SCHATZ C, TOUTAIN A, SZAFLIK J–Warsaw UDZIELA M, OLDAKM, FEDEROWICZ A, PLOSKIRAFAL, SZAFLIKJP, ALHARBI A, DENISD, AZAR N, MAUMENEE IH–Marseille, Chicago GAJECKA M–Poznan, Quito, Spokane KAROLAK JA, NOWAK DM, MOLINARI A, PITARQUE JA, BEJJANIBA, KOSINSKA J, PIOSKIR, SZAFLIKJP, SZAFLIKJ–Warsaw OLDAK M, FEDEROWICZ A, SZULBORSKIK, WIERZBOWSKA J, KOOK K, PARK S, CHOI A–Suwon CSUTAK A–Debrecen, Laurel STEIBER Z, SILVER DM, TOZSER J, BAGOSSI P, JAKAB A, BERTA A, angle glaucoma patients withnormaltensionglaucomaandprimaryopen Polymorphism ofendothelialnitricoxide synthase T786C in activator inhibitor 1and2genes patients, relationshipwithpolymorphismintheplasminogen Diabetic retinopathyinGreekCaucasiantype2diabetic RDH12 mutationandearly-onsetretinaldegeneration Analysis oflincRNAat13q32keratoconus locus gene inautosomaldominantopticatrophy Detection ofanovelprematurestopcodonintheOPA1 atastepofNF- B DNAbindinginorbitalfi broblast Nadja KNOP, KaiKAARNIRANTA Moderators: Anatomy /CellBiology T019 Ocularsymptomsarenotpredictiveofocularinfl ammation T018 Prevalence ofvisualimpairmentamongtheelderly: canit T017 Prevalence andriskfactorsforrefractive errorsamong T016 T015 07Long-termnanostructural effectsofhigh radiofrequency T027 Comparative endonasalanalysisoftheinferiorlateral wall of T026 Hypoxia InducibleFactor-1a (HIF-1a)andHeatShock T025 Measurementofscleral curvature usinganteriorsegment T024 Choroidalthicknessmeasurementsinchildrenusing T023 NormativedataformacularthicknessbySpectral Domain T022 Bloodbasementmembrane alterations inhumanretinal T021 T020 rf rf rf Vandoeuvre lesNancy CLOCHé V, BIGARDMA, PEYRIN-BIROULETL, ANGIOI K– YEKTA R–Mashhad, Tehran, Mashad OSTADIMOGHADDAM H, AZIMI A, HERAVIAN J, REZVAN F, YEKTA AA, HASHEMIH, KHABAZKHOOBM, SHAFAEE SH, YEKTA R, DERAKHSHAN A, HERAVIAN J, AZIMI A, RASHID TORABI M YEKTA AA, GHASEMIS, KHABAZKHOOBM, OSTADIMOGHADDAM H, AMELOOT F, AGRINIER N, MAALOUF T, ANGIOI K–Nancy JAE HOS–Seoul HUBAULT B, VALLE D, MEROLJC, ARNDT C, DUCASSE A–Reims ASSIMAKOPOULOU M–Patra PAGOULATOS D, PHARMAKAKISN, ARGYROPOULOU A, CHOI HJ, KANGMH, KIMSH–Seoul CRISTOBAL JA–Zaragoza PEIRO C, ASCASO F, REMONGARIJOL, PEREZ GARCIAD, PINILLAI, IBAÑEZ ALPERTE J, CRISTOBAL JA–Zaragoza PEREZ GARCIAD, PINILLAI, IBAÑEZ ALPERTE J, ASCASO F, Barcelona, Lisboa NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, NACHER V– RUBERTE J, LOPEZ-LUPPOM, RAMOSD, MENDES-JORGEL, VAN NOORDENCJF–Amsterdam SCHLINGEMANN RO, SIEMERINKMJ, GRIFFIOEN AW, KLAASSENI, HUSEVA YA, DENISOV SD–Minsk Mashhad, Tehran intracanal part Intermembranaceous spacesofhumanopticnerve in infl ammatory boweldisease. A largecross-sectionalsurvey be corrected? the universitystudentsofIran emergency centerinanUniversityHospital Activity andepidemiologyofarecently-openedophthalmic treatment ontherabbit skintissues the nasalfossaeinadultswithandwithout epiphora and normalconjunctiva. Proteins 90, 70(HSP90, 70)expressioninocularpterygium optical coherencetomography Spectral-Domain OCT OCT inhealthychildren. microaneurysms duringaging of ocularangiogenesis endothelial cellcultures: anewmodeltostudymechanisms CD34 marksangiogenictipcellsinhumanvascular THURSDAY – 53 EVER 2012 Programme book 54 EVER 2012 Programme book Jean-Jacques GICQUEL Thomas FUCHSLUGER, MarioNUBILE, Moderators: Cornea /OcularSurface T033 T032 T031 T030 Blood-retinal barrierserumferritintransport inmouseretina T029 Morphormetricchangesofopticnerveinexperimentally T028 T040 T039 Granulomatous conjunctivitisassociatedwithchronic T038 T037 T036 Changesinmeibography inpediatric T035 T034 rf rf rf rf rf rf rf rf 16:45 - 18:00 POSTER SESSION1 POSTER 16:45 -18:00 THURSDAY blepharitis inchildren blepharokeratoconjunctivitis induced type2diabeticrats Coimbra Limoges ROBERT PY, DUBOIS A, CHAIGNIERD, GARNIERF, PLOY MC– SUTTON G–Sydney MADIGAN MC, YOU JJ, WEN L, HODGES C, ROUFAS A, MCAVOY JW, ABALETTE P–Lille BAïZ H, MAURAGE CA, LAUMONIER E, ROULANDJF, L Evry, LaGaude, Paris DAULL P, GARRIGUEJS, FERAILLEL, BAUDOUIN C, ELENAP– La Gaude, Paris DAULL P, FERAILLEL, ELENAP, BAUDOUIN C, GARRIGUEJS–Evry, HORWATH-WINTER J–Graz BOLDIN I, RABENSTEINERDF, WOLTSCHE N, PöSCHLE:M:, Saint-Etienne DUMOLLARD JM, PEOC’HM, CAMPOLMIN, THURET G, GAINP– ESPINASSE M, CINOTTI E, PERROT JL, LABEILLEB, CAMBAZARDF, FUCHSLUGER T–Düsseldorf BATISTA A, LOUREIROC, DOMINGUESJP, SILVA JS, MORGADO AM Poitiers, Tours DJABAROUTI M, ZAKARI W, NOCHEZ Y, PISELLAPJ, GICQUELJJ– BREMOND-GIGNAC D–Poitiers, Tours, Amiens GICQUEL JJ, DJABAROUTIM, DUPONTL, ZAKARI W, PISELLAPJ, Lisboa, Barcelona NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, RUBERTE J– DUARTE CM, SIMõESM, CARRAPIçOB, PIRES VMR, NACHER V, MENDES-JORGE L, RAMOSD, LUPPOM, VALENçA A, CATITA J, KANG MH, LIMHU–Guri using molecularbiology Investigation ofbacterialcontamination ofcornealdonors tears andcorneas Secreted frizzledproteinsincontrolandkeratoconus (KC) therapies inarat modelofcornealscraping Ocular surfaceeffectsofantiglaucomacombination in arat modelof cornealscraping Comparison oftheanti-infl ammatory effectsofartifi cial tears cornea andskininnephropathiccystinosis microscopy andexvivoconfocalRamanspectroscopyof Coupling innovative imaging: invivomultilaserconfocal endothelial cells Comparison ofviral vectorsforgenetransfer tocorneal Corneal respiratory function by FAD autofl uorescence lifetime aberrometry innormalsubjects Tear fi lm break-uptimeevaluation byreal-timewavefront aberrometry inadultpatientswithmeibomiangland Tear fi lm break-uptimeevaluation byreal-timewavefront – 08Useoflissaminegreenbeforeconjunctival impression T048 The roleofcomplianceinoptimizingtheocularsurfaceafter T047 The ocularsurfacedrugcorrectioninpatientsafterLASIK T046 The effectofinfl iximab oncornealneovascularization in T045 Nicorandil: anewcaseofcornealulceration T044 Genetransfer ofHSV1-specifi c meganucleasetothemurine T043 Identifi cation offactorsregulatingdifferentiationandgrowth T042 Evaluation oflimbalstemcelldefi ciency: anewdiagnostic T041 07The contributionof tearosmolaritymeasurementtoocular T057 Epidemiologyofmicrobial keratitis: A reviewof508cases T056 Tear fi lm proteinsattachedtosoftcontactlenses T055 Roleofhumancornealstroma-derivedmesenchymal-like T054 Observation ofdendriticcellsincornealgraft diseasein T053 Riskfactorsforcontactlensesrelatedmicrobialkeratitis: T052 Observation ofdendritic cellsinsubclinicalcornealgraft T051 Wetability anddepositsaccumulationonanteriorsurface T050 Lacrymalsecretioninthenon-affectedfelloweyeof T049 SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I–Voronezh SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I–Voronezh LEE MA, CHUNGSK–Seoul TRECHOT F, BAZARDMC, BATTA B, ANGIOI K–Nancy Le Kremlin-Bicêtre, Gif-sur-Yvette, Paris DESSEAUX C, ROY P, CHAPELLIERB, LABETOULLE M– ROUSSEAU A, ERGANI A, GABISONE, CORRALM, GAILLEDRAT M, HOLAN V, TROSAN P, KRULOVA M, ZAJICOVA A–Prague POLI M, JUSTIN V, DAMOURO, BURILLONC–Lyon BRETILLON L, BRON A, CREUZOT-GARCHER C–Dijon, Paris MUSELIER A, MATHIEU B, BRIGNOLE-BAUDOUIN F, NIAZI A, HOFFART L, DORNADIN A, DRANCOURT M–Marseille Aarhus C NIELSEN K, VORUM H, EHLERSN, HJORTDAL J, HONORéB– PETROVSKI G–Debrecen, Oslo VEREB Z, ALBERT R, MOEMC, RAJNAVöLGYI E, FESUSL, BERTA A, WOJCIK L, WYLEGALA E, SMEDOWSKI A, ORSKIM–Katowice BOURCIER T, SAUER A–Strasbourg WOJCIK L, WYLEGALA E, SMEDOWSKI A, ORSKIM–Katowice Madrid URBANO-RODRIGUEZ R, RIOS-SANTOS R, SANCHEZ-RAMOSC– CHAMORRO E, BONNIN-ARIASC, RAMIREZ-MERCADOG, BOURCIER T, LABETOULLE M–Kremlin-Bicetre, Strasbourg MGARRECH M, ROUSSEAU A, SAUER A, KASWING, BARREAU E, Birmingham, Oxford, Birmigham TOMLINS PJ, BOWMAN S, BRON A, RAUZ S, CURNOWSJ– cytology andfl ow cytometryinpatientswithsjögren’s two-step LASIK rabbits cornea of limbalstemcellsforcornealsurfaceregeneration impression cytology tool basedonkeratin 13immunostainingincorneal surface assessmentinsoftcontactlens wearers stem cellsinimmunityandwoundhealing keratoplasty usingconfocalmicroscopyimaging keratoconus patientafterdeepanteriorlamellar a prospectivemulticentercasecontrolstudy disease usingconfocalmicroscopyimaging of bluelight-fi ltering contactlens patients withrecurrentunilateral herpetickeratitis syndrome OTRSSIN1 16:45 -18:00 SESSION1 POSTER 04Quantifi cation oftearfi lm thicknessinhealthysubjectsusing T064 Oculargranulomatosis associatedwithbrimonidine T063 Polymeric membranes forcornealepitheliumengineering T062 Prospectivestudyofanewmatrixtherapy agent(RGTA) for T061 Whole exomesequencingidentifi es amutationfornovel T060 Assessment oftheimprovementqualityvisionafter T059 Qualityofvisioninpatientswithherpetickeratitis T058 T071 T070 Postoperative astigmatisminduction-femtosecondlaser- T069 T068 T067 Cornealcross-linkingandFerrara ®intracorneal ringsfor T066 The roleofConfocalMicroscopyinevaluation andtreatment T065 rf rf rf rf assisted penetrating keratoplasty vspenetrating keratoplasty the treatmentofprogressivekeratoconus: About 23cases of infectiouskeratitis ultrahigh resolution OCTimaging macrophages anddendriticcellsinvitro? treatment. Doesbrimonidinehaveaneffectonhuman based onchitosanandstructural proteins the treatmentofneurotrophiculcers form ofhereditarybenignintraepithelial dyskeratosis aberrometry inpatientswithmeibomianglanddysfunction Meibopatch© treatment, withOQASandHartmann-Shack Saint-Etienne DUMOLLARD JM, ACQUART S, GARRAUD O, THURET G– HA THI BM, HE Z, CAMPOLMIN, PISELLIS, GAINP, PEOC’HM, SICARD F, JANYB, BENNAID, BREMOND-GIGNAC D–Amiens DOBROWOLSKI D, MILKA M, WYLEGALA E–Sosnowiec WYLEGALA E–Katowice, Sosnowiec DOBROWOLSKI D, JANISZEWSKA D, TARNAWSKA D, KRYSIK K, GABISON E–Paris BEN MHAMEDM, PEREIRAD, DOANS, COCHEREAU I, FROUSSAERT-MAILLE F, RIGAL-SASTOURNE JC–Clamart LUSSATO M, DELBARREM, BLAVIER B, LEDUCC, CREPYP, WOWRA B–Katowice ORSKI M, WYLEGALA E, TARNAWSKA D, WOJCIK L, SMEDOWSKI A, SCHMETTERER L–Vienna KAYA S, WERKMEISTER R, LEITGEBR, ALEX A, GARHOEFERG, LABALETTE P–Lille, France BOUABANE I, MAURAGE CA, LABALETTEM, ROULANDJF, WOJCIK L–Katowice, Cracow SCZUBIALKA K, NOWAKOWSKA M, ORSKIM, SMEDOWSKI A, WOWRA B, WYLEGALA E, GROLIKM, DOBROWOLSKID, Rouen GUEUDRY J, AIFA A, PORTMANN A, DELCAMPE A, MURAINEM– Toulouse, Durham, Singapore HAWTHORNE F, AFSHARI NA, CALVAS P, MALECAZEF, YOUNG T– SOLER V, TRAN-VIET KN, ST.GERMAIN E, FOURNIEP, KLEMM T, Poitiers, Tours, Brest DUPONT L, NOCHEZ Y, PISELLAPJ, COCHENERB, GICQUELJJ– LABETOULLE M–LeKremlin-Bicêtre ROUSSEAU A, KASWING, BARREAU E, M’GARRECHM, stem cells human corneas: anewcluefortheexistence ofendothelial Identifi cation oflabel-retainingendothelialcells inadult keratoplasty Assessment ofangleandanteriorchamberchangesafter Surgical approachincornealperforations anddeepulcers Rituximab andperipheral lamellargraft Severe corticoresistantMoorenUlcers: managementwith 08Expressionofstromelysins2and3inrabbit corneal T078 Impactofphotodynamicinactivation (PDI)onbFGF, HGF, T077 T076 T075 Oneyearstoredcorneas: isitpossible? T074 ImprovingDSAEKdonorgrafts cutusingmicrokeratome T073 Exvivotestbenchforpreclinicalassessmentofintra corneal T072 06Effi cacy ofgaspermeable scleral lenses inrefractory T086 Keratoconus screeningbasedondataofthehighresolution T085 Effi cacy ofamnioticmembrane transplantation (AMT)on T084 Distributionofthecentral cornealthicknessinadult T083 Three yearvisualoutcomesandcorrelationwithgraft T082 The correlationbetweencentral cornealthicknessand T081 Gelatinousdroplike dystrophy(GDLD)inaSudanesepatient T080 Cornealbiomechanicsaftercornealcross-linkingfor T079 rf rf BISCHOFF M, FOTH HJ, SEITZB–Homburg/Saar, Kaiserslautern SZENTMARY N, STACHON T, WANG J, EPPIG T, LANGENBUCHER A, IRION L, MCKEEH, BRAHMA A, CARLEYF–Manchester DUMOLLARD JM, GAINP, THURET G–Saint-Etienne HE Z, CROUZETE, PISELLIS, CAMPOLMIC, FORESTF, PEOC’HM, DUMOLLARD JM, GAINP, THURET G–Saint-Etienne HE Z, CAMPOLMIN, NEFZAOUI C, PISELLIS, PEOC’HM, Saint-Etienne PEREIRA S, THEILLIERE C, PISELLIS, THURET G, GAINP– BERNARD A, NEFZAOUI C, GRIOT O, CAMPOLMIN, ACQUART S, Saint-Etienne BERNARD A, CAMPOLMIN, NEFZAOUI C, THURET G, GAINP– Paris DOAN S, ELLUARD M, GABISONE, COCHEREAU I, DELCAMPE A– Homburg, Erlangen LANGENBUCHER A, GILLNERM, KANNENGIESSERM, EPPIG T– KOEV K–Sofi a ASOKLIS R–Vilnius GALGAUSKAS S, LIUTVINAITER, JUODKAITEG, TUTKUVIENE J, LIM FPM, ANG M, HTOON H, TAN D, MEHTA J–Singapore ASOKLIS R–Vilnius JURKUTE N, PAJAUJIS M, GALGAUSKAS S, KRASAUSKAITE D, Riyadh, Cardiff AKHTAR S, GUGGENHEIMJ, ALKATAN H, KIRAT O, ALMUBRAD T– Bologna CELLINI M, STROBBEE, GIZZIC, BALDUCCIN, CAMPOSEC– ARDAN T–Prague KGF, TGFß1 and VEGF secretionofkeratocytes invitro margin dissectedcorneas ultrastructural comparative analysisonbothwhiteandclear Big bubbletechniquedissectionplane: histologicaland in organculture Rabbit, rat andpigcorneas: maincharacteristics andstorage motorization andpressuremonitoring new medicaldevicesisneededmorethanever severe dryeyesyndrome anterior segmentOCTCasia1000 corneal surfaceinbullouskeratopathy eyes residents ofLithuania endothelial keratoplasty (dsaek) thickness ineyesfollowingdescemetstrippingautomated cataract orprimary openangleglaucoma endothelial cellsinhealthypatientsandwith keratoconus epithelium uponUVradiation THURSDAY 55 EVER 2012 Programme book 56 EVER 2012 Programme book 04Usefulnessoftheopticalcoherencetomography Spectralis® T094 Combinedtreatmentsforkeratoconus: anumericalapproach T093 Infl uence ofintraocular pressureonthephotorefractive T092 Abilityofkeratoconus matchindexandkeratoconus match T091 Causes ofintracorneal ringsegmentsexplantation T090 Laser subepithelialkeratomileusis (LASEK)versus T089 Ukraine implantationresultsofcollagen-based T088 BostonKeratoprosthesis (Type I): visualprognosisand T087 11Functionalandbiomechanical changesinkeratoconic T101 Graft thicknessandvisualacuityafterautomated endothelial T100 Cornealectasiaafterexcimersurgeryandthe T099 Cornealhystomorphologyandmyopicregressioninpatients T098 SubBowman’s keratomileusis forthecorrectionof T097 Revisitingcornealstorage usingabioreactor: T096 Adaptingadermatologicalmulti-laserfl uorescent confocal T095 16:45 - 18:00 POSTER SESSION1 POSTER 16:45 -18:00 THURSDAY 5 and6mmindiameter corneas afterimplantationofintracorneal ringsegments keratoplasty mandelbrot B. fractal theoryinophthalmology after LASIKinthelongfollow-upperiod anisometropia afterpenetrating andlamellarcornealsurgery proof ofconcept microscope forophthalmologyapplications corneal pathology anterior segmentmoduleinthediagnosisandmonitoringof keratectomy formyopiacorrection. anumericalanalysis and healthycorneas probability inthedifferenciationofformefrustekeratoconus correct myopicastigmatism femtosecondsub-Bowmankeratomileusis (FSBK)to rabbits bioengineered substitutesofdonorcornealallografts in complications PERIS-MARTINEZ C, ARGUDO M, ESPANA-GREGORI E–Valencia RABOT A, SOLER V, FOURNIEP–Nice, Toulouse St.-Petersburg KACHANOV ANDRE, NIKULINSERGE, BAUER SVETA, ZIMINBORIS– BAUER SVETA, ZIMINBORIS–St.-Petersburg NIKULIN SERGE, KACHANOV ANDRE, CHURAKOV TIMUR, FRUSCHELLI M–Siena MENICACCI F, MENICACCI FL, MENICACCI C, BATISTI C, ESPOSTIG, ACQUART S, PISELLIS, THURET G–Saint-Etienne GAIN P, BERNARD A, NEFZAOUI C, CAMPOLMIN, GRIOT O, CAMBAZARD F, CAMPOLMIN, GAINP, THURET G–Saint-Etienne GRIOT O, GRIVETD, ESPINASSEM, PERROT JL, LABEILLEB, RAMIRO P, MATEO J, CASASP, PADGETT E–Zaragoza JIMENEZ DELRIOB, DELBUEYMA, CRISTOBAL JA, CRUZ N, Zaragoza, Madrid ASCASO F, CRUZ N, LAVILLA L, JIMENEZB, PEIROC, PALOMINO C– DEL BUEYMA, LANCHARESE, CRISTOBAL JA, CALVO B, CASASP, PALOMINO C–Zaragoza, Madrid CASAS P, ASCASO F, CRUZ N, JIMENEZB, DOBLAREM, DEL BUEYMA, LANCHARESE, CALVO B, LAVILLA L, CRISTOBAL JA, DELBARRE M, LUSSATO M, RIGAL-SASTOURNE JC–Clamart GARCIA-GONZALEZ M, TEUS MA–Madrid CANADAS SUAREZ P, ARRUABARRENA C, HERNANDEZ-VERDEJOJL, TEUS MA–Madrid CANADAS SUAREZ PILAR, IGLESIASMLUZ, GARCIA-GONZALEZ M, GRIFFITH M–Odessa, Linköping BOYCHUK IRYNA, PASECHNIKOVA NV, LEUSM, BUZNYKOI, DE LAPAZ M, STOIBER J, MICHAELR–Barcelona, Salzburg 18We don’t graft asmanyendothelialcellswethink T108 Comparisonofdecellularizationmethodsforhumancorneal T107 Clinical andtherapeutic aspectsofvernalkerato T106 Monochromaticaberrations inchildrenandyouth T105 T104 The currentpractice andresearchesoforthokeratology T103 Interest ofendosaver®usingonendothelialgraft T102 16Cultivating oral mucosaepithelialtransplantation (COMET) T116 Treatment ofligneousconjunctivitswithsubconjunctival T115 Epithelialthicknessandstructureinpatientswith T114 Biocompatibleofhumanacellularcorneamatrix T113 Targeting hostkinasesforthetreatmentofherpeskeratitis T112 Infl uence ofculturetimeonmaintenancelimbalepithelial T111 T110 We don’tgraft asmanyendothelialcellswethink T109 DUMOLLARD JM, GAINP, THURET G–Saint-Etienne HE Z, PERRIERE, CARAG, CAMPOLMI N, FORESTF, PEOC’HM, LAZREG S–Blida MOCKO L, WYLEGALA E, ZAJAC M–Katowice, Wroclaw LAIHIA JK, KAARNIRANTA K–Turku, Kuopio LEINO L, JAUHONEN HM, KARIE, PYLKKäNENL, POUTANEN J, LU F–Wenzhou, Zhejiang Marseille GUENOUN S, PROUSTH, CONRATH J, RIDINGSB, HOFFART L– WYLEGALA E–Katowice DOBROWOLSKI D, WOWRA B, ORZECHOWSKA-WYLEGALAB, GABISON E, DOANS, AJZENBERG N, COCHEREAU I–Paris WOJCIK L–Katowice ORZECHOWSKA-WYLEGALA B, ORSKIM, SMEDOWSKI A, WOWRA B, WYLEGALA E, DOBROWOLSKID, NASINNYK I, PASYECHNIKOVA N, LEUSM–Odessa ALEKSEEV O, JENNINGSS, AZIZKHAN-CLIFFORD J–Philadelphia BORDERIE V–Paris GHOUBAY D, SANDALIO, GOLDSCHMIDTP, BULLETJ, LAROCHEL, ZURRIA M–Casoria-Naples GARRAUD O, THURET G, GAINP–Saint-Etienne TRONE M, NEFZAOUI C, ALDOSSARY M, CAMPOLMIN, ACQUART S, THURET G, GAINP–Saint-Etienne NEFZAOUI C, TRONE M, CAMPOLMIN, ACQUART S, THEILLIERE C, counts tellus (Part 1): whatearlypost-operative endothelialcell lenticules conjunctivitis in Algeria different cycloplegicconditions clinical study healthy adults–resultsfromarandomised phase1 Cis-urocanic acideyedropsaresafeandwelltolerated in in China reconstruction followed bypenetrating keratoplasty (PK)inocularsurface fresh frozenplasma(ffp): aboutthreeseverecases congenital aniridiaafterCOMETprocedure progenitors intheexplantculturesystem recovery Cornea innervation: fromphysiologictodrug-induced cultured allograft inthesamepatient (part 2): comparisonofcelllossafterautograft andorgan OTRSSIN1 16:45 -18:00 SESSION1 POSTER Andrzej GRZYBOWSKI Dominique BREMOND-GIGNAC, Marko HAWLINA, Moderators: History / Paediatric Neuro-ophthalmology / Strabismology / 13Opticalcoherencetomography: awindowintothebrain of T123 Jugularvenousthrombosissecondarytoidiopathic T122 Bilateral non-arteriticischemicopticneuropathydueto T121 Vincristine-induced unilateral ptosis T120 Lyme borreiosiswithocularmanifestationsduringchildhood T119 Use of widefi eld digitalretinalimaging(RETCAMII)in T118 Comparative studyofthreeexophthalmometersand T117 10Retinalcirculationand intracranial pressure in idiopathic T130 Extraocular bloodfl ow inmultiple sclerosis (MS)patients T129 Axonallossinmultiplesclerosis: amorphologicaland T128 Retinathicknessmeasurementsprovideasensitive T127 Three-dimensional geometriesrepresentingtheretinal T126 Relationshipbetweenretinalnervefi ber layerthickness T125 ContributionofMRIincasesisolatedmydriasis: T124 intracranial hypertension functional analysisofretinalnervefi bbers and specifi c diagnostictoolinParkinson’s disease and healthyeyes nerve fi ber layerinmultiplesclerosis, opticneuritis, and theduration andseverityofparkinsondisease description ofneurovascular confl icts. schizophrenic patients myelofi brosis: arare causeofbilateral papilledema excessive useoftransdermal estrogenbytransgender patient period paediatric retinaldiseases computed tomographic biometry PIERRU A, VIGNAL C, GENEVOIS O, PAQUES M–NICE, Paris, Rouen JANKOWSKA-LECH I–Warsaw FAVARD A, MAJZOUBS, NOCHEZ Y, PISELLAPJ–Tours PABLO L–Zaragoza ALARCIA R, ROCHEJC, SERALM, POLO V, LARROSAJM, FERNANDEZ-PEREZ S, SATUE M, IDOIPEM, FUERTES I, OTIN S, GARCIA MARTIN E, BAMBOM, PRIETO E, DELAMATA G, PABLO L–Zaragoza, Madrid LARROSA JM, POLO V, GONZALEZ-GARCIAC, GARCIA-FEIJOOJ, EGEA MC, FERNANDEZ-PEREZ S, HERREROR, IDOIPEM, OTIN S, GARCIA MARTIN E, DELAMATA G, SATUE M, BAMBOM, ARA M, CABEZÓN L, IBANEZJ, DELBUEYMA, LÓPEZDEL VAL J–Zaragoza JIMENEZ DELRIOB, ASCASO F, CRISTOBAL JA, PÉREZD, TRECHOT F, BRAUN M, CLOCHE V, ANGIOI K–Nancy LOBO A, CRISTOBAL JA–Zaragoza CABEZON L, ASCASO F, RAMIROP, QUINTANILLA MA, GUTIERREZL, Zaragoza MATEO J, JIMENEZB, ASCASO F, LAVILLA L, PEIROC, IBANEZJ– WIERICKX K, T’SJOEN G–Ghent DE ZAEYTIJDJ, DEPOTTER R, MONSTREYS, LEROY BP, HEYLENSG, BATTA B, TRECHOT F, GEORGEJL, ANGIOI K–Nancy SPEEG-SCHATZ C–Strasbourg SAUER A, HANSMANN Y, JAULHAC B, BOURCIER T, PINELLO L, MAZZAROLOM–Padua ROBERT PY–Limoges, Brive DELMAS J, MARTIN S, LOUSTAU JM, BOURMAULT L, ADENIS JP, 17Visual functionimprovementafteridebenonetherapy in T137 Postural controlinchildrenwithearlystrabismus without T136 Aicardi syndromewithmacrocrania T135 Dyslexiaandeyemovements T134 Aninteresting caseofMohr-Tranebjærg Syndrome T133 T132 Anewtechniqueofnoninvasive evaluation ofthe T131 T143 T142 ComparisonoflatencyP100wave inchildren T141 Alteredfunctionalconnectivityofprimaryvisualcortexin T140 Neurotrophickeratopathy associatedwithcongenital T139 Analysisofchangesinthemaculaandretinalnervefi ber T138 rf rf ROCHE O, DUFIERJL, KAPOULAZ–Paris ORSSAUD C, GAERTNER C, CREUXC, ESPINASSE-BERRODMA, DENION E–Caen DEGOUMOIS A, LUX AL, RYSANEK B, PONTEK, EMERY E, TRAVERSO CE–Genoa VAGGE A, CAVANNA M, IESTERM, PARISIO A, BURTOLO C, FERREIRA EL–Rome, JuizdeFora HALFELD FURTADO DEMENDONCAR, ABBRUZZESE S, Montreal CHINNERY PF–Harpenden, Munich, Liestal, Newcastleupon Tyne, RUDOLPH G, KORTüM K, ROULEAU J, COPPARD N, MEIER T, GALLENMüLLER C, BAILIEM, NWALI N, GRIFFITHS PG, FSADNI MG, KLOPSTOCK T, METZG, YU-WAI-MAN P, BüCHNERB, GENEVOIS O, MURAINEM, PAQUES M–Rouen, Paris DYKXHOORN D, GOLDBERGJL–Miami ALSHAMEKH S, HERTZ J, DEROSAB, UDDINS, PATEL R, SALEROE, DECOCK C–Ghent BUIJSROGGE M, CLAERHOUTI, DELBEKEP, WALRAEDT S, PILECKI W, RUSIECKI L, KALKAD, SZAWROWICZ T–Wroclaw YAN X, LINX, ZHOU Y, LIU Y, JIANG T–Guangzhou, Beijing PUEYO V–Zaragoza SATUE M, BAMBOMP, ARA M, EGEAMC, FERNANDEZ-PEREZS, HERRERO LATORRE R, GARCIA-MARTIN E, DELAMATA G, MINGUEZ E–Zaragoza CRUZ N, CASASP, ASCASO F, CRISTOBAL JA, DELBUEYMA, ORSSAUD C, ROBERT M, ROCHEO, DUFIERJL–Paris Leber hereditaryopticneuropathy amblyopia Leber’s HereditaryOpticNeuropathy Persistence oftreatmenteffectidebenonein intracranial pressurewithretinal vesselanalyzer conditions induced pluripotentcellsinfeederandfeeder-free Generating humanretinalganglioncellsfrom infantile hemangiomas The useofpropranolol inthetreatmentofperiocular demonstrating some pathologicaldisorders adult comitantstrabismus usingresting-functionalmri agenesis ofthecorpuscallosum Alzheimer’s disease(AD) layer byopticalcoherencetomography inpatientswith THURSDAY 57 EVER 2012 Programme book 58 EVER 2012 Programme book 80 93 EVENINGSESSION 18:00 -19:30 THURSDAY 19:00 2826 18:50 2825 2824 18:40 2823 18:30 2822 18:20 18:10 2817 2816 19:12 19:00 18:48 2813 18:36 18:24 18:12 18:00 80 2821 18:00 I Retinaloximetry-challenges, possibilitiesandfuture outlook RV SIS MEVICR.net: Clinicaltrialsindiabeticretinopathy andretinal JM 2811 2815 2814 2812 Rebekka HEITMAR, EinarSTEFANSSON Jose CUNHA-VAZ vascular disease Retinal oxygen saturation inhealthanddisease Open discussion FIGUEIRA J–Coimbra monotherapy inthetreatmentofpatientswithhighriskproliferative diabeticretinopathy. PROTEUS ranibizumab 0.5mgintravitreal injectionspluspanretinalphotocoagulation(PRP)versusandPRPin Prospective, randomized, multicenter, openlabel, phaseII/IIIstudytoassesseffi cacy andsafetyof CUNHA-VAZ J–Coimbra EUROCONDOR –EUFP7Project neuroprotective drugsadministeredtopicallytopreventorarrestDiabeticRetinopathy. A multicentric, prospective, phaseII-III, randomised controlledtrialtoassesstheeffi cacy of Neurodegeneration asanearlyeventinthepathogenesisofDiabeticRetinopathy: CUNHA-VAZ J–Coimbra dures. ProtocolnºECR-RET-2010-02. ClinicalTrials.gov Identifi er: NCT01145599 Identifying progressionofretinaldiseaseineyeswithNPDRdiabetestype2usingnon-invasive proce- MALTMAN J–Buckinghamshire Perspectives fornewtreatmentsat Allergan LAMBROU G–Strasbourg Investigator-initiated trials: acorporate perspective SCHLINGEMANN RO–Amsterdam Novel therapeutic targetsindiabeticretinopathy POURNARAS CJ–Geneva Oxygen distributionintheretina GIBSON J–Birmingham Clinical aspectsofretinaloximetry HUDSON C, PATEL SR, SHAHIDI AM, KULASEKARAS, FLANAGAN JG–Waterloo, Toronto Extraneous factorsaffectingretinaloximetry STEFANSSON E, GEIRSDOTTIR A, HARDARSONS–Reykjavik Oxygen metabolisminagerelatedmaculardegeneration BEK T–Denmark Diabetic retinopathyandoximetry HAMMER M, HELLER T, JENTSCHS, MANDECA A, SCHWEITZERD, MüLLERUA–Jena Light fl icker andoxygen saturation indiabetes HARDARSON S–Reykjavik Euterpe Uranie VNN ESO 18:00 -19:30 EVENING SESSION 91 2855 2854 19:12 2853 18:54 2852 18:36 18:18 2847 2846 19:12 2845 19:00 2844 18:48 18:36 2842 18:24 18:12 2835 2834 19:12 2833 18:54 2832 18:36 18:18 80 2831 18:00 80 2851 18:00 2841 18:00 POcular immunology for 360° from basic science to clinical practice IM FP Aslamellaraspossible: anupdateonpros andconsofcorneal SIS I Eyeandbrain inglaucoma G SIS COS 2843 lamellar surgery Talin BARISANI-ASENBAUER, UwePLEYER Jean-Jacques GICQUEL, MarioNUBILE Georg MICHELSON, Doina GHERGHEL rf ARAIE M–Tokyo Neuroprotective therapy ofthevisual pathway inglaucoma CORDEIRO MF–London Neurodegeneration ofthevisualpathway inglaucoma GHERGHEL DOINA–Birmingham Autonomic nervoussystemdysfunctioninglaucoma MICHELSON G, WAERNTGES S, ENGELHORN T, HORNEGGERJ, DöRFLER A–Erlangen Quantitative assessmentofthevisualpathway byDTI-MRIinGlaucoma JONAS JB–Erlangen Intracranial pressureandglaucoma NGUYEN AM, DENISP, GRANGEJD, KODJIKIAN L–Lyon PAPADIA M, HERBPRT CP–Lausanne Central serous chorioretinopathymisdiagnosedasposterioruveitis: frequencyandconsequences KNECHT P, MOKRIMR, HERBORT CP–Lausanne Secondary choriocapillaritisininfectiouschoroiretinitis BINTNER NORA, INIC-KANADA A–Vienna, Belgrade BARISANI-ASENBAUER T, BELIJS, STOJANOVIC M, MARINKOVIC E, STOJICEVIC I, MONTANARO J, STEINE, Immune responsestomodelantigenelicitedbyimmunizationviaconjunctiva associatedlymphoidtissue BOURCIER T–Strasbourg, Dijon, Grenoble SAUER A, PFAFF A, CREUZOT-GARCHER C, DALLEF, CHIQUETC, PELLOUXH, SPEEG-SCHATZ C, CANDOLFIE, IL-17A asapossibletargetofanti-infl ammatory andanti-parasitic treatmentintoxoplasmic uveitis KAUPPINEN A, LAAKSON, KINNUNENK, SALMINEN A, KAARNIRANTA K–Kuopio Infl ammasome activation byoxidative stressin ARPE-19 cells FERAOUN N, HESBERT A, MONNETD, BREZIN A, BATTEUX F–Paris New therapeutic approachesinuveitis GICQUEL JJ–Poitiers Is therestillroomforpenetrating keratoplasty in2012 SCORCIA V–Catanzaro New trendsinendothelialtransplantation: DSAEKvsDMEK NUBILE M–Chieti The interestofimagingforcorneallamellargrafting TOUBOUL D–Bordeaux Microkeratome vsfemtosecondlaserassistedendothelialtransplant cut BOURGES JL–Paris Interface qualityofendothelialkeratoplasty buttonsobtainedwithoptimisedfemtosecondlasersettings or falsepositive? Atypical panuveitisparasitic andHerpesvirusco-infectioninimmunocompetentadults: realco-infection THURSDAY Thalie Erato Clio 59 EVER 2012 Programme book

VNN ESO 18:00 -19:30 EVENING SESSION 90 2884 2883 19:06 2882 18:44 18:22 2877 2876 19:12 2875 19:00 2874 18:48 2873 18:36 2872 18:24 18:12 2864 19:06 2862 18:44 18:22 80 2861 18:00 80 2881 18:00 2871 18:00 I Metastaticdiseasefrom uvealmelanoma: prediction, detection PO SIS Retinalvesselanalysis-biomarkers andnewdevelopments SIS I Educationalcasepresentations inophthalmicgenetics MBGE SIS PBP 2863 and treatment Sarah COUPLAND, BertilDAMATO Leopold SCHMETTERER Bart LEROY, Graeme CMBLACK LEROY BP–Ghent Inherited retinaldisease VOTRUBA M–Cardiff Mitochondrial opticneuropathies BLACK GCM–Manchester Syndromic ophthalmicgenetics HALL G–Manchester Diffi cult counsellingissues PIPERNO-NEUMANN S–Paris Therapeutic optionsinmetastaticuvealmelanoma KEILHOLZ U–Berlin Metastatic uvealmelanoma: A liverdiseaseorasystemicdisease? KIVELÄ T, ESKELINS–Helsinki Staging ofuvealmelanomametastases ANGI M, KALIRAIH, DAMATO B, COUPLANDSE–Liverpool Serum biomarkers ofmetastaticdisease: currentpractice andfutureperspectives DAMATO B, COUPLANDSE–Liverpool Prediction ofmetastasis PIPERNO-NEUMANN S, LAURENT C–Paris SAULE S, COUTURIERJ, STERNMH, MARIANIP, DESJARDINSL, ROMAN-ROMAN S, BARILLOT E, Genetic analysesofuvealmelanomametastases COUPLAND SE, KALIRAIH, DODSON A, DAMATO B–Liverpool Biology ofmetastaticdisease SCHMETTERER L–Vienna Retinal vesselanalysisinanimalmodels HAMMER M–Jena Retinal vesselanalysisandoximetry -technicaladvances andclinicalapplications GARHOFER G–Vienna Combining vesselanalysiswithDopplerOCT SCHMETTERER L–Vienna Retinal vesselsasbiomarkers Gallieni 1&2 Gallieni 4 Gallieni 3 THURSDAY 61 EVER 2012 Programme book

AL ONN ESO 07:15 -08:15 EARLY MORNINGSESSION Moderator: Albert J. AUGUSTIN 08:00 07:45 07:30 07:20 07:15 Panel discussion Macular holes: anoptionforpharmacologicmanagement Vitreomacular traction: resolutionwithenzymaticvitreolysis Vitreomacular adhesion: pathologyandimplications Welcome andintroductions BREAKFAST CIS vitreomacular traction andmacular hole An innovativenewapproach totreating Uranie FRIDAY 65 EVER 2012 Programme book 66 EVER 2012 Programme book 08:15 - 09:45 FIRST MORNINGSESSION FIRST 08:15 -09:45 FRIDAY 92 3235 09:27 3233 09:09 3232 08:51 08:33 3227 09:25 3226 09:15 3225 09:05 3224 08:55 3223 08:45 3222 08:35 08:25 3215 3214 09:27 3213 09:09 08:51 08:33 81 3211 08:15 81 3231 08:15 3221 08:15 I Central serous chorioretinopathy: what’s new? RV SIS I Neuronal deathprocesses inretinal disease PBP SIS EVICR.net: Clinicaltrialsin AMD andrare diseases JM 3234 3212 Francine BEHAR-COHEN, Alain GAUDRIC Neville OSBORNE Jose SAHEL CSCR/ DRPE: asamedisease? GRUS F–Mainz Neuroprotection andautoimmunity in glaucoma VAVVAS D, MURAKAMI Y, KAYAMA M, MILLERJW–Boston RIP Kinases, necroptosisand redundancyinneuronalcelldeath ALARCóN-MARTíNEZ L, AVILéS-TRIGUEROS M, AGUDO-BARRIUSO M, VILLEGAS-PéREZ MP–Murcia VIDAL-SANZ M, SALINAS-NAVARRO M, VALIENTE-SORIANO FJ, ORTíN-MARTíNEZ A, NADAL-NICOLáSFM, Retinal neuronaldeathcausedbyocularhypertension BAGNOLI P, DALMONTEM–Pisa Neuroprotective factorsagainstretinalinjuryinresponsetohypoxia: newperspectives RUSSO R, BAGETTA G, CORASANITIMT–Cosenza, Catanzaro Autophagy: anewway toretinalneuroprotection Open discussion HOLZ F, SCHMITZ-VALCKENBERG S, FLECKENSTEINM–Bonn Sparing ofthefoveaingeographic atrophy HOLZ F, SCHMITZ-VALCKENBERG S, CHARBELISSAP–Bonn Stargardt maculardystrophy NAOR J–Emeryville Study Assessing Double-masKed UveitistReAtment(SAKURA) RICH C–Fort Worth Perspectives fornewtreatmentsat Alcon -part2 BURIAN G–Basel Perspectives fornewtreatmentsatNovartis SAHEL JA–Paris Gene therapy inrare diseases HOLZ F, FLECKENSTEINM, SCHMITZ-VALCKENBERG S–Bonn Markers ofdiseaseprogressioninatrophic AMD BEHAR-COHEN F–Paris Other therapeutic options RUIZ MORENOJM–Alicante Photodynamic therapy inthetreatmentofCSCR POURNARAS CJ–Geneva Role ofcorticosteroidsinCSCR BANDELLO F–Milano Correlation betweenspectral-domain OCTfeaturesandfundusauto-fl uorescence patternsinCSCR GAUDRIC A–Paris Euterpe Uranie Erato IS ONN ESO 08:15 -09:45 MORNINGSESSION FIRST 92 3265 3264 09:27 3263 09:09 3262 08:51 08:33 3255 3254 09:27 3253 09:09 3252 08:51 08:33 3244 3243 09:21 3242 08:59 08:37 81 3241 08:15 81 3261 08:15 3251 08:15 I Structure andfunctioninglaucomamanagement G SIS Beyondagerelated maculardegeneration SIS I Controversies inneuro-ophthalmology andpaediatrics NSPH SIS IM Ingeborg STALMANS, LucaROSSETTI Piergiorgio NERI, Andrew DICK Andrzej GRZYBOWSKI, Francisco ASCASO CASTELO-BRANCO M, REIS A–Coimbra Controversies relatedtomfVEPuse ASCASO F–Zaragoza neurodegenerative diseases Is theeyeawindowtomind?RNFLthicknessmeasurementsbyOCT asabiomarker for GRZYBOWSKI A–Poznan Atropine useinchildhoodmyopiatreatment MOJON D–Zurich Strabismus surgery: minimallyinvasive ornot? HAWLINA M–Ljubljana GCA diagnosiscontroversies STALMANS I–Leuven Into practice: clinicalexamples SUNARIC MEGEVAND G–Geneva Linking ittogether: structure-functioncorrelation BRON A–Dijon Detecting progressionusingstructural measurements ROSSETTI L–Milano Detecting progressionusingvisualfi elds STALMANS I–Leuven Why shouldwecareaboutrate ofprogressioninglaucomamanagement? LUHMANN U–London Macrophages andtheageingdiseasedretina KEANE PA–London Imaging andtheageingretina XU H–Belfast Parainfl ammation andtheageingretina CHAN C–Bethesda Molecular pathologyofinfl ammation inage-relatedmaculardegeneration Gallieni 1&2 Thalie Clio FRIDAY 67 EVER 2012 Programme book 68 EVER 2012 Programme book 08:15 - 09:45 FIRST MORNINGSESSION FIRST 08:15 -09:45 FRIDAY 91 3286 3285 09:15 3284 09:03 3283 08:51 08:39 08:27 3274 09:28 09:11 08:54 08:37 81 3271 08:15 81 3281 08:15 I Myopia–genesis, prevalence andcontrol EOVS SIS PUvealmelanoma PO FP 3282 3275 3273 3272 Franziska RAUSCHER Martine JJAGER, Ann SCHALENBOURG AMIRYAN AG, SAAKYAN S–Moscow Ultrasound featureschangingduringuvealmelanomalocaltreatment TURCOTTE S, BERGEROND, ROUSSEAU A, MOURIAUX F–Quebec Primary transpupillary thermotherapy forsmallsuspiciouschoroidalnevi KLETTNER A, FABY H, HILLENKAMPJ, ROIDERJ–Kiel pigment epithelium–implicationsfortranspupillary thermotherapy inuvealmelanoma Temperature-dependent vascular endothelialgrowthfactor(VEGF)inductioninhumanretinal DE LANGEMJ, VERSLUIS M, JAGER MJ, LUYTENGPM, VAN DER VELDEN PA–Leiden Pre-clinical analysisofCrizotinibinuvealmelanoma RAMASAMY P, HENRY M, LINGE A, HORGANN, MURPHYC, CLYNES M, KENNEDY S, MELEADY P–Dublin Proteomic analysisofuvealmelanoma JAGER MJ, VAN ESSEN TH, BRONKHORSTIHG, VERDUYN W, ROELENDL, MAAT W, LUYTENGPM–Leiden A comparisonofHLAgenotypewithinfl ammation inuvealmelanoma KRATZER T–Aalen (New) Approaches toreduceprogressionofmyopiawithspectaclesfromCarlZeiss Vision ATCHISON DA–Kelvin Grove Correction ofperipheral refractive errorsanditsimpactonvisualperformance OHLENDORF A–Aalen The infl uence ofperipheral refractive errorsonmyopiadevelopment SANKARIDURG P–Sydney Myopia -Itsetiologyandprevalence SCHAEFFEL F–Tübingen Visual, ocularandrefractive developmentinchildren Gallieni 3 Gallieni 4 ENT ESO 09:50-10:35 SESSION KEYNOTE 10:30 00 3311 10:00 09:50 Award oftheEVER certifi cate ofhonour ALLIKMETS R–New York Genetics andtreatmentofStargardtdisease Introduction byBartLEROY KEYNOTE LECTURE KEYNOTE Rando ALLIKMETS Genetics andtreatment ofStargardt disease Uranie FRIDAY 69 EVER 2012 Programme book 70 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 FRIDAY 20 3437 3436 12:06 3435 12:00 11:48 3433 11:36 11:24 3432 11:12 3414 3413 11:54 3412 11:36 11:18 10 3431 11:00 3421 11:00 10 3411 11:00 MEVICR.net: Readingcentres JM I Endophthalmitisfrom theocularsurfacetovitreous: RV SIS PFrom bankingtografting COS FP

3434 Tunde PETO Christophe CHIQUET, Alain BRON Vincent BORDERIE, ChristopherLIU prevention, diagnosis, treatment rf rf HE Z, CROUZETE, PISELLI S, CAMPOLMIC, FORESTF, PEOC’HM, DUMOLLARDJM, GAINP, THURET G–Saint-Etienne IRION L, MCKEEH, BRAHMA A, CARLEYF–Manchester GRUENERT A, ROSENBAUM K, GEERLINGG, FUCHSLUGER T–Duesseldorf Impact ofcornealdonorpost-mortemtimeontherate ofculturemediumcontaminations PEREZ-PAYÀ E, LAGUNAS C–Barcelona, Valencia, Bellaterra HERRERO C, MARCHANS, TRAVER E, MON Inhibition of Apaf-1 asapotentialtherapeutic strategy toimprovecornealquality THURET G–Saint-Etienne HA THI BM, HEZ, CAMPOLMIN, PISELLIS, GAINP, PEOC’HM, DUMOLLARDJM, ACQUART S, GARRAUD O, Characterization ofcellcyclemodifi cations inducedbyelectricpulsesinhumancornealendothelium Saint-Etienne JUMELLE C, CAMPOLMIN, BERNARD A, PISELLIS, AUDOUARD E, GRANIERJ, SODERH, GAINP, THURET G– laser pulses: proofofconcept Delivery ofmoleculesintocornealendotheliumusingnanoparticlesactivated byfemtosecond BORDERIE V, BULLETJ, TOUZEAU O, BASLIE, LAROCHEL–Paris Risk factorsforendothelialcelllossaftercornealtransplantation BRON A–Dijon Management ofpostoperative endophthalmitis CHIQUET C–Grenoble Microbiological diagnosisofbacterialendophthalmitis LABETOULLE M–LeKremlinBicêtre Is therearational fortheuseoftopicalantibioticsbeforeandafterintravitreal injections MONTAN P–Stockholm Prevention ofendophthalmitisincataract surgery both whiteandclearmargindissectedcorneas Big bubbletechniquedissectionplane: histologicalandultrastructural comparative analysison Rabbit, rat andpigcorneas: maincharacteristics andstorage inorganculture PETO T, EVICR.NETREADINGCENTREEXPERT COMMITTEE–London EVICR.net ReadingCentreNetwork TAVA R, ORZAEZ M, SANCHOM, GUIMERÀ A, VILLA R, Euterpe Uranie Erato EODMRIGSSIN 11:00 -12:30 SECOND MORNINGSESSION 20 3466 3465 12:00 3464 11:48 3463 11:36 3462 11:24 11:12 3454 3453 12:06 3452 11:44 11:22 3444 3443 12:06 11:44 11:22 10 3451 11:00 3441 11:00 10 3461 11:00 I Controversies incurrent conceptsofglaucoma G SIS Research challengesofanti-microbial oculartherapy SIS I Vascular tumours oftheretina and choroid PO SIS IM 3442 Tero KIVELÄ, Ann SCHALENBOURG Sayeh POURJAVAN, Andrzej GRZYBOWSKI Regis KOWALSKI GAUDRIC A, DAMATO B, DESJARDINSL, ZOGRAFOSL–Paris, Liverpool, Lausanne therapeutic approach Debate: Epi-andperipapillarycapillaryhemangiomas andhemangioblastomas: insearchofanoptimal ZOGRAFOS L–Lausanne Choroidal hemangioma: photodynamicvs. radiotherapy GAUDRIC A–Paris Von Hippel-Lindau’s disease: general andocularmanagement KIVELÄ T, LINDAHLP, POLVI A, MAJANDER A, MÄKITIEO, LEHESJOKI AE, LINNANKIVI T–Helsinki Coats’ reactionandangiomasoftheretinafrommutationsaffectingtelomeremaintenance MUNIER F–Lausanne Coats’ disease: classifi cation andcurrenttreatment SCHALENBOURG A–Lausanne Vascular tumoursoftheretinaandchoroid: classifi cation, diagnosisandtreatment KOTECHA AACHA–London Biomechanical conceptsinGlaucoma MOZAFFARIEH M–Basel Non-IOP loweringtreatment OSBORNE N–Oxford Pathogenesis ofglaucoma: doeslightplayapartintheprocess? GRZYBOWSKI A–Poznan Historical conceptsofglaucoma KOWALSKI R–Pittsburgh Is antibioticresistanceamajorprobleminophthalmology? SHANKS RM, ROMANOWSKIE, KOWALSKI R–Pittsburgh Biofi lms inocularinfection ROMANOWSKI E–Pittsburgh Is thereananti-adenoviral drugonthehorizon? RAJU L–Pittsburgh Clinical challengesofocularanti-microbialtherapy Gallieni 1&2 Thalie Clio FRIDAY 71 EVER 2012 Programme book 72 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 FRIDAY 20 3486 12:00 3484 11:48 11:36 11:24 3482 11:12 3476 3475 12:00 11:48 3473 11:36 3472 11:24 11:12 10 3471 11:00 10 3481 11:00 PColourvision EOVS FP PCataract surgery LC FP

3485 3483 3474 Werner SPILEERS, MiguelCASTELO-BRANCO Marie -José TASSIGNON, RafaelI. BARRAQUER Predicting chromaticsensitivityinnormaltrichromatsandsubjectswithcongenitaldefi ciency AYCHOUA N, JUNOY MONTOLIO F, JANSONIUSNM–Groningen Infl uence ofmultifocalintraocular lensesonstandardautomatedperimetrytestresults MAINDRON C, LELOIRM, KOHANDANI TAFRESHI M, LAMARDM, COCHENERB–Brest Contribution of3DanteriorsegmentreconstructionbyrotativeUBMtothesizingphakicIOL MICHAEL R, VRENSEN G, BARRAQUER RI–Barcelona, Leiden Morphology ofage-relatedcuneiformcorticalcataracts: thecaseformechanicalstress. BARREAU G, MOUNIERM, MARINB, ADENIS JP, ROBERT PY–Limoges endophthalmitis, aFrench study Intracameral cefuroxime injectionattheendofcataract surgeryreducestheincidenceof DALY MK, SIRACUSE-LEE D, LEGUTKO PA–Boston, Novato rate duringcapsulorrhexis portionofcataract surgeryintrainees Effi cacy ofsurgicalsimulatortraining versustraditional wetlabtraining onthecomplication DE LAPAZ M, BARRAQUER J, ALVAREZ DE TOLEDO JP–Barcelona Evolution ofcataract surgery: Barraquer experience KEUKEN A, RODRIGUEZ-CARMONAM, BARBURJL–London Detection ofcolourvisionchangesinpatientswithsystemicdiseasesthatcanaffecttheeye RODRIGUEZ -CARMONAM, KONSTANTAKOPOULOU E, KEUKEN A, BARBURJL–London, Kestern Age-corrected monocularlimitsofnormaltrichromacy KRASTEL H, LEERSS, KALTAKJI F, KIRCHHUEBELR, JONASJB–Mannheim, Sulzbach, Wetzlar Effects ofviewingtimepseudoisochromaticplates KONSTANTAKOPOULOU E, BARBURJL–London Colour visionasascreeningtoolforsub-clinicalretinaldisease BI W, TSUJIMURA S, PLANTG, BARBURJL–London, Kagoshima The contributionoftherod/melanopsindrivenganglioncellstodynamicpupillightrefl ex response BARBUR JL, RODRIGUEZ-CARMONAM–London Gallieni 3 Gallieni 4 UCTM ESO 12:35 -13:35 SESSION LUNCHTIME Moderators: Gabriel COSCAS, Francesco BANDELLO 32 3515 13:35 3514 13:23 3513 13:11 3512 12:59 12:47 23 3511 12:35 End ofsession LOEWENSTEIN A–Tel Aviv Management ofinfl ammation inRVO DE SMETM–Lausanne Infl ammation inuveitis COSCAS G–Creteil Clinical markers ofinfl ammation BEHAR-COHEN F–Paris Early markers ofinfl ammation TADAYONI R–Paris Infl ammation inretinadisease LUNCHTIME CIS LUNCHTIME Focus onInfl ammation inretinal disease Uranie FRIDAY 73 EVER 2012 Programme book 74 EVER 2012 Programme book 13:35 - 15:05 FIRST AFTERNOONSESSION FIRST 13:35 -15:05 FRIDAY 44 3635 3634 14:47 3633 14:29 14:11 13:53 3615 3614 14:47 3613 14:29 3612 14:11 13:53 33 3611 13:35 33 3631 13:35 EVICR.net: General Assembly (members only) JM I Macularsurgery RV SIS I Therapeutics inthepipelineforunmetneedsophthalmology COS SIS 3632 Efstratios MENDRINOS, ConstantinPOURNARAS Thomas FUCHSLUGER, EinarSTEFANSSON Revisiting transconjunctival sutureless25gaugevitrectomyformacularsurgery Erlangen-Nuremberg CORDES A, SCHRAGE N, NASSN, SELS–Potsdam, München, Sankt Augustin, Halle, Cologne, Aachen, STORSBERG J, SCHMIDT C, REHFELDTS, KOBUCH K, MESSNER A, RÖTHGENH, DUNCKERGIW, KNAKM, Synthetic eyeprosthesis PLEYER U–Berlin SEGRAs anewtherapeutic optiononthehorizon? BONINI S–Rome Recombinant NFGfortreatmentofocularsurfacediseases STEFANSSON E, GUDMUNDSDOTTIR B, ASGRIMSDOTTIR G, LOFTSSON T–Reykjavik Nanoparticles fordrugdelivery FUCHSLUGER T–Düsseldorf Gene therapy approachesincornealpathologies MENDRINOS E–Geneva submacular hemorrhagedueto AMD Vitrectomy withsubretinal t-PA, gastamponadeandintravitreal ranibizumab forthetreatmentof POURNARAS CJ–Geneva Morphology ofsurgicalILM-specimensinepiretinalmembranes, macularholes, anddiabeticretinopathy STAPPLER T–Liverpool Clinical andOCToutcomesforfull-thicknesslamellarmacularholesurgery GAUDRIC A–Paris Myopic foveoschisis: OCTfi ndings, surgicalindicationsandresults GOTZARIDIS S, LIAZOSST, MORPHISG–Athens Euterpe Uranie Erato IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 14:35 3665 14:23 3663 14:11 3662 13:59 13:47 3654 3653 14:41 3652 14:19 13:57 3644 3643 14:41 3642 14:19 13:57 33 3641 13:35 33 3661 13:35 3651 13:35 I Recentdevelopmentsinocularbloodfl G SIS ARVO@EVER: Translating ocularimmunologyfrom the JM PAMD RV FP IM

3666 3664 laboratory totheclinic Gisèle SOUBRANE, Anita LEYS Ingeborg STALMANS, LeopoldSCHMETTERER Justine SMITH, Sally ATHERTON TADAYONI R, HOLZF, HEAH TGH, HELDNERS, THE AURA STEERINGCOMMITTEEFOR–Paris, Bonn, Montville, Berlin Retrospective analysisofthereal-worldutilizationranibizumab inwAMD TOLD R, BINDERS, KREBSI, BOLTZ A, SCHMETTERERL–Vienna ranibizumab orbevacizumab inpatientswithneovascular age-relatedmaculardegeneration A randomized observerandsubjectmasked trialcomparingthevisualoutcomeaftertreatmentwith SCHMETTERER L–Vienna, Mannheim, Graz BOLTZ A, JONASJB, PALKOVITS S, TAO Y, RENSCHF, WEGER M, GARHöFERG, FRANTAL S, EL-SHABRAWI Y,exudative age-relatedmaculardegeneration Relevance ofcomplementfactorHpolymorphismsintheresponsetointravitreal bevacizumab in BERENDSCHOT T, TIAN Y, VAN DER VEEN R, MAKRIDAKIM, MURRAY I, KIJLSTRA A–Maastricht, Manchester Lutein decreasescomplementfactorDinage-relatedmaculardegeneration BARBAZETTO I, SORENSONJ, ENGELBERT M–New York age-related maculardegeneration Afl ibercept inclinicalpractice: Evaluation ofthefi rst 50patientstreatedwithantiVEGFtrap for BRETILLON L, SIMONE, ACAR N, BRON A, CREUZOT-GARCHER C–Dijon The LDLreceptorintheretina: themissinglinkinaging, thenewtargetindietaryprevention JONAS JB–Mannheim From retinalvenouspressuretointra-cranial pressureinglaucoma PINTO LA–Lisboa Spontaneous venouspulsationrevisited-relevance toglaucoma? STALMANS I–Leuven Metabolism inglaucomausingretinaloximetry SCHMETTERER L–Vienna Individual ONHbloodfl ow patternsduringchangesinperfusionpressure CHAN C–Bethesda Immunological aspectsofage-relatedmaculardegeneration: implicationsfortreatment BODAGHI B–Paris Regulatory T celltherapy foruveitis MCKENNA KC–Pittsburgh Exploiting theimmuneresponsetohaltprogressionofocularmelanoma PLEYER U–Berlin Translating ocularimmunologyfromthelaboratory totheclinic-keratoplasty - ow andglaucoma Gallieni 1&2 Thalie Clio FRIDAY 75 EVER 2012 Programme book

IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 42 3687 3686 14:29 3685 14:23 3684 14:17 3683 14:05 3682 13:53 13:47 3675 3674 14:47 3673 14:29 3672 14:11 13:53 13:35 33 3681 13:35 PBasicmechanismsinocularpathology PO FP Ocularsurfacedisorders inchildren SIS NSPH 3671 Steffen HEEGAARD, KarinLOEFFLER Jean-Jacques GICQUEL, DominiqueBREMOND-GIGNAC rf rf rf rf ROSNER M, FABIAN ID, PRIEL A, FRIDMANE, GREENBERGG, ROSENN–Tel Hashomer DE KEIZERRJW, AL SABAIN, BAL TA, DEGROOT V–Antwerp, Mechelen COFFIN-PICHONNET S, LANGLOISB, JACOMET PV, PUTTERMAN M, BADELONI, MORAXS, GALATOIRE O–Caen, Paris PHILIPPAKIS E, TOUITOU V, CHARLOTTE F, RIGOLET A, LEHOANGP, BLOCH-QUEYRAT C, BODAGHI B–Paris Ophthalmological manifestationsofIgG4-relateddisease MADIGAN MC, VAN DENBERG C, MORELAND A, LIANGJ, LORDS, DEMIR A, JAISWAL S, JAGER MJ–Sydney, Leiden Macrophage markers andC3dinthecentral &peripheral choroidofyoung, agedand amdeyes MADIGAN MC, MUNOZ-ERAZOL, CONWAY RM–Sydney MOULIN A, NICOLASM, HAMEDANIM, SCHALENBOURG A, ZOGRAFOSL–Lausanne RUNX2 expressioninconjunctival melanocyticproliferations GICQUEL JJ, PISELLAPJ, BREMOND-GIGNAC D–Poitiers, Tours, Amiens Noninvasive assessmentofthetearfi lm stabilityinchildren YEUNG A–Nottingham Limbal stemcelldefi ciency inchildren DOAN S–Paris ’s ocularsurfacediseases The indicationsofcyclosporine A inchildren MORTEMOUSQUE B–Bordeaux Cutaneous andocularsignsofchildhoodrosacea BREMOND-GIGNAC D–Amiens Diagnosis andtreatmentofvernalconjunctivitis Congenital orbitalteratoma A patientwitheyelidandanteriororbitalmyeloproliferative hypereosinophilicsyndrome Idiopathic orbitalinfl ammation: areportof18cases Valproic acid(VPA), aclassIandIIhistonedeacetylase(HDAC) inhibitorandconjunctival melanoma Gallieni 3 Gallieni 4 FRIDAY 77 EVER 2012 Programme book

UIESMEIG 15:10 -15:50 BUSINESS MEETINGS Agenda Business meetingsofthescientifi . CommentontheEVERactivities 4. 2 candidatesforsectionchair. In additiontotheagenda, thesections Otherbusiness 5. . Nextyear’s meeting: 3. Reportoftheprogramme secretary 2. Reportofthechairsection 1. RV -Retina/ Vitreous ...... • PBP-Physiology/BiochemistryPharmacology ...... • PO-Pathology /Oncology ...... • NSPH-Neuro-ophthalmology/Strabismology /Paediatric ophthalmology/History ...... • MBGE-MolecularBiology/GeneticsEpidemiology ...... • LC-LensandCataract ...... • IM-Immunology/Microbiology ...... • G-Glaucoma ...... • EOVS -Electrophysiology, PhysiologicalOptics, Vision Sciences ...... • COS-Cornea/OcularSurface ...... • ACB - Anatomy /CellBiology ...... • proposalsfor 2014Keynote speakers • proposalsof 2013Courses • proposalsof 2013SpecialInterestSymposia(SIS) • nominationofthe2013sectionprogramme secretary(differentfromthesectionchair) • c sections LC and RV willnominateatleast Gallieni 1&2 Gallieni 1&2 ...... Gallieni 4 Gallieni 3 Gallieni 3 Gallieni 4 Uranie Thalie Thalie Erato Clio FRIDAY 79 EVER 2012 Programme book

ENT ESO 15:55 -16:35 SESSION KEYNOTE 16:30 60 3711 16:05 15:55 Ophthalmic Research Award SPAETH G–Philadelphia Priorities ofOphthalmicResearch Introduction byUwePLEYER RESEARCH LECTURE OPHTHALMIC George L. SPAETH Priorities ofOphthalmicResearch Uranie FRIDAY 81 EVER 2012 Programme book

OTRSSIN2 16:35 -17:30 SESSION2 POSTER Anna-Maria STEVENS Aachal KOTECHA, MichèleDETRY-MOREL, Moderators: Glaucoma 03To assesscircumpapillary retinalarteriesandveinsthickness F013 Correlationofvarious opticnerveheadparameters obtained F012 Retinalpigmentepithelium(rpe)alterations correspondto F011 Structure–functionrelationship: assessmentofmacular F010 Opticdisctorsiondirectionpredictsthelocationof F009 Persistent ocularhypertensionfollowingintravitreal injections F008 IOPmanagementinglaucoma/OHTfollowingintravitreal F007 To assessthedifferenceincornealbiomechanical F006 Comparation betweenKeeler andORAIOPmeasurements F005 RelationshipbetweenIOPandbiomechanicalcornealvalues F004 24-hourintraocular pressureofhealthyhumansinsupine F003 Comparisonofintraocular pressuremeasurementswiththe F002 Comparisonofthreedifferentmethodsintraocular F001 with circumpapillaryretinalnervefi ber layer(cRNFL) (cRAT andcRVT) atopticdisc (OD)borderandcorrelatethem tomography (OCT) by 3Dnon-mydriaticretinalcamera andopticalcoherence retinal nervefi ber layer(rnfl ) degeneration inglaucoma perimetry ganglion cellcomplexwithFD-OCTandstandardautomated patients withmyopia glaucomatous damageinnormaltensionglaucoma of anti-VEGFagentsordexamethasoneintravitreal implant anti-VEGF injections contact lenses properties inhealthysubjectswithandwithouttheir obtained byORA position: rhythmandreproducibility tonometry non-contact tonometersandgoldmannapplanation reichert pt100, thekeeler pulsairintellipuffportable cornea pressure (IOP)measurementsincludingpropertiesofthe VASS C–Wien PEREIRA I, WEBER S, HOLZERS, RESCH H, KISSB, FISCHERG, KANG KD, JUNGSH–Incheon, Gangneung KERNT M, HUEBERT I, MANN T, NEUBAUER A, HIRNEISSC–Munich EL ASRI F, MESSAOUDI R, DOT C, MAY F, RENARDJP–Paris, Lyon EL CHEHABH, GIRAUD JM, FENOLLANDJ, FRANCOZM, SENDOND, LEE K–Seoul DUSSART C, DOT C–Lyon, Paris AGARD E, ELCHEHAB H, RUSSO A, RACT MADOUXG, SWALDUZ B, ANSARI E–Maidstone DE FAYS A, POURJAVAN S–Brussels FUENTES BROTO L, SEGURACLAVO F–Zaragoza LOPEZ DELAFUENTEC, SANCHEZ-CANO A, PINILLAI, FUENTES BROTO L, SEGURACLAVO F–Zaragoza LOPEZ DELAFUENTEC, SANCHEZ-CANO A, PINILLAI, MOTTET B, CHIQUETC, APTEL F, NOELC, ROMANETJP–Grenoble ROMANET JP–Grenoble APTEL F, HUBANOVA R, ZHOU T, ARNOL N, CHIQUETC, Katowice SMEDOWSKI A, WYLEGALA E, WEGLARZ B, ORSKIM, WOJCIK L– 00Reproducibilityofretinalnervefi ber layerparameters F020 Scanninglaserpolarimetryinglaucomasuspects: infl uence F019 Glaucomadiagnosticaccuracy : comparisonofRTVue-100 F018 Average nervewidthmeasurementobtainedbyoptical F017 Macularganglioncell-Innerplexiformlayerthickness F016 F015 Asymmetryinhemifi eld macularthicknessasanindicatorof F014 F028 Effectivnessofbrimonidinanddorsolamidasadditional F027 The impactofbrimonidineonthelossretinalnerve fi ber F026 F025 F024 F023 Stereometricparameters changevs. HRT Topographic F022 The infl uence of TSD (topographic standarddeviation)and F021 rf rf rf rf BAMBO M, PRIETO E, DELAMATA G, FERNANDEZ-PEREZS, RAIMONDI M, LANTERIS, ROSSIGCM–Pavia MILANO G, VERTICCHIO VERCELLIN AC, LOMBARDOS, BOSSOLESIL, MAY F, RENARDJP–Paris FENOLLAND J, GIRAUD JM, ELCHEHABH, FRANCOZM, SENDOND, SHENG-YAO HSU–Hualien MESSAOUDI R, MAY F, RENARDJP–Paris FRANCOZ M, FENOLLANDJ, GIRAUD JM, ELCHEHABH, SENDOND, GIZZI C, CELLINIM, CAMPOSEC–Bologna CHEN Y, KOBAYASHI N, KOBAYASHI K–Koriyama, Fukushima BIONDI P, AVITABILE T–Catania, Foggia GAGLIANO C, LONGO A, UVA MG, REIBALDIM, AMATO R, RUSSO V, Podgorica RADUNOVIC M, RADUNOVIC M, RADUNOVIC A, KUJUNDZICH– SMEDOWSKI A, WYLEGALA E, ORSKIM, WOJCIK L–Katowice Marlow WARREN RJ, MALTMAN J–Polch, Amsterdam, Graz, Schlieren, PFENNIGSDORF S, DEJONGL, MAKKS, FOURNICHOT Y, MORGAN- SCHULZ S, ZINSERG–Heidelberg HOLZER S, PEREIRAI, KISSB, VASS C–Wien Bucharest POPA CHERECHEANU A, DASCALU AM, SERBAND, STANA D– Bucharest POPA CHERECHEANU A, DASCALU AM, SERBAND, STANA D– SATUE M, GARCIA-MARTIN E, FERRERAS A–Zaragoza measured withscanninglaserpolarimetryinhealthyeyes of thelens and CirrusHD coherence tomography andglaucoma measurement andreproducibilitywithSD-OCT tissue toanacuteinducedIOPelevati Biomechanical responseoflaminacribrosaandprelaminar early glaucomatousstructural orfunctionalprogression palmitoylethanolamide: Visual Fieldand Pattern-ERG Clinical trialfortheevaluation ofneuroprotective effectsof therapy tobeta-blockers-comparable analysis layer (RNFL)thicknessinglaucomadiabeticpatients or ocularhypertension combination inpatientswithprimaryopen-angleglaucoma the effi cacy andtolerability ofbimatoprost/timololfi xed Combined analysisoffi ve observational studiesevaluating possible infl uence onRNFLT classifi cation andprofi le shape Manual placementofSD-OCTperipapillarycirclescan: patients comparedtonormativedatabase Defects inmacular-retinal layeranalysisofglaucoma glaucoma progression Change Analysis (TCA)agreementinearlydetectionof retest variability of theHRT stereometricparameters RH (refferenceheight)test/retestvariability uponthetest/ FRIDAY 83 EVER 2012 Programme book 84 EVER 2012 Programme book F037 Valuation ofsurgeryincombinationchamberanglelens F036 F035 Safetyandeffi cacy ofphacoemulsifi cation andintraocular F034 Angleclosureglaucomaassociatedwithvenlafaxine F033 F032 F031 Effi cacy andsafetyassessmentofpreservative-free F030 F029 03Experimentalapplicationofhigh-frequency electricwelding F043 Changesinanteriorsegmentafter-iridotomy withnd: F042 The morphologicalchangesintheeyetissuesduring F041 Glaucomasurgeryinapatientwithprominentepiscleral F040 Nonpenetrating deepsclerectomyversustrabeculectomy in F039 Ex-pressglaucomashuntforthetreatmentofcomplex F038 rf rf 16:35 - 17:30 POSTER SESSION2 POSTER 16:35 -17:30 FRIDAY Odessa ZADOROZHNYY O, PASYECHNIKOVA N, NAUMENKO V, LAZAR Y– MATEO J, ASCASO F, CRISTOBAL JA–Zaragoza IBANEZ J, PEREZ GARCIAD, JIMENEZDELRIOB, RAMIROP, GAVRILOVA I, CHUPROV A–Kirov GARCÍA-MARTÍN E, BAMBOMP, PEREZ-OLIVAN S–Zaragoza PRIETO CALVO E, DE LAMATA G, FERNANDEZ-PEREZS, SATUE M, CRISTOBAL JA–Zaragoza IBANEZ J, PEREZD, MATEO OROBIA A, ASCASO F, PEIRO C, ANSARI E–Maidstone LIASKA A, ANDRIANOPOULOU K–Lamia CRISTOBAL JA, DELBUEYMA–Zaragoza RAMIRO P, CABEZONL, IBAÑEZJ, PINILLAI, PEREZD, VAN DE VEIRE S, WEBERS C, BECKERSH–Maastricht KIM S, CHOIHJ–Seoul TURCOTTE S, FREDETTEMJ–Quebec FLEITMAN J, KENLEYR–Irvine, SanDiego CUCHERAT M, ROULANDJF–Lyon, Lille ROULAND JF–Lille La Gaude, Sousse, Tunis ELENA P, VIAUD-QUENTRIC K, CHARFEDDINER, REKIKR– glaucoma versus combined(phacotrabeculectomy) surgery sequential (1stphacoemulsifi cation,2nd trabeculectomy) Marginally controlledopenangleglaucomaandcataract: Case fromhellinnarrowangleglaucomapatient angle-closure glaucoma lens implantationineyeswithend-stagechronic treatment Prostaglandin drugpartitioningintocontactlensmaterial meta-analysis ocular hypertension. An adjustedindirectcomparison (T2345) forthetreatmentofopen-angleglaucomaand Relative effi cacy andsafetyofpreservative-free latanoprost hypertensive orglaucomatouspatients latanoprost (T2345)versusXalatan™inocular ischemia-reperfusion inrats retinal ganglioncellsurvival aftertransient retinal Multiple topicaladministrations ofRamiprilenhance of biologicaltissuesforiridoplastyand trabeculectomy OCT yag laserfornarrowanglemeasuredwithspectral domain implantation drainages forglaucomasurgery vessels bilateral primary open-angleglaucoma 09Experimentalglaucomamodelusingpolyurethane F049 Glaucomatousopticneuropathycomplicatedbypituitary F048 Megalocornea, irisdesinsertionandcrystallineluxationin F047 Epidemiologyofprimarycongenitalglaucoma: astudy F046 Effi cacy ofpneumatictrabeculoplasty inpatientswith F045 F044 02IOPloweringeffectoflowintensityultrasound onexperi- F052 Experimentalglaucomamodelintwolinesofrats using F051 F050 rf KIM C, RHOS, LEEN, LEEC, KIMN, PARK S, CHOIB–Seoul, Incheon PESCE G, MONTRONEF, VELLA G, GARRIBBA AP–Bari PALACIAN M, BAMBOM–Zaragoza RERO LATORRE R, GARCIA-MARTIN E, DELAMATA PEREZG, SATUE ARA GABARREM, EGEAESTOPINAN, FERNANDEZ-PEREZS, HER- AZIZ A, DENISD, MATONTI F–Marseille MARTY A, BECCAT S, AMARI E, NORDMANNJP, DENISP–Lyon, Paris Paris, Dijon RENARD JP, SELLEME, BAUDOUIN C, BRON A–Grenoble, Lyon, Lille, APTEL F, DENISP, ROULANDJF, NORDMANNJP, LACHKAR Y, Incheon, Jeju KIM C, RHOS, LEEN, LEEC, KIMN, PARK S, CHOIB, CHOIM–Seoul, LEWIN-KOWALIK J–Katowice SMEDOWSKI A, PIETRUCHA-DUTCZAK M, WYLEGALA E, MOONS L–Leuven DE GROEFL, GAUBLOMME D, JANSSENSE, DEKEYSTER E, microbeads inrats adenoma: casereport congenital glaucoma lasting 11years combination withprostaglandinmonotherapy primary openangleglaucomaandocularhypertensionin clinical trial open-angle glaucoma: preliminaryresultsofamulticenter Ultrasonic circularcyclocoagulationinpatientswithprimary mental glaucomamodelusingmicrobeadsinrats polystyren microspheres(BeadModel) mouse modelofglaucoma Retinal MMPexpressionisupregulatedinanexcitotoxic OTRSSIN2 16:35 -17:30 SESSION2 POSTER 06Vision insubjectswithhyperawareness ofafterimagesand F066 Visual capacityinalbinomice. Are albino micegoodfor F065 F064 F063 The effectofsimplifi ed andtraditional chinese character on F062 Relationshipbetweenvisualacuityandotheroptical F061 Fish-eyediseasewithretinalinvolvementassociated F060 Eyerefraction: acomparative studybetween F059 Undercorrectionofrefractive errorandcognitivefunction. F058 Mesopicpupilamplitudedependingontheageand F057 Morphometricalindicesinacquiredmyopia F056 Vision qualityinpopulationresearchofchildrenand F055 Changesincontrast sensitivityperceptionduetoprotector F054 Controlledpupilarmiosistoimprovemesopicvisualfunction F053 Miguel CASTELO-BRANCO, Werner SPILEERS Moderators: Sciences Vision Electrophysiology, PhysiologicalOptics, “visual snow” every neuroscience’s experiment? accommodative reponsesinmyopesandemmtropes parameters inno presbyopiceyes mutation intheLCAT gene autorefractometer, aberrometerandsubjectivetest The BeijingEyeStudy2011 wavelenght ofthe stimuli adolescents inSiemianowiceSlaskie(southernPoland) fi lter vsnovelprotectiveopticalfi lter ofselectiveabsorbance screens forweldingtasks: conventionalprotectiveoptical in driversover40yearsold ALISSA R, BI W, BESSERO AC, PLANTG, BARBURJL–London DE LA VILLA P, SANCHEZ-RAMOS C–Madrid VICENTE TEJEDOR J, RAMÍREZL, TORETS C, CARRALEROS, Sulzbach, Wetzlar KRASTEL H, KALTAKJI F, LEERSS, JERCHELN, JONASJB–Mannheim, Perenchies, Nantes, Lille CHARLIER J, CABON M, ZANLONGHIX, DEFOORT-DHELLEMMES S– XU D, XIN W–Wenzhou FUENTES BROTO L,PINILLAI–Zaragoza SEGURA CALVO F, SANCHEZ-CANO A, LOPEZDELAFUENTEC, BOUTBOUL S, BORDERIE V, LAROCHEL–Paris FUENTES BROTO L, PINILLAI–Zaragoza SEGURA CALVO F, SANCHEZ-CANO A, LOPEZDELAFUENTEC, SCHMIDBAUER M–Mannheim SáNCHEZ-RAMOS RODAC–Madrid BONNIN ARIAS C, RAMIREZ-MERCADOG, LOBATO RINCON LL, NAVARRO VALLS J, NAVARRO BLANCOC, BOYCHUK IRYNA, GORBATUK TL–Odessa Katowice, Wroclaw MOCKO L, WYLEGALA E, ZAJAC M, JOZWIK A, LEWANDOWSKA M– SANCHEZ-RAMOS C–Madrid LOBATO RINCONLL, LANGA-MORAGA A, NAVARRO-VALLS J, BONNIN ARIAS C, AGUIRRE-VILACORO V, CHAMORROE, LOBATO RINCONLL, CHAMORROE, SANCHEZ-RAMOSC–Madrid NAVARRO VALLS J, RAMIREZ-MERCADOG, PÉREZ-CARRASCOMJ, pseudoisochromatic plates Spatial tuningaffectsdiagnosticeffi cacy of potentials Evaluation ofmagnitudeandphasesweep-visualevoked 03Colourvisionlossesindiabetestheabsenceof F073 Normalaging: capturingchangesincontrast acuityatlow F072 Normalrange ofCambridgelowcontrast grating test: F071 Detectionofcoloursignalsinobjectsdefi ned byluminance F070 Newclinicalmeasuretoassessthevisualawareness in F069 FunctionalactivityofretinalneuronsandMullercellsin F068 Comparisonofvisualevoked potentialsbetweenpremature F067 F076 F075 Evidenceofneuroplasticityinthehumanvisualcortex F074 rf rf BARBUR JL, ANSARI I, CANNINGC–London, Dubai London GILLESPIE-GALLERY H, KONSTANTAKOPOULOU E, BARBURJL– KHABAZKHOOB M, MOHAMMADIANM–Mashhad, Tehran OSTADIMOGHADDAM H, YEKTA AA, HERAVIAN J, AZIMI A, HICKEY J, RODRIGUEZ-CARMONAM, BARBURJL–London ALSHAGHTHRAH A, DICKINSONC, MURRAY I–Manchester Moscow ZUEVA M, NEROEV V, TSAPENKO I, BYCHKOV P, SARYGINA O– HAN SJ, JEONSY–Seoul GARCHER C, BRETILLONL–Dijon THIERRY M, BUTEAU B, PASQUIS B, ACAR N, BRON A, CREUZOT- MACHALINSKA A–Szczecin Kuopio, Jyväskylä VOTTONEN P, PÄÄKKÖNEN A, TARKKA I, KAARNIRANTA K– proliferative retinopathy light levels a populationbasedstudy contrast peripheral fi eld loss(PFL) idiopathic full-thicknessmacularholes and full-termchildrens ity andgeneexpressioninrat retina Fructose dietinducedshort-termimpairmentofconesensitiv- after sodiumiodateadministration inmice Adjuvant stemcell-based therapy inacuteretinalinjury age-related maculardegeneration following benefi cial anti-VEGFtreatmentinexudative FRIDAY 85 EVER 2012 Programme book 86 EVER 2012 Programme book 03DiagnosisofHerpeticUveitisis Aided byConfocal F083 F082 The dynamicsofmolecularmarkers expressionofblood F081 Oxidativestressactivates NLRP3infl ammasomes in F080 Polyphenolic compoundsreduceinfl ammation in F079 CytokinesinpatientswithHLA-B27+acuteanterioruveitis F078 Adhesionmoleculesinexperimentalautoimmuneuveitis F077 F089 Syphiliticuveitis: Vilnius regionperspetive: 6casereports F088 LatticedystrophycomplicatedbyCryptococcuscurvatus F087 F086 Regulationofimmuneresponseinpost-operative F085 F084 Piergiorgio NERI, François WILLERMAIN Moderators: Immunology /Microbiology rf rf 16:35 - 17:30 POSTER SESSION2 POSTER 16:35 -17:30 FRIDAY KNOLL A, LUTZ T, GRULICH-HENN J, MACKENSEN F–Heidelberg ASOKLIS R–Vilnius STECH S, STRUPAITE R, KARALIUTEZ, CIMBALAS A, SVEIKATIENE J, Sunderland, Bristol IRION L, MORGANS, KOERNER R, JOHNSONE–Manchester, ARICI MK–Vienna, Sivas OBWALLER A, POLAT ZA, WALOCHNIK J, VURAL A, DURSUM A, Dijon, Grenoble, Nancy, Besançon GAUCHER D, CANDOLFIE, PREVOST G, BOURCIER T–Strasbourg, SAUER A, CREUZOT-GARCHER C, CHIQUETC, BERRODJP, SALEHM, GAILLEDRAT M, ERGANI A–Le Kremlin Bicêtre, Paris, Gifsur Yvette LABETOULLE M, GABISONE, ROUSSEAU A, HUOT N, CHAPELLIERB, KNOLL A, POSTOLE S, MACKENSEN F–Heidelberg Pittsburgh ROMANOWSKI E, YATES K, MAHF, GORDON Y, KOWALSKI R– VELICHKO LN, MALETSKIY AP, VIT VV, CHEBOTARYOV YEP–Odessa KAUPPINEN A–Kuopio LAAKSO N, KINNUNENK, SALMINEN A, KAARNIRANTA K, KAUPPINEN A–Kuopio HäNLER M, SUURONEN T, SALMINEN A, KAARNIRANTA K, JAKOB E, UMANSKYL, BECKHOVE P, MACKENSEN F–Heidelberg BRUYNS C, WILLERMAIN F–Brussels DEWISPELAERE R, LIPSKID, MAKHOULM, JUDICEL, CASPERSL, in amousemodelofherpeskeratitis HSV1-specifi c meganucleasemayreduceocularinfection Microscopy withtheHRT RCM model fl uoroquinolone-resistant MRSAintheNZWrabbit keratitis fl uoroquinolone inreducingthecolonycountsof An antimicrobialpeptidecanenhancetheactivityofa at thedifferenttypesoftreatment lymphocytes activating atpatientswithanuvealmelanoma ARPE-19 cells ARPE-19 cells arthritis –acasereport Tocilizumab foranterioruveitisandjuvenileidopathic infection Results fromin-vivotoxicological andeffi cacy studies combination forthetreatmentof Acanthamoeba keratitis. Miltefosine andpolyhexamethylenebiguanide, anewdrug endophthalmitis 05Successfulmanagementofrecurrent Acanthamoeba keratitis F095 Serratamolide asanovelhemolyticfactorproducedby F094 Evaluation oftheearlydiagnosisuveitistoxoplasma using F093 F092 Baselinepredictivefactorsofvisualprognosisinacute F091 UseoftufPCRforstaphylococcalandstreptococcalgenus F090 12Uveitisandocularwall granulomas associatedwithbrimoni- F102 F101 Iritisandangleclosureglaucomacausedbycaterpillarhairs F100 Oculargranuloma, uveitisandX-linked chronic F099 Effi cacity andsafetyof TNF alphablockers inpatientswith F098 EffectoftocilizumabforuveitisaccompaniedwithCastleman F097 F096 rf rf rf Vienna BARISANI-ASENBAUER T, WALOCHNIK J, MEJDOUBIL, BINDERS– Pittsburgh SHANKS RM, STELLAN, LAHRR, WANG S, KOWALSKI R, LIUX– BECCAT S, WALLON M, SEVE P, PEYRONF, KODJIKIAN L–LYON, Lyon ROMANET JP–Grenoble, Paris CHIQUET C, LABETOULLE M, GERMIR, BERNHEIMD, MORANDP, Grenoble, CHUdeDIJON, Lyon, Saint-Etienne, Dijon CAMPOLMI N, ROMANETJP, BRON A, GAINP, MAURIN M– CHIQUET C, CREUZOT-GARCHER C, COMBEY A, CORNUTPL, MAURIN M, CHIQUETC, VANDENESCH F–Lyon, Grenoble CORNUT PL, BOISSETS, BENITO Y, BURILLONC, ETIENNEJ, LABALETTE P, MAURAGE CA–Lille JEEVA I, HARDISTY A, KOLB S, HOOLEJ, LONG V, WOOD M–Leeds BLASETTI F, TARALLO S, DORES, PINNA A–sassari, Sassari Paris KURUN S, ANGIOI K, LOCATELLI A, TERRADA C, BODAGHI B–Nancy, LEHOANG P, BODAGHI B–Paris GUINDOLET D, SAADOUND, CASSOUX N, FARDEAU C, TOUITOU V, TOBE A, OSHITARI T, YAMAMOTO S–Chiba NGUYEN AM, DENISP, GRANGEJD, KODJIKIAN L–Lyon using topicalandsystemicmiltefosine Serratia marcescens only westernblot real-time PCR treated for VZV acuteretinalnecrosisusingquantitative Time profi le ofviral DNAinaqueoushumorofpatients bacterial postcataract endophthalmitis detection inendophthalmitis dine treatment Hospitals, UK Paediatric rheumatologyclinicoutcomeatLeeds Teaching granulomatous disease Behçet’s diseaseuveitis disease immunocompetent adults: realco-infectionorfalsepositive? Atypical panuveitisparasitic andHerpesvirusco-infectionin OTRSSIN2 16:35 -17:30 SESSION2 POSTER 17Damageoftolerance toglucose(TG) isthepredecessorof F117 Galenicandanalyticdevelopmentof Tacrolimus 0.06%eye F116 Blindnessduetomistake of antituberculosistreatment F115 Correctinginfl uence ofarsenicmineral water onstructural F114 Retinalvesselreactivityaftercigarettesmoking F113 The infl uence ofageonretinalvesseloxygenation F112 Howmuchfl icker isenough? F111 Flicker-induced retinalvasodilatation isnotdependent F110 Examinationofbetweeneyeretinaloxygenation saturation F109 F108 F107 Hypoxia stimulatesthesynthesisandreleaseofBrain F106 Effectsoflowintensityultrasound (LIUS)onthemacular F105 F104 ProtectiveeffectsofCrepidiastrumdenticulatumon F103 Neville OSBORNE, Gerhard GARHOFER Moderators: Physiology /BiochemistryPharmacology metabolic changes, whichneedall-roundresearch insular diabetes(ID)andisaccompanied bydifferent drops immobilization-emotional stress characteristic oftheretinarat eyesinmodelchronic subjects on complementfactorHpolymorphisminhealthyyoung in theperi-papillaryregion in experimentalbranch retinalveinocclusioninrats Effects ofintravitreal injectionofanti-TNF Natriuretic Peptide (BNP)inRPEcells degeneration modelinvitro oxidative stress-inducedretinaldegeneration GUSHCHA S, BABOV KD, YAROSHENKO NA–Odessa YVES, LIMAT S, DELBOSCB–Besançon GAUTHIER AS, RIVAL B, SAHLERJ, FAGNONI-LEGAT C, GUILLAUME Limoges, Bangui ROBERT PY, ZOLOTARYOVA TA–Odessa GUSHCHA S, NASIBULLIN BA, YAROSHENKO NA, CUBBIDGE R, SUMMERSRJ, HEITMARR–Birmingham HEITMAR R, CUBBIDGER–Birmingham HEITMAR R, SUMMERSRJ–Birmingham WERKMEISTER R, GARHöFERG, SCHMETTERERL–Vienna NAPORA KJ, TOLD R, PALKOVITS S, KAYA S, BOLTZ A, SCHMIDLD, CUBBIDGE R, VEKRIA P, KALITZEOS A, HEITMARR–Birmingham ANDRIANAKI A, GILODIN, CONTI A, POURNARASCJ–Geneva La Gaude, Sousse, Tunis ELENA P, SENSEBYF, BERMONF, CHARFEDDINER, REKIKR– ARJAMAA O, AALTONEN V–Turku Seoul, Jeju KIM NK, KIMCY, CHOIMJ, RHOS, PARK S, CHOIBH–Incheon, DOLY M–ClermontFerrand RANCHON-COLE I, RAMCHANIBENOTMAN K, CERCYC, REBIKAH, Gangneung, Gyeonggi, Incheon JUNG SH, AHN HR, LEEHJ, KIMCY, KANGKD, NHOCW– with Augmentation oftheocularpenetration ofdexamethasone from light-induceddamage Supplement enrichedinantioxidants protectstheretina -blocker and YAYA G, Y ASSAMINA S, MGBALI J, GINOUXJ– -agonist co-administration andanti-VEGF 13Aqueouserythropoietinlevelinretinalveinocclusion F123 F122 F121 F120 Sunglasseswithwidetemplesandthickframe severely F119 EffectsofIrifrin2,5%onthedisturbancespupillary- F118 rf rf rf SHIN HJ, LEESH–Seoul SOININEN T, KAARNIRANTA K, KARJALAINENRO–Kuopio REINISALO M, PAIMELA T, RYHäNEN T, KAUPPINEN A, KOSKELA A, MOURIAUX F–Caen DENION E, DUGUE AE, COFFIN-PICHONNETS, AUGY S, SCHMETTERER L–Vienna FUCHSJAEGER-MAYRL G, WERKMEISTER R, GARHOFERG, SCHMIDL D, BOLTZ A, KAYA S, PALKOVITS S, TOLD R, MOURIAUX F–Caen DENION E, DUGUE AE, AUGY S, COFFIN-PICHONNETS, BUSHUYEVA N, MALIEVA O–Odessa protectiveeffectofwood-derivedphenoliccompounds Oxidative stressinretinalpigmentepithelialcells: Eye motionincreasestemporal visualfi eld extent pressure inhealthyhumans regulation duringexperimentalincreaseofintraocular Role ofnitricoxide inopticnerveheadbloodfl ow constrict temporal visualfi eld extent accommodative systeminpatients FRIDAY 87 EVER 2012 Programme book 88 EVER 2012 Programme book 7 3 90 SECOND AFTERNOONSESSION 17:30 -19:00 FRIDAY 83 3834 18:36 3832 18:14 17:52 3826 3825 18:30 3824 18:18 3823 18:06 3822 17:54 17:42 3815 3814 18:42 3813 18:24 18:06 17:48 73 3811 17:30 73 3831 17:30 3821 17:30 I Newtrends inthetreatment ofdiabeticmacularoedema RV SIS I From ocularsurfacetoganglioncells ACB SIS Surgery RV FP 3833 3812 Pascale MASSIN, Jean- Antoine CPOURNARAS Hannu UUSITALO, GiedriusKALESNYKAS Jean-Paul BERROD, JostBJONAS Role oflaser KALESNYKAS G–Kuopio Changes inretinalganglioncellmorphologyafteropticnervecrushand experimentalglaucoma ZACK DJ–Baltimore and hopefullytotheclinic Retinal neuroprotection: the pathfromcell-basedhighcontentscreening, toanimalmodels, BEUERMAN R, YUAN ZH–Singapore Post-surgical intra-ocular infl ammation inamousemodel andhighmobilitygroupbox protein1 UUSITALO H–Tampere Ocular surfacesinthetreatmentofglaucoma ARNDT C, BONNAY G, RAMONTL, DIEBOLDMD, DUCASSE A, BOULAGNON C–Reims Cytopathological fi ndings inthevitreousofpatientswithretinaldetachment DROUECHE Z, LAMARDM, QUELLECG, CAZUGUEL G, ROUXC, COCHENERB–Brest Content-based MPEG-4videostreamretrieval forvideo-guidedeyesurgery CASTRO NAVARRO J, GARCÍAFERNÁNDEZM–Lugodellanera, Oviedo membrane (ERM)surgery Implication offunctionalandanatomicalpreoperative characteristics intheoutcomesofepiretinal CREUZOT C, ISAICOR, NICOT F, BRON A–Dijon Macular sensitivityandstructureinepiretinalmembranes 6monthsaftersurgicaltreatment CONART JB, HUBERT I, BERRODJP–Nancy Outcomes ofmacularholesurgeryinhighlymyopiceyes: acase-controlstudy BERROD JP, SELTON J, CONART JB, HUBERT I–Vandoeuvre-les-Nancy of thevitrectomycutter Incidence oftearsandretinaldetachmentsaftermacularsurgeryaccordingtothedepression MASSIN P–Paris Case presentation WOLFENSBERGER T–Lausanne Role ofvitrectomy POURNARAS JA–Lausanne Role ofanti-VEGF BANDELLO F–Milano Role ofcorticosteroids CONRATH J–Marseille Euterpe Uranie Erato EODATRONSSIN 17:30 -19:00 SECOND AFTERNOONSESSION 84 3865 3864 18:42 18:24 3862 18:06 17:48 3854 3853 18:45 3852 18:20 17:55 3846 3845 18:45 3844 18:30 3843 18:15 3842 18:00 17:45 73 3841 17:30 73 3861 17:30 3851 17:30 I Myopiaandglaucoma G SIS Killercasesinuveitis: challengesandcontroversies SIS I Thebluelightphotoreceptor andipRGCs: NSPH SIS IM 3863 Review andupdateoftheirrole inhumanhealth Sayeh POURJAVAN, K. ShengLIM Piergiorgio NERI, CarlPHERBORT Aki KAWASAKI KARDON RANDY–Iowa Melanopsin anditsroleinphotophobia LUCAS R–Manchester The importanceofbluelightexposuretocircadianintegrity andgeneral health KAWASAKI A–Lausanne Chromatic pupillometryasanovelmeanstoassessouterretinalfunction inhealthanddiseasestates KARDON RANDY–Iowa Rod, coneandmelanopsincontributionstothepupillightrefl ex LUCAS R–Manchester Anatomic andphysiologicconsiderations oftheintrinsically-photosensitiveretinalganglioncells POURJAVAN S–Brussels Interesting case-reports LIM K–London Glaucoma surgeryinhighmyopia CHAVES A–Brussels Refractive surgeryinmyopic, glaucomatouspatient KHAWAJA A–London The associationbetweenmyopiaandglaucoma-causalityorclassifi cation? DICK A–Bristol Infectious drivenautoimmunity-howtotreat? NERI P, ARAPI I, PIRANI V, CAPUANO V–Torrette-Ancona, Ancona TB ornot TB...or whatelse?! BOUCHENAKI N, HERBORT CP–Lausanne How abenigngranulomatous uveitiscanbecomeakillercase PAPADIA M, HERBORT CP–Lausanne Killer casesduetooccultchoroidalinfl ammation: howtopreventthem HERBORT CP–Lausanne Primum nonnocereetoccidere PAVESIO C–London Progressive serpiginouschoroidopathy–whattodo? Gallieni 1&2 Thalie Clio FRIDAY 89 EVER 2012 Programme book

EODATRONSSIN 17:30 -19:00 SECOND AFTERNOONSESSION 84 3885 3884 18:42 3883 18:24 3882 18:06 17:48 3877 3876 18:36 3875 18:30 3874 18:18 3873 18:06 3872 17:54 17:42 73 3871 17:30 73 3881 17:30 SPatients asstakeholders inEuropean ophthalmology WS From refractive surgery tocornealgrafting FP COS Nadja KNOP, ErichKNOP Harminder SDUA, Frederic CHIAMBARETTA rf rf SUTTIE A–Kirkcaldy Visual impairment, blindnessinanagingsociety STALMANS I–Leuven Initiating aglaucomainterestgroupinBelgium ZIERHUT M–Tübingen Deutsche Uveitis Arbeitsgemeinschaft (DUAG) -Howpatientscansupportresearch HOLZAPFEL S, OSTROWSKI A–Berlin DBSV – A successstoryinformingapatientorganizationforblindandpartiallysightedpeople ANGERMANN W–Hannover EBU -EuropeanBlindUnion The voiceofblindandpartiallysightedpeopleinEurope DOBROWOLSKI D, JANISZEWSKAD, TARNAWSKA D, KRYSIK K, WYLEGALA E–Katowice, Sosnowiec ROBERT PY, DUBOIS A, CHAIGNIERD, GARNIERF, PLOY MC–Limoges AKHTAR S, KIRAT O, ALKATAN H, ALMUBRAD T–Riyadh Stromal alteration inpost-lasikectasiacornea SALVADOR CULLAB, JEONGKJ, PASCHALIS EI, CHIANGHH, GIPSONIK, DOHLMANCH, KOHANE DS–Boston New improvementsinBostonKeratoprosthesis (KPro): titaniumsurfacemodifi cations WYLEGALA E, TARNAWSKA D, WROBLEWSKA CZAJKAE, JANISZEWSKAD, WOWRO B, DOBROWOLSKID–Katowice Spectral domainOCT-assisted “big bubble” deepanteriorlamellarkeratoplasty inkeratoconus patients BARRAQUER J–Barcelona Large optico-reconstructivecornealgrafts incomplicatedcases Saint-Etienne BERNARD A, AUDOUARD E, THURET G, PEOC’HM, DUMOLLARDJM, GRANIERJ, SODERH, MOINEB, GAINP– Study ofstromalfemtosecondlaserablationfordeepcornealcutoptimization Surgical approachincornealperforations anddeepulcers Investigation ofbacterialcontaminationcornealdonorsusingmolecularbiology Gallieni 3 Gallieni 4 FRIDAY 91 EVER 2012 Programme book

Yellox...putting a stop to ocular inflammation† fewer drops. less time.*

SYMPOSIUM “New aspects of managing post-surgical inflammation” Saturday 13 th October 2012 7:15 – 8:15 a.m. Room: Uranie

Yellox® (bromfenac sodium sesquihydrate) 0.9 mg/ml eye drops, solution. be used with caution in these patients. There have been reports that ophthalmic in eye, ocular discomfort, epistaxis, cough, nasal sinus drainage and face swelling. Prescribing Information. Please refer to the Summary of Product Characteristics NSAIDs may cause increased bleeding of ocular tissues (including hyphaema) in Rare (0.01% to <0.1%; isolated reports from post-marketing experience of more ® before prescribing Yellox . Pharmaceutical form: Eye drops containing 0.9 mg/ conjunction with ocular surgery. Yellox should therefore be used with caution in than 20 million patients): corneal perforation, corneal ulcer, corneal erosion – ml bromfenac (as sodium sesquihydrate) in clear yellow solution; one drop patients with known bleeding tendencies or who are receiving other medicinal serious, scleromalacia, corneal infiltrates, corneal disorder, corneal scar and contains approximately 33 micrograms bromfenac. Indication: Treatment of products that may prolong bleeding time. Ocular infection: An acute ocular asthma. Please consult the Summary of Product Characteristics for a full list of side postoperative ocular inflammation following cataract extraction in adults. Dosage infection may be masked by the topical use of anti-inflammatory medicinal and administration: For ocular use. Use in adults, including the elderly: The dose products. Excipients: Since Yellox contains benzalkonium chloride, close effects. Overdose: If Yellox is accidentally ingested, fluids should be taken to is one drop of Yellox in the affected eye(s) twice daily, beginning the day after monitoring is required with frequent or prolonged use. Benzalkonium chloride is dilute the medicinal product. Pharmaceutical precautions: Do not store above cataract surgery and continuing through the first 2 postoperative weeks. The known to discolour soft contact lenses, and has been reported to cause eye 25°C. Legal Category: POM. Marketing Authorisation Number: treatment should not exceed 2 weeks as safety data beyond this is not available. irritation, punctuate keratopathy and/or toxic ulcerative keratopathy. Special EU/1/11/692/001. Marketing Authorisation Holder: Croma Pharma GmbH, Paediatric population: Safety and efficacy in paediatric patients have not been instructions regarding drop instillation: Multiple topical ophthalmic medicinal Industriezeile 6, A-2100 Leobendorf, Austria. Date of preparation: April 2011. established. Hepatic or renal impairment: Safety and efficacy have not been products should be administered at least 5 minutes apart. Avoid contaminating established in patients with hepatic disease or renal impairment. the dropper-tip and solution, and tightly close the bottle when not in use. Contact Adverse events should be reported. Reporting forms and Contraindications: Known hypersensitivity to bromfenac, any of the excipients, lenses should not be worn during treatment with Yellox. Interactions: Formal information can be found at www.yellowcard.gov.uk. Adverse or other non-steroidal anti-inflammatory medicinal products (NSAIDs). History of interaction studies have not been performed, but no interactions with antibiotic events should also be reported to Bausch & Lomb UK Ltd on asthma, urticaria or acute rhinitis precipitated by acetylsalicylic acid or by other eye drops used in conjunction with surgery have been reported. Fertility, 01748 828864. medicinal products with prostaglandin synthetase inhibiting activity. Special pregnancy and lactation: Pregnancy: There are no adequate data from the use warnings and precautions: Topical NSAIDs and corticosteroids may both slow of bromfenac in pregnant women, and the potential risk for humans is unknown. References or delay healing; their concomitant use may increase this potential. Yellox contains In general, the use of Yellox is not recommended during pregnancy unless the 1. Yellox, Summary of Product Characteristics sodium sulphite, which may cause allergic-type reactions, including anaphylactic benefit outweighs the potential risk. Breast-feeding: It is unknown whether symptoms and life-threatening or less severe asthmatic episodes in susceptible bromfenac or its metabolites are excreted in human milk. The use of Yellox is in 2. Donnenfeld ED et al. Ophthalmology 2007; 114(9):1653-62 patients. Cross-sensitivity: There is the potential for cross-sensitivity to general not recommended during breastfeeding unless the benefit outweighs the 3. Donnenfeld ED, Donnenfeld A. Int Ophthalmol Clin. 2006; 46(4):21-40 acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, so caution is potential risk. Fertility: No pregnancy testing or contraceptive measures are 4. Baklayan GA et al. J Ocul Pharmacol Ther. 2008; 24(4):392-8 required among patients with a history of sensitivities to these medicinal products. required. Effects on ability to drive and use machinery: Transient blurring of 5. Nevanac, Summary of Product Characteristics: 2009 Susceptible persons: In susceptible patients, continued use of topical NSAIDs, vision may occur on instillation. If blurred vision occurs at instillation refrain from 6. Acular, Summary of Product Characteristics: 16 Feb 2010 including Yellox, may result in potentially sight-threatening complications driving or using machines until vision is clear. Undesirable effects: In clinical trials 7. Voltarol, Summary of Product Characteristics: 04 May 2010 (epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or (n = 973), a total of 3.4% of patients had 1 adverse reactions. The most common corneal perforation). Patients with evidence of corneal epithelial breakdown or most important reactions were abnormal sensation in eye (0.5%), corneal 035-2011-04-BMF should immediately discontinue use of topical NSAIDs and be closely monitored. erosion (mild or moderate, 0.4%), eye pruritus (0.4%), eye pain (0.3%) and eye In at-risk patients, concomitant use of ophthalmic corticosteroids with NSAIDs redness (0.3%). Summary of adverse reactions: Uncommon (0.1% to <1%): Date of preparation: June 2011 may increase risk of corneal adverse events. Postmarketing experience with reduced visual acuity, haemorrhagic retinopathy, corneal epithelium defect Yellox is a registered trademark used by Bausch & Lomb Incorporated by NSAIDs: Patients with complicated ocular surgeries, corneal denervation, corneal (reported with QID use, off-label use, QID), corneal erosion (mild or moderate), permission of Croma Pharma GmbH. epithelial defects, diabetes mellitus and ocular surface diseases (e.g. dry eye corneal epithelium disorder, corneal oedema, retinal exudates, eye pain, eyelid Bausch + Lomb is a registered trademark of Bausch & Lomb Incorporated. syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of bleeding, vision blurred, photophobia , eyelid oedema, eye discharge, eye Yellox is licensed in all EEA member states, not in Switzerland time may be at increased risk for corneal adverse reactions. Topical NSAIDs should pruritus, eye irritation, eye redness, conjunctival hyperaemia, abnormal sensation ©Bausch & Lomb Incorporated.

† Yellox is the first and only twice-daily topical ocular NSAID indicated * Yellox has demonstrated clinical efficacy in two weeks with BID dosing. for the treatment of postoperative inflammation in patients who have Treatment duration & dosing is relative to current clinical standards undergone cataract extraction.1 In a large phase III trial, BID Yellox for across Europe as well as older available NSAIDs.3-7 14 days controlled ocular inflammation (SOIS=0) in 59.3% of patients vs 26.9% with placebo (p<0.0001).2 AL ONN ESO 07:15 -08:15 EARLY MORNINGSESSION BREAKFAST CIS SATURDAY Uranie 95 EVER 2012 Programme book 96 EVER 2012 Programme book 08:15 - 09:45 FIRST MORNINGSESSION FIRST 08:15 -09:45 SATURDAY 92 4235 4234 09:27 4233 09:09 4232 08:51 08:33 4227 4226 09:15 4225 09:09 4224 09:03 4223 08:51 4222 08:39 08:27 4216 09:30 4214 09:15 4213 09:00 4212 08:45 08:30 81 4211 08:15 81 4231 08:15 08:15 I Unmetneedsintreatment ofretinal diseases RV SIS I Updateonkeratoconus pathophysiology COS SIS Dystrophy, Infl RV FP

4221 4215 Gisèle SOUBRANE Isabelle AUDO, EberhartZRENNER, PierreBITOUN François MALECAZE, JosephCOLIN rf rf rf Prevention of AMD GATZIOUFAS Z–Homburg/Saar Endocrinology andkeratoconus MENEZO ROZALENJL, PERIS-MARTINEZ C–Valencia Oxidative stressinkeratoconus JUN A–Baltimore Infl ammation inthepathogenesisofkeratoconus TOUBOUL D–Bordeaux Biomechanics inkeratoconus SOLER V, CASSAGNE M, FOURNIEP, MALECAZEF–Toulouse Genetics ofkeratoconus SAAB S, BUTEAU B, LECLEREL, CREUZOT-GARCHER C, BRON A, BRETILLONL, ACAR N–Dijon HUBAULT B, SETROUKE, ZAMBROWSKIO, DUCASSE A, ARNDT C–Reims DELMAS J, DARDEML, AJZENBERG D, ADENIS JP, ROBERT PY–Limoges JOUFFROY T, BODAGHI B, ROZENBERGF, LEHOANGP–Paris Etiologic distributionofnecrotizingretinopathies: anine-yearexperienceatuniversityreferral centre LE MEURG, LEBRANCHUP, PEREON Y, BILLAUD F, IVAN C, CHAUVEAU C, ROLLINGF, WEBER M–Nantes Effi cacy andsafetyofgenetherapy with AAV4 inchildhoodblindnessduetorpe65mutations BITOUN P, PIPIRASE, BENZACKEN B, DELAHAYE A–Bondy ARHGEF26/SGEF controlsfoveaformation, immunity, neurodevelopmentandarteriosclerosis KITIRATSCHKY V, SACHS H, STINGLK, WILHELM B–Tübingen, Reutlingen, Dresden ZRENNER E, BARTZ-SCHMIDT KU, GEKELERF, GREPPMAIERU, HEKMAT A, HOERTDOERFER G, KERNSTOCK C, Clinical studyresultswithnewwirelesselectronicsubretinalimplantalpha-ims BEHAR-COHEN F–Paris Targeted delivery LOEWENSTEIN A–Tel Aviv Non diabeticCME BODAGHI B–Paris Reccurence ofvasculitis LEROY BP–Ghent Genetic retinaldiseases STAURENGHI G–Ponte Lambro Geographic atrophy CREUZOT C–Dijon plasmalogen defi ciency Comparative studyofpost-natalretinalvascular developmentinmicemodelsofiPLA2inhibitionand Circadien cycleandchroniccentral serouschorioretinopathy Ocular prognosisofcongenitaltoxoplasmosis (genotypesIIandIII) ammation, Miscalleneous Euterpe Uranie Erato IS ONN ESO 08:15 -09:45 MORNINGSESSION FIRST 91 4266 4265 09:15 4264 09:03 08:51 4262 08:39 08:27 4254 4253 09:21 4252 08:59 08:37 4246 4245 09:15 4244 09:03 4243 08:51 4242 08:39 08:27 81 4241 08:15 81 4261 08:15 4251 08:15 I Cataract andglaucomasurgery, combinedorstaged? G SIS Neuro-ophthalmology 1 FP PRetinalphysiologyandpharmacology PBP FP NSPH

4263 Thierry ZEYEN Aki KAWASAKI, Antonella BOSCHI Leopold SCHMETTERER, Amandio ROCHADESOUSA rf Kuopio REINISALO M, PAIMELA T, RYHäNEN T, KAUPPINEN A, KOSKELA A, SOININEN T, KAARNIRANTA K, KARJALAINENRO– BRON A, BRETILLONL–Dijon, Saint-Etienne ACAR N, BERDEAUX O, HEZ, GREGOIRES, CABARETS, MARTINE L, GAINP, THURET G, CREUZOT-GARCHER C, Cicrulating markers ofretinalandopticnerve lipids KOEHRER P, SAABS, BRON A, ACAR N–Dijon Polyunsaturated fattyacidsandPlasmalogensindiabetics ROCHA DESOUSA A, PEREIRA-SILVA P, AZEVEDO-PINTO S, RODRIGUES-ARAUJO J, Ghrelin’s expressionintheeyeanditsimplicationreductionofintraocular pressure FOKINA DV, BOIKO EV, REITUZOV VA–St. Petersburg Drug deliverybyionichydrogelcontactlensesinpreoperative prophylaxisofintraocular infections Ghent MARTENS TF, VERCAUTEREN D, FORIERK, DESCHOUTH, REMAUT K, DEMEESTERJ, DESMEDTSC, BRAECKMANSK– An exvivoassaytomeasuretheintravitreal mobilityofnanomedicinesforretinalgenetherapy MCNAUGHT A–Cheltenham Combined approach: practical tips ZEYEN T–Leuven Staging thesurgeries: glaucomafi rst orcataract fi rst? BRON A–Dijon Combined approach, theyieldofmicroincisionsforcataract surgery SUNARIC MEGEVAND G–Geneva Cataract andglaucoma surgery, combinedorstaged: wheredowestand? CALVO PéREZP–Zaragoza FERRANDEZ ARENAS B, GIL-ARRIBASL, FERRERAS AMEZ A, ARA GABARREM, SATUé PALACIáN M, BAMBO MP, Evaluation oftheretinalfi ber layerthicknessasabiomarker forsleepapneasyndrome ARNAUD M, NADEAU S, AZIZ A, HAMDANJ, DENISD–Marseille Strabismus andvisualacuityinchildrenwithocularcoloboma BENNAI D, CRETUI, FICHTEN A, SEVESTREH, COPINH, BREMOND-GIGNAC D–Amiens Four-year- oldchildwithopticnervegliomarevealedbyaproptosis DE KEIZERRJW, SCHUTTEP–Edegem, Leiden Apoplexy inpituitarytumors, clinicalandMRIanalyses GRZYBOWSKI A, SCHMIDTD–Poznan, Freiburg Boleslaw Wicherkiewicz: interestingcontributortoEuropeanophthalmology LORENZ B–Giessen Chromatic pupillometryashighlysensitivetestingmethodofphotoreceptorfunctioninretinaldystrophies Oxidative stressinretinalpigmentepithelialcells: protectiveeffectofwood-derivedphenoliccompounds TAVARES-SILVA M, PINHOS–Porto Gallieni 1&2 SATURDAY Thalie Clio 97 EVER 2012 Programme book 98

EVER 2012 Programme book Intermediate 08:15 - 09:45 FIRST MORNINGSESSION FIRST 08:15 -09:45 SATURDAY in ahands-onapproach. a options treatment practical and techniques developed newly by diagnosis differential and clinical practical its of as well as 92 4287 4286 09:21 09:15 09:03 4284 4283 08:51 4282 08:39 08:27 09:30 09:15 4274 4273 09:00 4272 08:45 08:30 ic osrcie G hs e smtm i iiil tgs ad t aypoai fr i ee mr wd-ped icesn clinic increasing wide-spread, more even is form asymptomatic its and stages, initial in symptoms few has MGD obstructive Since also inasubsequentdestructionoftheglandtissue. disease.eye dry of defilipid a in only not results glands Meibomian the of obstruction Chronic evaporativewith ciency eye dry Ocular and Film Tearthe of Surface Society report (TFOS). MGD Thisthe chronic diffuse dysfunction of the with Meibomian glands appears to represent the disease most frequent underly surface ocular of focus the into come has (MGD) Disease Gland Meibomian 81 4271 08:15 knowledge on MGD is desirable in order to allow a timely diagnosis and effective therapy. State of the art concepts of MGD path 81 4281 08:15 ACB Course 14 PPhysiologicalopticsandvisualfunction EOVS FP

4285 4275 Erich KNOP, NadjaKNOP MGD -Pathophysiology, diagnosisandclinicaltreatment John L. BARBUR, Graham HOLDER rf rf THIERRY M, BUTEAU B, PASQUIS B, ACAR N, BRON A, CREUZOT-GARCHER C, BRETILLON L–Dijon MACHALINSKA A–Szczecin DELETTRE C, BONNET WERSINGER D, LENAERSG, TANIZAWA Y, HAMELC–Montpellier, Ube Characterization ofvisualimpairmentina Wfs1 mousemodelof Wolfram syndrome HOFFART L, CASADESSUSO, GEORGESG, SIOZADE L, DEUMIéC–Marseille scattering measurements Characterization ofhumancornealgrafts’ transparency byopticalcoherencetomography and BARGARY G, BARBURJL–London The effectofdiscomfortglareonparallel processingofvisualinformation JIA Y, BARGARY G, BARBURJL–London Effect oflightsourcesizeondiscomfortglarethresholds PATTERSON EJ, BARGARY G, BARBURJL–London Can scatteredlightimprovevisualperformance? European Perspectives onthePractical ClinicalSituationforMGD, Round table BREMOND-GIGNAC D, CHIAMBARETTA F–Amiens, Clermont-Ferrand Special featuresofMGDinchildren: howtodiagnosetreatandtheFrench perspectiveonMGD HORWATH-WINTER J, RABENSTEINERDF, BOLDINI–Graz & The Austrian perspective onMGD Identifi cation ofMGDindryeyepatientsanditstreatmentthepractical clinicalsetting PURSLOW C–Plymouth perspective onMGD Physical therapy inMGDasacornerstoneforimprovementofsignsandsymptoms& The British KNOP N, KORB DR, BLACKIE CA, KNOPE–Berlin, Boston Obvious, non-obviousMGDandnewtherapy options&theGermanperspectiveonMGD KNOP E, KNOPN, SULLIVAN DA–Berlin, Boston Anatomy, physiologyandpathophysiologyofthemeibomiangland Fructose dietinducedshort-termimpairmentofconesensitivity andgeneexpressioninrat retina Adjuvant stemcell-basedtherapy inacuteretinalinjuryaftersodiumiodateadministration inmice Gallieni 4 Gallieni 3 re explained re disease but ophysiology ing cause al

ENT ESO 09:50-10:35 SESSION KEYNOTE 10:30 10:00 09:50

4311 Award oftheEVER certifi cate ofhonour AMBATI J–Lexington Diced Alu: Canningtheblindinginfl ammasome Introduction byBahram BODAGHI KEYNOTE LECTURE KEYNOTE Jayakrishna AMBATI Diced Alu: Canningtheblindinginfl ammasome SATURDAY Uranie 99 EVER 2012 Programme book 100 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 SATURDAY 21 4426 12:20 4425 12:10 4424 12:00 4423 11:45 4422 11:30 11:15 4416 4415 12:15 4414 12:00 4413 11:45 4412 11:30 11:15 10 4411 11:00 10 4421 11:00 I Pathogenesis ofmacularoedemaandneurodegeneration in RV SIS MSOIE/CAC -Indocyaninegreen angiography (ICGA): RV JM Matus REHAK, Peter WIEDEMANN Carl PHERBORT, PiergiorgioNERI vascular retinal diseases is itstillrelevant today? Discussion PARRAVANO M, VARANO M, VIRGILI G–Rome, Firenze Integrated imagingapproachinRAPdiagnosis TRAN THC, QUERQUESG–Lille, Paris indocyanine greenangiography Anatomic responseofoccultchoroidalneovascularization tointravitreal ranibizumab: astudyby KANG SW, JHKIM, HAHS–Seoul Anatomical locationofpolypoidalchoroidalvasculopathy lesionsinferredfromsimultaneousICGA-OCT NICOLO M–Genova Advances incentral serouschorioretinopathy: fromdiagnosistotreatment HERBORT CP–Lausanne ICGA ininfl ammatory diseases NERI P, ARAPI I, CAPUANO V, PIRANI V–Ancona ICGA: whyIthinkthatitisstillrelevant today REHAK M, WIEDEMANN P, RAO NA–Leipzig, Los Angeles Neurodegeneration inretinaldiseasesandnewstrategies initsinhibition REHAK J–Olomouc Twenty yearsresultsofretrospectiveinterventionalstudy Treatment ofmacularoedemaduetobranch retinalveinocclusionwithlaserinducedarterialconstriction. POURNARAS CJ–Geneva Vasomotor reactionofretinalarteriolesinhypoxic andischemicconditions WIEDEMANN P, REHAKM–Leipzig Combination ofranibizumab andlaserphotocoagulationinCRVO YANDIEV Y, BRINGMANN A, WIEDEMANN P–Leipzig Role ofretinalglialcellsinpathogenesismacularoedema DEISSLER H, LANGG–Ulm In vitrostudiesonthemechanismofaction VEGF anditsinhibitorsonblood-retinabarrier Euterpe Uranie EODMRIGSSIN 11:00 -12:30 SECOND MORNINGSESSION 20 4447 12:06 4445 12:00 4444 11:48 4443 11:36 4442 11:24 11:12 4435 4434 12:12 11:54 4432 11:36 11:18 10 4431 11:00 10 4441 11:00 POcularsurfaceanddryeye COS FP Current managementofkeratoconus SIS COS

4446 4433 Dominique BREMOND-GIGNAC, Thomas FUCHSLUGER Rafael I. BARRAQUER, RalphMICHAEL rf rf MADIGAN MC, YOU JJ, WEN L, HODGESC, ROUFAS A, MCAVOY JW, SUTTON G–Sydney DAULL P, FERAILLEL, ELENAP, BAUDOUIN C, GARRIGUEJS–Evry, LaGaude, Paris BENAYOUN Y, ADENIS JP, CASSEG, FORTE R, ROBERT PY–Limoges, Naples Effects ofsubconjunctival bevacizumab oncornealneovascularization: resultsofaprospectivestudy HAMED AZZAM S, BRISCOED, TOMKINS O, SHEHADEHM, GARZOZIH–Afula, Haifa corneal ablationformyopia Evaluation ofintraocular pressureaccordingtocornealthicknessbeforeandafterExcimerlaser CANADAS SUAREZ PILAR, HERNANDEZ-VERDEJOJL, DEBENITO LLOPISL, DRAKEP, TEUS MA–Madrid Keratocyte densityaftermicrokeratome LASIKversusfemtosecondlaser-assisted LASIK SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I–Voronezh Pathogenetic evaluation oftheocularsurfacedrugcorrectioninpatientsbeforeLASIK GICQUEL JJ, DJABAROUTIM, ZAKARI W, BREMOND-GIGNAC D, PISELLAPJ–Poitiers, Amiens, Tours Assessment ofdryeyeafterLASIKbyreal-timemeasurementhigherorderaberrations variation CAPOROSSI ALDO, MAZZOTTA C, PARADISO AL–Siena Cross linkingforkeratoconus -clinicalresultscomparingepitheliumremoval versusnoremoval VEGA-ESTRADA A, ALIO JL, MICHAELR, BARRAQUER RI–Alicante, Barcelona the RETICSmulticentricalstudy Visual andrefractive outcomesofintracorneal ringsegmentsinthetreatmentofkeratoconus: BARRAQUER RI, ALFONSO J, MURTA J–Barcelona, Oviedo, Coimbra Keratoconus patternsandintrastromal segments FOURNIE P, TOUBOUL D, ARNE JL, COLINJ, MALECAZEF–Toulouse, Bordeaux Long-term resultsofdeepanteriorlamellarkeratoplasty inpatientswithkeratoconus COLIN J–Bordeaux Keratoconus andkeratectasia Secreted frizzledproteinsincontrolandkeratoconus (KC)tearsandcorneas Comparison oftheanti-infl ammatory effectsofartifi cial tearsinarat modelofcornealscraping SATURDAY Thalie Erato 101 EVER 2012 Programme book 102 EVER 2012 Programme book 1 0 23 SECOND MORNINGSESSION 11:00 -12:30 SATURDAY 20 4468 4467 12:08 4466 11:58 4465 11:50 4464 11:40 4463 11:30 4462 11:20 11:10 4457 12:06 4455 11:54 4454 11:42 4453 11:30 4452 11:24 11:12 10 4451 11:00 10 4461 11:00 PImaging2/ Treatment inglaucoma G FP MOOGsession1-Uvealmelanoma JM

4456 Gordana SUNARICMEGEVAND, Anna-Maria STEVENS Bertil DAMATO, NathalieCASSOUX rf rf Diagnostic abilityforglaucomaofimagingtechnologiesbasedonopticnerveheadparameters PIPERNO-NEUMANN S–Paris high riskuvealmelanomapatients(FOTEADJ) A randomized multicentricphaseIIIongoingstudyofadjuvant fotemustine versusobservation in Paris, paris DESJARDINS L, LEVYC, LUMBROSO-LEROUICL, CASSOUXN, SASTREX, ASSELAIN B, PLANCHERC, COUTURIERJ– Fine needleaspiration biopsyinuvealmelanoma: theCurieexperience GRANGE JD, MONTEIRO S, BENTALEB Z–Lyon Lethal metastaticciliarybodymelanomawithouthepaticdiseaseinayounggirl ALJAMAL R, KIVELÄ T–Helsinki Uveal melanomaamongFinnishchildrenandadolescents DESJARDINS L–Paris, Orsay CASSOUX N, COUTURIERJ, PLANCHERC, LUMBROSO-LEROUICL, LEVYC, ASSELAIN B, DENDALER, AERTS I, Pediatric uvealmelanoma PAOLI V, DELASJ, CAUJOLLE JP–Nice Second courseofprotonbeamtherapy forrecurrentuvealmelanoma MASCHI C, GASTAUD P, GALJ, CAUJOLLE JP–Nice When shouldweretreatchoroidalmelanomas? CAUJOLLE JP, PAOLI V, CHAMOREYE, MASCHIC, HANNOUN-LEVIJM–Nice Local recurrenceafteruvealmelanomaprotontherapy: prognosticconsequences LIASKA A, ANDRIANOPOULOU K–Lamia Bruxelles, Liège, Antwerpen, Isnes, Seattle POURJAVAN S, COLLIGNONN, DEGROOT V, GEENSP, MAGINNESS M, MARSHALL A, ROY C, ALVAREZ M– STARfl oTM, anewsuprachoroidal drainage implantforglaucoma: 3monthsclinicalresults VAN DE VEIRE S–Maastricht Therapeutic optionsfornarrowangleglaucoma LIASKA A, PAPAKONSTANTINOU D, THEODOSIADIS P, CHATZISTEPHANOU K–Lamia, Athens model ofglaucomaprogressionaftersurgicaltreatment. Advanced openangleglaucomawithcontrolledintraocular pressureandcataract: one-yearpredictive GIZZI C, CELLINIM, CAMPOSEC–Bologna JONAS JB, JONASS, JONASR, HOLBACH L, DAI Y, SUNX, PANDA-JONAS S–Mannheim, Erlangen, Shanghai Parapapillary atrophy: histologicalgammazoneanddelta GIL ARRIBAS L, ARA M, FERRERAS A, SATUE M, BAMBOM, FERRANDEZB–Zaragoza 2nd trabeculectomy) versuscombined(phacotrabeculectomy) surgery Marginally controlledopenangleglaucomaandcataract: sequential(1stphacoemulsifi cation, Biomechanical responseoflaminacribrosaandprelaminartissuetoanacuteinducedIOPelevati Gallieni 1&2 Clio EODMRIGSSIN 11:00 -12:30 SECOND MORNINGSESSION 20 4486 4485 12:00 4484 11:48 4483 11:36 4482 11:24 11:12 4477 4476 12:06 12:00 4474 11:48 4473 11:36 11:24 10 4471 11:12 11:00 11:00 PFunctional studiesofretinal cells ACB FP Neuro-ophthalmology 2 FP NSPH

4481 4475 4472 Heli SKOTTMAN, Goran PETROVSKI Andrzej GRZYBOWSKI, Francisco ASCASO rf rf rf SCHLINGEMANN RO, SIEMERINKMJ, GRIFFIOEN AW, KLAASSENI, VAN NOORDENCJF–Amsterdam HYTTINEN J, VAINIO I, KHAMIDAKH A, JUUTI-UUSITALO K, LUUKKANENH, SKOTTMAN H, NYMARKS–Tampere Assessment oftheretinalpigmentepithelialfunctions-modellingapproach SKOTTMAN H, VAAJASAARI H, NYMARKS, JUUTI-UUSITALO K, HYTTINENJ, UUSITALO H, ILMARINEN T–Tampere functionality Human pluripotentstemcellderivedretinalpigmentepitheliumfulfi lls requirementsoftheinvitro PETROVSKI G, ALBERT R, KRISTóFE, ZAHUCZKYG, BERTA A, FESUSL–Debrecen in theretina Triamcinolone regulatedapopto-phagocyticgeneexpressionpatternsintheclearance ofdyingcells VIIRI J, HYTTINENJ, SALMINEN A, KAARNIRANTA K–Kuopio ARPE-19 cells The p62/sequestosome1bindsirreversiblytoproteinaggregatespriorautophagyclearance in KAARNIRANTA K, VIIRI J, HYTTINENJ, SALMINEN A–Kuopio AICAR induceseffectivelyautophagyclearance in ARPE-19 cells BUIJSROGGE M, CLAERHOUTI, DELBEKEP, WALRAEDT S, DECOCKC–Ghent ALSHAMEKH S, HERTZ J, DEROSAB, UDDINS, PATEL R, SALEROE, DYKXHOORN D, GOLDBERGJL–Miami BIKBOVA G, OSHITARI T, YAMAMOTO S–Chiba advanced glycationend-productsinadultrat retinas Neuroprotective andregenerative effectofneurotrophin-4onneuronaldegeneration inducedby SATUE M, BAMBOM, GARCIA-MARTIN E, FERRANDEZB, GIL-ARRIBASLM, ARA M–Zaragoza Correlation betweenfunctionandstructureofretinalnervefi ber layerinParkinson disease MONTEIRO M, AFONSO C–SãoPaulo with frequencydomain-OCT Quantifi cation ofaxonallossinpseudotumorcerebrisyndromeusingmacularthicknessmeasurements MONTEIRO K, CHARLIERJ, DEFOORT-DHELLEMMES S–Compiègne, Pérenchies, Lille Evaluation ofanewtechniquetoevaluate thevisualpursuitininfants HALFELD FURTADO DEMENDONCAR, ABBRUZZESE S, BAGOLINI B, NOFRONII, FERREIRAEL–Rome, JuizdeFora -MG Importance ofvisualevoked potentialinamblyopicchildren mechanisms ofocularangiogenesis CD34 marksangiogenictipcellsinhumanvascular endothelialcell cultures: anewmodeltostudy The useofpropranolol inthetreatmentofperiocularinfantilehemangiomas feeder-free conditions Generating humanretinalganglioncellsfrominducedpluripotentinfeederand Gallieni 4 Gallieni 3 SATURDAY 103 EVER 2012 Programme book

UCTM ESO 12:35 -13:35 SESSION LUNCHTIME Moderator: Ramin TADAYONI 31 4513 13:30 4512 13:10 12:50 24 4511 12:40 12:35 Summary LOEWENSTEIN A–Tel Aviv VEGF Trap-Eye: updateonongoingclinicaltrials WEBER M–Vertou The VIEW Studies: clinicalresultsinwet AMD TADAYONI R–Paris VEGF Trap-Eye: featuresofthemolecule Introduction LUNCHTIME CIS LUNCHTIME in 2012andbeyond The managementofneovascular AMD SATURDAY Uranie 105 EVER 2012 Programme book

IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 45 4636 4635 14:50 4634 14:35 4633 14:20 4632 14:05 13:50 4618 4617 14:41 4616 14:35 14:29 4615 4614 14:23 4613 14:11 13:59 4612 13:47 33 4611 13:35 33 4631 13:35 FAN Club RV JM up inthespeakers room. keyand memory USB a on case interesting single a of presentation powerpoint a bring to welcome are session this at Presenters In additionenfaceOCTcaseswillbepresented. Each casepresentationlastsfor10minuteswith5discussion. This session isopentoallEVERdelegates. Cases withretinalimagingarepresentedanddiscussedapanel. International Fluorescein Angiography Club-www.fan-int.org PVascular Diseas FP I Keratoprostheses 1 COS SIS RV Anita LEYS Constantin POURNARAS, Albert J. AUGUSTIN Christopher LIU, Thomas FUCHSLUGER rf rf rf rf BUSUTTIL A, HEROLDJ, LIUC–Hastings, Brighton Psychological factors andcomplicationsinOOKPassessment andsurgery LEE R, ONGG, LAMF, WHITE J, HEROLDJ, LIUC, HULLC–Brighton, London A studyofthereallifeperformance of OOKPopticalcylinders AVADHANAM V, HAWKES G, BRITTAIN P, HEROLDJ, THORP S, LIUC–Brighton Oculoplastic complicationsofOOKP surgery LIU C, NORRIS J, FRANCISI, AVADHANAM V, THORP S, HEROLDJ–Brighton Advances inimagingoftheOOKPlamina COLBY K–Boston Boston Keratoprosthesis in2012: preventingcomplications andoptimizingoutcomes ETXEBARRIA J, ORIVE A, SANTAMARIA A, FEIJOOR–Bilbao Infection andinfl ammation inBoston Type 1KPro KALITZEOS A, SUMMERSRJ, HEITMARR–Birmingham GARCIA FERNÁNDEZM, CASTRONAVARRO J, GONZÁLEZCASTAÑO C–Oviedo AKNIN I, MELKIL–GolfeJuan, Cannes Bremen, Heidelberg, GiessenandMarburg, Dresden, Marlow, Ludwigshafen SEKUNDO W, SANDNERD, MALTMAN J, SHIRLAW A, HATTENBACH L–Karlsruhe, Bonn, München, Munster, AUGUSTIN A, HOLZF, HARITOGLOU C, MEYER W, LOMMATZSCH A, BOPPS, SCHEUERLE A, MAIERM, FORTOUL V, DENISP, KODJIKIAN L–Lyon Ozurdex® Clinical andSD-OCTpatternofretinalvenousocclusionwithcystoidmacularoedematreated RADOI C, AFRIAT M, DUCASSE A, ARNDT C–Reims Prevention ofocularhypertensioninpatientsreceivingintra-vitreal steroids SCHMETTERER L–Vienna WEIGERT G, SACU S, GEORGOPOULOSM, PALKOVITS S, BLUMR, REZARS, EIBENBERGERK, SCHMIDT-ERFURTH U, after successfulvitrectomy The infl uence ofretinaloxygenation on theclinicaloutcomesineyeswithepiretinalmembrane PALKOVITS S, WERKMEISTER R, TOLD R, GRÖSCHELM, LEITGEBR, GARHÖFERG, SCHMETTERERL–Vienna Doppler Fourier-domain opticalcoherencetomography Response ofretinalbloodfl ow tosystemichyperoxia asmeasuredwithdual-beambidirectional Retinal vascular reactivity overextendedvesselsegments Pars planavitrectomyforvalsalva retinopathy: acaseseries retrospective caseseriesanalysis Dexamethasone drugdeliverysystem(Ozurdex)forthetreatmentofrefractory diabeticmacularoedema: macular oedemasecondarytoretinalveinocclusion A retrospectivedatacollectionstudyinpatientsreceivingtwoormoreOZURDEX®injectionsfor Euterpe Uranie SATURDAY Erato load it load 107 EVER 2012 Programme book 108 EVER 2012 Programme book 13:35 - 15:05 FIRST AFTERNOONSESSION FIRST 13:35 -15:05 SATURDAY 44 4657 4656 14:47 4655 14:35 4654 14:23 4653 14:11 13:59 4652 13:47 4648 4647 14:41 4646 14:35 4645 14:29 4644 14:23 14:11 4643 13:59 4642 13:47 33 4641 13:35 33 4651 13:35 PImaging COS FP PTranslational research inglaucoma G FP Leopold SCHMETTERER, PierreJeanPISELLA Neville OSBORNE, Alain BRON rf rf rf rf rf Evaluation oflowertearmeniscusshapewithOCT DE GROEFL, GAUBLOMME D, JANSSENSE, DEKEYSTER E, MOONSL–Leuven VAN DE VELDE S, VAN BERGEN T, SIJNAVE D, HOLLANDERSK, MOONSL, STALMANS I–Leuven control inDutchBeltedRabbits Topical applicationof AMA0076, alocallyactingrhokinase (ROCK)inhibitor, resultsinarobustIOP STALMANS I–Leuven VAN BERGEN T, JONCKX B, HOLLANDERSK, SIJNAVE D, VAN DE VELDE S, VANDEWALLE E, MOONSL, STASSEN JM, Inhibition ofplacentalgrowthfactorimprovessurgicaloutcomeglaucoma surgery SIJNAVE D, HOLLANDERSK, VAN BERGEN T, VAN DE VELDE S, VANDEWALLE E, MOONSL, STALMANS I–Leuven wound healing Outcome improvementofglaucomafi ltration surgerythroughtheeffectoflocalrock-inhibitionon HOLLANDERS K, SIJNAVE D, VAN BERGEN T, VAN DE VELDE S, MOONSL, STALMANS I–Leuven ROCK-inhibitor (AMA0076) The effectofBenzalkonium chlorideontheintraocular pressureloweringeffi cacy ofalocal BAUDOUIN C–Paris, Gainesville DENOYER A, FRUGIER J, GODEFROY D, DEGARDINJ, BRIGNOLE-BAUDOUIN F, HARRISONJK, ROSTENE W, degeneration inananimalmodelofglaucoma Blockade ofthechemokinereceptorCXCR3lowersintraocular pressureandpreventsretinal STALMANS I–Leuven, Lisbon, Reykjavik VANDEWALLE E, PINTO LA, OLAFSDOTTIR OB, STALMANS P, VAN CALSTERJ, ZEYEN T, STEFANSSON E, Oximetry inglaucoma: correlationofmetabolicchangeswithstructural andfunctional SICARD F, JANYB, BENNAID, BREMOND-GIGNAC D–Amiens BATISTA A, LOUREIROC, DOMINGUESJP, SILVA JS, MORGADO AM–Coimbra GICQUEL JJ, DJABAROUTIM, DUPONTL, ZAKARI W, PISELLAPJ, BREMOND-GIGNAC D–Poitiers, Tours, Amiens DJABAROUTI M, ZAKARI W, NOCHEZ Y, PISELLAPJ, GICQUELJJ–Poitiers, Tours TARNAWSKA D, KOCOT A, JASTRZEBSKAM, WYLEGALA E, RATUSZNA A–Katowice low-frequency dielectricspectroscopy Spatial arrangement ofcollagenfi brils innormalandkeratoconus humancorneastudiedby Saint Etienne, Saint-Etienne THURET G, ESPINASSEM, GRIVETD, HEZ, CAMPOLMIN, PERROT JL, LABEILLEB, CAMBAZARDF, GAINP– functional confocalmicroscopyinophthalmology Fluorescence multi-laserscanningmicroscopyofthecorneaandocularadnexa: anewera for DUMOLLARD JM, FORESTF, GAINP, THURET G–Saint-Etienne GRIVET D, ESPINASSEM, CINOTTI E, LABEILLEB, CAMBAZARDF, PERROT JL, CAMPOLMIN, PEOC’HM, dermatological laser-scanning microscope: newperspectives In vivolaserscanningmicroscopyofcornea, conjunctiva andocularadnexawithahandheld BANDLITZ S, PURSLOWC, MURPHYPJ, PULT H–Cardiff Assessment ofangleandanteriorchamberchangesafterkeratoplasty Corneal respiratory functionbyFAD autofl uorescence lifetime meibomian gland Tear fi lm break-uptimeevaluation byreal-timewavefront aberrometryinadultpatientswith Tear fi lm break-uptimeevaluation byreal-timewavefront aberrometryinnormalsubjects Retinal MMPexpressionisupregulatedinanexcitotoxic mousemodelofglaucoma Thalie Clio IS FENO ESO 13:35 -15:05 AFTERNOONSESSION FIRST 44 4675 14:47 4673 14:29 4672 14:11 13:53 466a 4669 14:53 4668 14:45 4667 14:37 14:29 4666 4665 14:19 4664 14:09 4663 14:01 4662 13:53 13:45 33 4661 13:35 13:35 MOOGsession2: Retinoblastomaandothertumours JM I Ocularstraylight: newdevelopments LC SIS 4674 4671 Theodora HADJISTILIANOU, SteffenHEEGAARD Ralph MICHAEL, Thomas JTP VAN DENBERG rf VAN BREE MCJ, VAN DENBORN LI, VAN DENBERG TJTP–Rotterdam, Amsterdam Clinical relevance ofstraylight inpatientswithretinitispigmentosa TASSIGNON MJ, ROZEMAJ–Antwerp Straylight values inpseudophakes -standardIOLversusbag-in-the-lens IOL COCHENER B–Brest Straylight asindicationforcataract surgery ROZEMA J–Antwerp A statisticaleyemodelthatincorporates straylight VAN DENBERG TJTP–Amsterdam New straylight issues intreatmentoftheeye SAAKYAN S, AMIRYAN AG, ZAHAROVA G, TSYGANKOV A–Moscow Schwannoma oftheciliarbody(clinicalcase) VAN GINDERDEURENR, MISSOTTEN G, VAN CALLSTERJ–Leuven Diagnosis ofchoroidallymphoma, diffi culties andpossibilities MESQUIDA M, SOLEM, LLORENS V, ADAN A–Barcelona LARSEN A, STENMANL, RASMUSSENP, PRAUSE JU, RALFKJAERE, HEEGAARDS–Copenhagen Acute lymphoblasticleukemia intheeyeregion penhagen, Kgs. Lyngby RASMUSSEN P, HOTHER C, JOSHI T, REKER D, RALFKAER U, WORKMAN C, RALFKAER E, GRøNBæK K, HEEGAARD S–Co- B-cell lymphoma MicroRNA profi ling inocularadnexalextranodal marginalzonelymphomaanddiffuselarge PARROZZANI R, PILOTTO E, DARIO A, MIGLIONICOG, MIDENAE–Roma, Padova squamous cellcarcinoma. Combined topical5-Fluoruracil andextensivesurgeryinthemanagementofcorneo-conjunctival MAMUNUR R, KIVELÄ T–Helsinki Bilateral primaryirispigmentepithelialcysts DE FRANCESCOS, GALLUZZIP, RENIERI A, BORRIM, MAZZERAL, MENICACCI C, HADJISTILIANOU T–Siena Natural historyofanearlydiagnosedretinocytoma: casereportandliterature review SAAKYAN S, JARWAH A, YAKOVLEV S, KOBYAKOV G–Moscow Indications forintraarterial chemotherapy inpatientswithadvanced retinoblastoma Siena HADJISTILIANOU T, CORIOLANIG, BRACCO S, GENNARIP, CAINIM, CERASE A, GALIMBERTI D, DEFRANCESCOS– Successful treatmentofmacularretinoblastomawithsuperselectiveophthalmicarteryinfusion Pink pseudohypopyonasapresentingfeatureoflargeB-celllymphoma Gallieni 1&2 Gallieni 4 SATURDAY 109 EVER 2012 Programme book

OTRSSIN3 15:05 -16:20 SESSION3 POSTER Alexandre MOULIN, Rita VAN GINDERDEUREN Moderators: Oncology / Pathology S007 Iristuberculousgranuloma simulatingmedulloepithelioma S006 S005 Amelanotic conjunctival melanoma: diagnosisand S004 Sebaceous carcinoma: diagnosisandtherapeutic diffi culties S003 Digitalanalysisofthechangesincarcinomatousconjunctiva S002 Structural changesofthecorneainapatientwith S001 05Bilateral choroidalmetastases aspresentationof S015 Antitumorevaluation ofthenewBcl-2/Bcl-xlinhibitor S014 Identifi cation ofmRNAsandproteinsspecifi cally associated S013 Treatment ofmacularoedemafollowingprotonbeam S012 The mitoticindexinsecondaryenucleatedeyesofpreviously S011 Acaseofspontaneouslyregresseduvealmelanoma S010 Anewandstandardisedmethodtosampleanalyse S009 Nevermissuveallymphoma S008 rf rf dissemination ofcutaneousmalignant melanoma S44563 inprimaryhumanuvealmelanomaxenografts with transformation inocularmalignantmelanomacells intravitreal implant therapy forchoroidalmelanomawithdexamethasone700µg treated uvealmelanomapatients vitreous biopsies therapeutic management using Aperio nuclearv9algorithm microscopy images mucopolysaccharidosis (Hurler- Scheie)inconfocal Courbevoie PRIETO E, DELAMATA G, PUEYO V, RUIZ-MORENO O–Zaragoza FERNANDEZ-PEREZ S, SATUE M, GARCIA-MARTIN E, BAMBOM, MARIANI P, PIPERNO-NEUMANN S, DEPILS, DECAUDIN D NEMATI F, DEMONTRIONC, SASTREX, KRAUS BERTHIER L, DE ROSAMC, TECCE MF–Campobasso, Brescia, Fisciano COSTAGLIOLA C, SEMERAROF, ROMANOMR, CAPUTO M, BAILLIF S, GASTAUD P, CAUJOLLE JP–Nice JARDINS L–Paris BAKALIAN S, CASSOUXN, LEVY C, LUMBROSO-LEROUICL, DES- AMIRYAN AG, SAAKYAN S, TATSKOV RA–Moscow VAN GINDERDEURENR, VAN CALSTERJ–Leuven LAVILLE MA, CASSOUXN, MOURIAUX F–CAEN, PARIS MESQUIDA M, SOLEM, LLORENS V, ADAN A–Barcelona DE FRANCESCOS, MICHELIL, MENICACCI F, DELUCA A–Siena HADJISTILIANOU T, TOTI P, CORIOLANIG, CERASE A, MADIGAN MC, MUNOZ-ERAZOL, CONWAY RM–Sydney HERRERO R, GARCIA-MARTIN E, DELAMATA G–Zaragoza SATUE M, BAMBOM, ARA M, EGEAMC, FERNANDEZ-PEREZS, GAVARD-PERRET A, LAGIER J, CAUJOLLE JP–Nice ASOKLIS R, PAULAVICIENE R, PETROSKAD–Vilnius JANISZEWSKA D, PUZOLLOD–Katowice, Messyna WYLEGALA E, SMEDOWSKI A, TARNAWSKA D, WOJCIK L, BESNIARD A, DEPLATER L, LOCKHART BP, DESJARDINSL, lymphoma Pink pseudohypopyonasapresentingfeatureoflargeB-cell (HDAC) inhibitor andconjunctival melanoma Valproic acid(VPA), aclassIandIIhistonedeacetylase –Paris,

S022 S021 S020 Posttraumatic periorbitalnecrotizingfasciitis S019 AcutedacryoadenitisasatypicalpresentationinSjögren S018 Massiveanteriorchamberinvolvementinadvanced S017 Retinoblastoma–riskfactorsandqualityoflife S016 03Ophthalmologicalsymptomsincarotid-cavernoussinus S023 rf rf rf ROSEN N–Tel Hashomer ROSNER M, FABIAN ID, PRIEL A, FRIDMANE, GREENBERGG, Mechelen DE KEIZERRJW, AL SABAI N, BAL TA, DEGROOT V–Antwerp, PUTTERMAN M, BADELONI, MORAXS, GALATOIRE O–Caen, Paris COFFIN-PICHONNET S, LANGLOISB, JACOMET PV, FERNANDEZ-TIRADO FJ–Zaragoza DE LAMATA G, SATUE M, BAMBOM, ARA M, EGEAMC, FERNANDEZ-PEREZ S, HERREROR, GARCIA-MARTIN E, FERNANDEZ-PEREZ S–Zaragoza SATUE M, GARCIA-MARTIN E, BAMBOM, PRIETO E, DELAMATA G, MENICACCI F, TOTI P, MICHELIL, HADJISTILIANOU T–Siena DE FRANCESCOS, MASTRANGELOD, DELUCAMC, BOGDANICI T, ROMEEN A, COSTIND, BOGDANICIC–Iasi ROBERT PY–Limoges DO TN, BOIVINFAURE L, HOUDART E, CHAPOT R, ADENIS JP, Congenital orbitalteratoma hypereosinophilic syndrome A patientwitheyelidandanteriororbitalmyeloproliferative Idiopathic orbitalinfl ammation: areportof18cases Syndrome retinoblastoma followingintra-arterial chemotherapy fi stulas SATURDAY 111 EVER 2012 Programme book 112 EVER 2012 Programme book Christophe CHIQUET Karine ANGIOI, Antoine BREZIN, ConstantinPOURNARAS, Moderators: Retina / Vitreous 00Ratiooffovealthicknesstochoroidalincaucasians S030 Diabeticmacularoedemaandchoroidalthicknessmeasured S029 Repeatabilityofretinalthicknessandvolumemetricsin S028 Stage 1macularholesofGassclassifi cation illustrated by S027 Peripapillary changesdetectedbySDOCTineyeswithhigh S026 The humanfovearevisited-aproposednewstrategy based S025 Topography ofthehumanHenleFiberLayer(HFL)as S024 08Automatedmeasurement ofretinalvascular caliberand S038 Multimarkers fordiabeticretinopathyscreening S037 Visual acuityandcentral macularthicknesscomparison S036 Improvingdiabeticretinalclinicsinadistrictgeneral hospital S035 Changesinmacularthicknessmeasurementsrepeatability S034 Subfovealchoroidalthickness. The Beijingeyestudy S033 Dexamethasoneintravitreal implantinpatientswithmacular S032 SubfovealchoroidalthicknessinCaucasians S031 15:05 - 16:20 POSTER SESSION3 POSTER 15:05 -16:20 SATURDAY retinopathy arteriovenous ratio intype2diabeticpatients without injection andvitrectomyfordiffusediabeticmacularoedema between posteriorsub-Tenon’s capsuletriamcinolone to conformUKnationalscreeningcommitteeguidelines with ageusingCirrusFourier-domain opticalcoherence a retrospectivestudy oedema relatedtobranch orcentral retinalveinocclusion, by EDISD-OCT Heidelberg spectralis opticalcoherencetomography neovascular age-related maculardegeneration usingthe Optical Coherence Tomography scans: areviewof4cases myopia on neural connectivityforanalysisofretinalimages revealed byimagingandhistology LEE DW, BAEJH, JANGHJ, KIMJM, CHOICY–Seoul HAJDU A–Debrecen BERTA A, MOLNAR AM, TOZSER J, NAGY V, DOMOKOS B, CSUTAK A, TOROK ZS, TUKACS E, MAROS-SZABOZS, CSOSZE, NONOMURA S, OSHITARI T, YAMAMOTO S–Chiba City MALIK A, MOORESJ, PAUL B, ISLAMN–London SANCHEZ-CANO A, LOPEZDELA FUENTE C, FUERTES MI–Zaragoza PINILLA I, GARCIA-MARTIN E, IDOIPEM, FUENTESL, STEINMETZ P–Mannheim BENZERROUG M, SERREROM, BREMOND-GIGNAC D, MILAZZOS STEINMETZ P–Mannheim SCHMIDBAUER M–Mannheim DEL BUEYMA, CRISTOBAL JA–Zaragoza ASCASO F, ZABADANIK, VILLéN L, MATEO J, CASASP, JIMENEZB, DEGLI ESPOSTIS, COMYNO, KEANEPA, TUFAIL A, PATEL P–London BENTALEB Z, DENISP, KODJIKIAN L–Lyon MATRI L–Tunis CHEBIL A, BEN ACHOUR B, BOULADIM, KORT F, MGHAIETHF, EL SJÖSTRAND J, POPOVIC Z–Göteborg SJÖSTRAND J, POPOVIC Z–Göteborg Amiens – 05Effectsofarteriolarconstrictiononretinalgeneexpression S045 The effectsofexerciseonperipapillaryretinaloxygenation S044 Cataract surgeryandthedexamethasonedrugdelivery S043 RE-MI-DO Study: resultatsofamulticenterstudy S042 Intravitreal bevacizumab injectionwithgridlaser S041 RoleofSp1transcription factorinthepathogenesisof S040 Preoperative vitrectomytreatmentpreventing S039 04The invitro anti-infl ammatory andanti-angiogenic S054 Two year follow-upoflow-levellasertherapy (LLLT) in S053 Five-yearfollow-upresultsofphotodynamictherapy for S052 AMDatrophicareas. Characteristics, evolutionstudy, S051 The ringlike distributionprofi le ofmacularpigmentappears S050 Prognosticimplicationofchoroidalthicknessin S049 Plasmataurinelevelsinage-relatedmaculardegeneration S048 Ozurdeximplantinretinalveinocclusions. 3-monthsclinical S047 SD-OCTstudyofvitreoretinaltraction attheobstructionsite S046 VEKRIA P, CUBBIDGER, HEITMARR–Birmingham FERNANDEZ-LARRIPA S, FERRERAS A, ABECIA E–Zaragoza GARCIA-MARTIN E, DELAMATA G, SATUE M, BAMBOMP, ARA M, EGEA ESTOPINAN C, FERNANDEZ-PEREZS, HERREROR, POMMIER S, MEYERF–L’Ile surlaSorgue, Aix enProvence KIM HS–Seoul Philadelphia DONOVAN K, ALEKSEEV O, CHO W, AZIZKHAN-CLIFFORD J– YUKIHIKO TAKAHASHI W–Juiz deFora, Salvador, SãoPaulo ARAúJO FERRAZD, DEOLIVEIRAMAIAJUNIORO, HALFELD FURTADO DEMENDONCAR, FERREIRAEL, LANCON A, LIZARDG, LATRUFFE N–Dijon KOEV K, AVRAMOV L, BORISSOVA K–Sofi a KANG HM, KOH HJ–Seoul GONZALEZ C–Toulouse Minneapolis, Minnesota, London, Waterford VAN KUIJK E, LIEWM, BEATTY S, GILBERT C, HAMMONDC– YI JH, KWONHJ, LEECS, LEESC–Seoul PINNA A, ZINELLU A, TENDAS D, CARRU C–Sassari VARDARINOS A, EMPESLIDIS T, BANERJEES–Leicester BUEY MA, CRISTOBAL JA–Zaragoza ASCASO F, PADGETT E, VILLéN L, NúñEZE, PEIROC, CRUZ N, DEL KOEFERL P, BRINGMANN A, WIEDEMANN P, REHAK M–Leipzig system forthetreatmentofretinalvenousocclusion oedema inretinalveinocclusion dexamethasone implantationineyeswithmacular vein occlusion photocoagulation formacularoedemainbranch retinal diabetic retinopathy vitreous haemorrhage potential ofanewresveratrol-based formula (Resvega) patients withage-relatedmaculardegeneration (AMD) polypoidal choroidalvasculopathy and itsinterest. 3yearsfollow-up highly heritable: atwinstudy macular degeneration (nvAMD) ranibizumab-treated eyeswithneovascular age-related outcomes inthefi rst 17patients in patientsdiagnosedwithbranch retinalveinocclusion and müllercellsinanexperimentalretinalveinocclusion OTRSSIN3 15:05 -16:20 SESSION3 POSTER 02Intraocular pressureresponsetoacetazolamideinpatients S062 Isolatedjuxtapapillaryhaemangioma S061 Effectsofbevacizumab onnewbornrat retinalproteoglycans S060 Age relatedmaculardegeneration inthealgerianpopulation S059 Subfovealperfl uorocarbon liquid(SFCL)extraction: S058 Prognosticfactorsforvisualoutcomeafterintravitreal S057 Incidenceofretinalpigmentepithelialtearsafterintravitreal S056 Docosahexaenoic acidprotectshumanRPEcellsagainst S055 09Acuteworseningofretinal lesionsduringoral steroid S069 Ocularmanifestations of Takayasu arteritis S068 Macularinvolvementinnoninfectiousintermediate, S067 Aqueousfl are andchoroidalthicknessinpatients with S066 Cytomegalovirusretinitis(CMVR)withandwithout S065 EffectofResvegainamodelchoroidalneovascularization S064 S063 treatement inacaseofintracular lymphoma posterior andpanuveitis chronic hepatitisCvirusinfection analysis ofoutcomesinHIVpatients extra-ocular CMV(EO-CMV)Infection–acomparative in mice with retinaldetachment differentiation, invitro gene expressionandoncellproliferation, deathand and comparisonwiththeitalianone a reportofthreecases in AMD bevacizumab injectionforpigmentepithelialdetachment degeneration bevacizumab injectionforneovascular age-relatedmacular oxidative stressviaPI3K/Aktm-TOR/p70-p85S6K pathways Brussels DE SAINTHAUBAIN N, DEHOUMF, CASPERS L, WILLERMAIN F– BAZEWICZ M, PIONB, LAHDAR, BROND, MAKHOULD, BUTEL N, NOELN, BODAGHI B–Paris MGHAIETH F, ELMATRI L–Tunis BOULADI M, CHEBIL A, LARGUECHEL, KORT F, BROURJ, TURKI F, CAMPOS EC–Bologna STROBBE E, CELLINIM, BALDUCCIN, LATERZA L, BRILLANTIS, GAN N, AGRAWAL R, TEOH S–Singapore FERNANDEZ-GARCIA V, GARCIA-LAYANA A–Pamplona IVANESCU A, REDONDO-EXPOSITO A, MORENO-ORDUñAM, RECALDE S, GARCIA-GARCIAL, FERNANDEZ-ROBREDOP, MARGARON P, ELENAP–LaGaude GRILLO-ANTONELLI S, CIMBOLININ, DUBOSH, FERAILLEL, ARNDT C, DUCASSE A, GHOUALI W–Reims PEFKIANAKI M, MICHAELIDESM–London MIGUEL N–SãoPaulo, RiodeJaneiro SHOLL-FRANCO A, MARQUEZINIM, PUNTAR T, MENDEZ-OTERO R, MONTEIRO M, KREMPELP, PORTES A, MATSUDA M, ALLODI S, LAZREG S, DELCOURT C, NOURIMT–Blida, Bordeaux, Algiers Oviedo CASTRO NAVARRO J, GARCÍAFERNÁNDEZM, BAJOFUENTE A– EL MATRI L–Tunis BOULADI M, CHEBIL A, KORT F, BOURAOUI R, MGHAIETHF, EL MATRI L–Tunis CHEBIL A, KORT F, BOURAOUI R, CHAKERN, LIMAIEMR, MARTINE L, BRETILLONL–Dijon BABCHIA N, DE ARAUJO A, LECLEREL, BUTEAU B, GREGOIRES, serotonin receptor5-HT1aagonistinrats the freeradical scavengerPhenyl-N-tert-butylnitroneanda Protection ofbluelightinducedretinaldegeneration by 06Value offundusautofl uorescence imaginginarare caseof S076 Pathologic fi ndings forpatientswithacuteandsymptomatic S075 Danger ofresearchinlasers: abouttwoexamplesofretinal S074 Effect ofhemodialysisontheophthalmologicfi ndings in S073 Werner syndromeaccompaniedwithrefractory CMEand S072 Diagnosisoftuberculosisuveitis S071 Oculareffectsofcombinedtherapy withpegylatedinterferon S070 05Earlyreactionalhyperplasia andneuronaldifferentiation S085 20versus23Gaugesclerotomiesforsiliconeoilextraction S084 Subretinalinjectionofrecombinanttissueplasminogen S083 Peripheral exudativehaemorrhagicchorioretinopathy S082 Anunusualcaseofvisualdisturbanceinayoungboy S081 Unilateral Terson syndrome. Outcomeafterearlyvitrectomy S080 Experimentalstudyoftheeffectfemtosecondlaser S079 High-altituderetinopathy S078 Dramatic effectofboluscyclophosphamideinaseverecase S077 Zaragoza MATEO J, JIMENEZB, ASCASO F, MATEO A, PéREZD, CASASP– CHOI MJ–Seoul Saint-Etienne CAMPOLMI N, GRIVETD, THURET G, BERNARD A, GAINP– CHIN H, JUNGJ–INCHEON, Incheon ROY S, YAMAMOTO S–Chiba, Boston OSHITARI T, KITAHASHI M, MIZUNOS, BABA T, KUBOTA-TANIAI M, NGUYEN E, BAILLIFGOSTOLI S–Nice MUSIALIK J–Katowice, Sosnowiec SMEDOWSKI A, WOWRA B, BLONSKA-FAJFROWSKA B, ORSKI M, WYLEGALA E, MANKOWSKI W, TARNAWSKA D, WOJCIK L, DUCOURNAU D, PACELLA E–Paris, Nantes, Saint-Etienne, Roma SCHMIDT MORANDD, GAUTHIER O, LAVAL A, HOLOPHERNE D, BOSCHER C, DUCOURNAU Y, GUILLAUBEY C, BOSSARDC, RADOI C, HAYATE F, DUCASSE A, ARNDT C–Reims GICQUEL JJ–Poitiers, LaRochelle DJABAROUTI M, FRISERL, GOBERT F, DEBEKETCHC, YANI N, XIROU T–Athens KABANAROU SA, FOTIOU P, ROUVAS AA, GEORGIADISOP, PEFKIANAKI M, MICHAELIDESM–London FERNANDEZ-PEREZ S, HERREROR, GARCIA-MARTIN E–Zaragoza DE LAMATA G, SATUE M, BAMBOM, ARA M, EGEAMC, ZADOROZHNYY O, PASYECHNIKOVA N, KOROL A–Odessa SWALDUZ B, DOT C–Lyon, Chamonix, Paris RUSSO A, AGARD E, BLEINJP, ELCHEHABH, RACT-MADOUX G, KURUN S, BAUDOT A, MAALOUF T, ANGIOI K–Nancy clonazepam associatedretinopathy fl oater impacts inseniorresearchers chronic renalfailurepatients WRN proteinsexpressioninhumanretinas (PegINF) andribavirin(RBV)inhepatitisC in theporcineeye detachment (RD)withproliferative vitreoretinopathy (PVR) of theciliaryepithelium(CE)inexperimental retinal in vitreoretinalsurgery degeneration. A reportofeightcases subretinal hemorrhagessecondarytoage-relatedmacular activator andintravitreal injectioninthemanagementof complicated withacuteonsetofvisualloss radiation oneye fundusandsclera morphology of lupusretinopathy SATURDAY 113 EVER 2012 Programme book 114 EVER 2012 Programme book 03Changesinchronobiologicalfunctionrelatedtoretina S093 Recurrentretinaldetachmentsecondarytohereditary S092 S091 Bilateral macularcolobomainapatientwithretinitis S090 Intraretinal brilliantblueinfi ltration duringmembrane S089 Longtermevolutionofcombinedhamartomathe S088 Age maculardegeneration-Alzheimer disease: relevance S087 Traumatic macularholerevealingaretinitispigmentosa: S086 S100 S099 S098 S097 Ocularsarcoidosis: whenshouldlabialsalivary glandbiopsy S096 Ischemicmaculopathywithtemporal macularthinningon S095 Bilateral intermediateuveitisasociatedwithretinosis S094 rf rf rf rf 15:05 - 16:20 POSTER SESSION3 POSTER 15:05 -16:20 SATURDAY be performed? retinopathy: aboutthreecases spectral-domain opticalcoherencetomography insicklecell pigmentosa degeneration P23Hline1transgenic rats congenital collagendisease pigmentosa like changes limiting internpeeling: acasereport retinaandretinalpigmentepithelium: areportoftwocases follow-up of Alzheimer disease and interestofophthalmologicexamindetection a casereport WANG Y, ZHOUJ, YOU Q–Mannheim, Beijing JONAS JB, WEI W, XUL, SHAO L, DUK, WANG S, CHENC, XUJ, ARA M, SATUE M–Zaragoza BAMBO M, FERRANDEZB, GARCIA-MARTIN E, GIL-ARRIBASL, HALDAR S, DAVIES N–London GONZALEZ C–Toulouse DENIS P, KODJIKIAN L–Lyon RAHMI A, BERNARDC, SEVEP, BANCELB, ISAAC S, BROUSSOLLEC, MEZIANI L, BONNELS, LAROCHEL, HAMARDP, MONINC–Paris SATUE M, IDOIPEM, DE LAMATA G, TORRóN C–Zaragoza HERRERO LATORRE R, FERNANDEZ-PEREZS, GARCIA-MARTIN E, SEGURA F, CUENCAN–Zaragoza, Alicante ESQUIVA GEMA, PEREZ-GARCIAD, RAMIROP, SANCHEZ-CANO A, PINILLA I, LAXP, FUENTESL, FERNANDEZ-SANCHEZL, GARCIA-MARTIN E, DELAMATA G, SATUE M–Zaragoza BAMBO M, ARA M, EGEAMC, FERNANDEZ-PEREZS, HERREROR, REKIK R, CHARFEDDINER–Tunis, Sousse XIROU T–Athens KABANAROU SA, KOUROUPAKI A, PORTALIOU DM, FERETISE, DENIS P, KODJIKIAN L–Lyon SAVARY P, LEALC, MACHKOUR-BENTALEB Z, CHAISEF, FORTOUL V, CASTRO NAVARRO J, GARCÍAFERNÁNDEZM–Oviedo GONZALEZ C–Toulouse BAUDOT A, KURUN S, MAALOUF T, ANGIOI K–NancyBrabois Subfoveal choriodalthickness: theBeijingEyeStudy Tomography measurements Infl uence ofcataract inreproducibilityofOpticalCoherence registration ofOCTtopography forstatisticalanalysis Assessment ofdifferentmethodsforinter-individual 4 yearsfollow-up AMD treatedbyseriesof3RanibizumabIVTprotocol, evolution ofatrophiclesionsassociatedtoneovascular Atrophic areasand/withneovascular AMD. Characteristics, ramipril inpatientswithStargardt’s disease Priminary observations oftheeffects ACE inhibitor S106 S105 S104 S103 S102 S101 S111 S110 S109 S108 S107 rf rf rf rf rf rf rf rf rf rf rf AKNIN I, MELKIL–GolfeJuan, Cannes Dresden, Marlow, Ludwigshafen München, Munster, Bremen, Heidelberg, GiessenandMarburg, MALTMAN J, SHIRLAW A, HATTENBACH L–Karlsruhe, Bonn, BOPP S, SCHEUERLE A, MAIERM, SEKUNDO W, SANDNERD, AUGUSTIN A, HOLZF, HARITOGLOU C, MEYER W, LOMMATZSCH A, BRETILLON L, ACAR N–Dijon SAAB S, BUTEAU B, LECLEREL, CREUZOT-GARCHER C, BRON A, ARNDT C–Reims HUBAULT B, SETROUKE, ZAMBROWSKIO, DUCASSE A, Limoges DELMAS J, DARDEML, AJZENBERG D, ADENIS JP, ROBERT PY– RADOI C, ZAMBROWSKI O, DUCASSE A, ARNDT C–Reims ESPOSTI G, ESPOSTIPL–Siena FRUSCHELLI M, SPARAGNA MC, DENARO R, MENICACCI F, PIERRU A, BAILLIF-GOSTOLI S, GASTAUD P–Nice VAN NOORDENCJF, KLAASSENI–Amsterdam SCHLINGEMANN RO, WISNIEWSKA-KRUK J, VOGELS IM, KALITZEOS A, SUMMERSRJ, HEITMARR–Birmingham GONZÁLEZ CASTAÑO C–Oviedo GARCIA FERNÁNDEZM, CASTRONAVARRO J, Pars planavitrectomyforvalsalva retinopathy: acaseseries retrospective caseseriesanalysis treatment ofrefractory diabeticmacularoedema: Dexamethasone drugdeliverysystem(Ozurdex)forthe secondary toretinalveinocclusion two ormoreOZURDEX®injectionsformacularoedema A retrospectivedatacollectionstudyinpatientsreceiving plasmalogen defi ciency development inmicemodelsofiPLA2inhibitionand Comparative studyofpost-natalretinalvascular Circadien cycleandchroniccentral serouschorioretinopathy (genotypes IIandIII) Ocular prognosisofcongenitaltoxoplasmosis maculopathy Peripheral capillarynetworkenlargementindiabetic 577nm diodelaserformacularoedema Subthreshold micropulsephotocoagulationwithtrueyellow coherence tomography after cataract surgeryusingenhanceddepthimagingoptical Measurement ofsubfovealchoroidalthicknessbeforeand on primaryretinalendothelialcells, pericytesandastrocytes A novelco-culturemodeloftheblood-retinalbarrierbased Retinal vascular reactivity overextendedvesselsegments OTRSSIN3 15:05 -16:20 SESSION3 POSTER 19Cornealchangesaftera3incisioncataract surgeryby S119 Sunfl ower cataract in Wilson’s disease: transmission S118 FYCO1mutationhotspotincongenitalcataract S117 Gaps betweenlensepithelialcellsduetocontractions S116 EffectofCrocussativusstigmas(saffron)extract onsodium S115 Age-relatedoxidation oflipidsandproteinsinrats’ S114 The lipidsoflensintheagingandcataractogenesis S113 Cationicaminoacidtransport activityanddetectionof S112 16Characteristics ofthecornealendothelium and S126 Manualrhexisvsfemtosecondlaserassistedin S125 Improvingeffectivelensposition: comparisonof S124 Clinicaloutcomesfollowingcataract surgeryinpatients S123 Cataract surgeryrationing inanageofausterity– S122 Bilateral phacoemulsifi cation intheday: awisedecision? S121 Saferposteriorcapsulepolishingusingthesiliconesleeve S120 Rafael BARRAQUER, RalphMICHAEL Moderators: Lens andCataract pseudoexfoliation syndromeinpatients withsenilecataract cataract surgery femtosecond laservsmanualcapsulotomy over 90yearsold cataract booking guidelines? Is aUKdistrictgeneral hospitalcompliantwithregional from I/Acannula 2.2mm electron microscopicstudy selenite inducedcataract formation crystalline lens B-defensin-1 incaninelensepithelialcells Vilnius KOVALIUNAS E, STECHS, JURKUTEN, CIMBALAS A, ASOKLIS R– LUSSATO M, RIGALSASTOURNE JC–Clamart MOUINGA ABAYI DA, LAAYOUN J, COLASE, ABRIEU M, BLAVIER B, FROUSSART F, RIGAL-SASTOURNE JC–Paris, Clamart M, COLAS E, ABRIEU M, LAAYOUN J, MOUINGA ABAYI DA, LUSSATO GOSCINIEWICZ P–Katowice, Zabrze MICHALSKA-MALECKA K, SLOWINSKA-LOZYNSKAL, HO J, MOORES, PAUL B, ISLAMN–Romford JIMENEZ B, ASCASO J, PINILLAI–Zaragoza RAMIRO P, CABEZONL, MINGUEZE, CRISTOBAL JA, PADGETT E, SENDON D, MESSAOUDI R, DOT C, MAY F, RENARDJP–Paris, Lyon GIRAUD JM, FENOLLANDJ, EL CHEHABH, FRANCOZM, SWALDUZ B, DUSSART C–Lyon, Paris DOT C, ELCHEHABH, AGARD E, RUSSO A, RACT-MADOUX G, LEE DW, CHOICY, BAEJH–Seoul BOISSET G, FAVEZ T, SCHORDERETD–Lausanne, Cairo, Sion ABOUZEID H, HELMYG, ELSADAM, SHERIFM, YACOUB M, HAWLINA M–Ljubljana ANDJELIC S, ZUPANCIC G, DRASLARK, PEROVSEK D, MAKRI OE, FERLEMI AV, LAMARI FN, GEORGAKOPOULOS CD–Patras KUDRYAVTSEVA Y, CHUPROV A, IVANOVA I–Kirov, NizhnyNovgorod KUDRYAVTSEVA Y, CHUPROV A, IVANOVA I–Kirov, NizhnyNovgorod OCHIAI H–Sagamihara Kanagawa 12SingleIOLsurfacemeasurementswith S132 Extraction oflensgeometryinanoptomechanicaleye S131 Customized intraocular lensesenhancebinocular S130 Visual acuityandcontrast sensitivityfunctionbetween S129 Intraocular lenspoweradjustmentcalculatoraftermyopic S128 Long-termendothelialcelllossafteriris-fi xated phakic S127 17Clearlensextraction inhighmyopic S137 Intraocular scattering, ausefultoolfortheindicationof S136 Comparative analysisofchangesinthemacularregion S135 Tele-ophthalmology researchinpost-phacoemulsifi cation S134 Moxifl oxacin superiortocefuroxime inreducing S133 E–Homburg KANNENGIESSER M, GILLNERM, LANGENBUCHER A, JANUNTS Erlangen, Homburg/Saar GILLNER M, EPPIG T, KANNENGIESSERM, LANGENBUCHER A– TARFAOUI N, NOCHEZ Y, PISELLAPJ–Tours MENEZO JL–Valencia PERIS-MARTINEZ C, DíEZ-AJENJO, MA, GARCíA-DOMENEMC, Santiago deCompostela. Galicia DíAZ ALEMáN VT, PAZOS M, LóPEZMJ,–Tenerife, Barcelona, PECHA F, BORDERIE V, LAROCHEL–Paris LECUEN N, SANDALIO, BASLIE, AMELINE B, BULLETJ, MINGUEZ E, CRISTOBAL JA, JIMENEZDELRIOB–Zaragoza CABEZON L, RAMIROP, PADGETT E, ZABADANIK, ITURBEF, PEIRO C, MINGUEZE–Zaragoza CRUZ N, CASASP, CRISTOBAL JA, DELBUEYMA, ASCASO F, PABLO L–Zaragoza GARCIA-MARTIN E, BAMBOM, PRIETO E, LARROSAJM, POLO V, DE LAMATA G, FERNANDEZ-PEREZS, SATUE M, YANG FP, LIM TH–Singapore Lyon, Nice BENBOUZID F, BAILLIFS, RENAUD F, DENISP, KODJIKIAN L– UV-Shack-Hartmann-Sensors processing model duringaccommodationusingautomaticimage depth-of-focus andoptimizestereoscopicvision same patient. A pilotstudy spheric andasphericintraocular lensesimplantedinthe LASIK/PRK intraocular lensforhighametropia capsulotomy? fl uidics parameters Ozil IntelligentPhacotechnologyaccordingtodifferent following cataract surgerybyphacoemulsifi cation with diagnostic outcomes(TORPEDO) study–preliminaryresults hydrophobic intraocular lenses early-phase adherenceofstaphylococcusepidermidisto SATURDAY 115 EVER 2012 Programme book 116 EVER 2012 Programme book 62 75 SECOND AFTERNOONSESSION 16:20 -17:50 SATURDAY 72 4728 4727 17:26 4726 17:20 4725 17:14 4724 17:08 16:56 4723 16:44 16:32 4716 4715 17:35 4714 17:20 4713 17:05 4712 16:50 16:35 62 4711 16:20 62 4721 16:20 I Conventionalsurgery forretinal detachment RV SIS PClinicaldiabeticeyedesease RV FP

4722 Elias FERETIS Pascale MASSIN, CatherineCREUZOT rf rf rf rf Indications andcontraindications RADOI C, ZAMBROWSKI O, DUCASSE A, ARNDT C–Reims FRUSCHELLI M, SPARAGNA MC, DENAROR, MENICACCI F, ESPOSTIG, ESPOSTIPL–Siena PIERRU A, BAILLIF-GOSTOLI S, GASTAUD P–Nice SCHLINGEMANN RO, WISNIEWSKA-KRUK J, VOGELS IM, VAN NOORDENCJF, KLAASSENI–Amsterdam ABDEL-HAY A, SIVAPRASAD S, KONSTANTAKOPOULOU E, EDGARDF, BARBURJL–London Severity ofcolourvisionlossindiabetes Amsterdam, Utrecht SCHLINGEMANN RO, VAN GEESTRJ, LESNIKOBERSTEINSY, VAN NOORDENCJF, KLAASSENI, GOLDSCHMEDINGRG– bevacizumab causestheangiofi brotic switchinproliferative diabeticretinopathy A shiftinthebalanceofvascular endothelialgrowthfactorandconnectivetissueby KERNT M, KOZAK I, FREEMAN W, KAMPIK A, ULBIGM, NEUBAUER A–Munich, LaJolla Matched pairsanalysisofretinalnavigatedlaserversusconventional SUZUKI N, YAMANE K–Higashi-Hiroshima, Hiroshima artefacts Determination oftheoptimalcolourspacefordistinguishingsmallretinalhaemorrhagesfromdust KATSIMPRIS J–Patras Complications followingconventionalsurgeryforretinaldetachment PAPPAS G–Heraklion Cryo treatmentandproblems ANASTASAKIS A–Heraklion To drain ornotandhowtodrain TSERVAKIS I–Athens Local v360degreeplomb MOURTZOUKOS S–Athens General planningandthoughtsfortheoperation THEOCHARIS IP–Athens oedema Subthreshold micropulsephotocoagulationwithtrueyellow577nmdiodelaserformacular depth imagingopticalcoherencetomography Measurement ofsubfovealchoroidalthicknessbeforeandaftercataract surgeryusingenhanced pericytes andastrocytes A novelco-culturemodeloftheblood-retinalbarrierbasedonprimaryretinalendothelialcells, Peripheral capillarynetworkenlargementindiabeticmaculopathy Euterpe Uranie EODATRONSSIN 16:20 -17:50 SECOND AFTERNOONSESSION 71 4746 4745 17:14 17:02 4744 4743 16:56 16:44 4742 16:32 4735 4734 17:32 4733 17:14 4732 16:56 16:38 62 4731 16:20 62 4741 16:20 PBloodfl PBP FP Keratoprotheses 2–Biomaterials SIS COS Gerhard GARHOFER, SveinnHARDARSON Thomas FUCHSLUGER, ChristopherLIU rf rf ow andpharmacology DENION E, DUGUE AE, COFFIN-PICHONNETS, AUGY S, MOURIAUX F–Caen HAMM G, DESBENOITN, LEGOUFFER, BRUNELLE A, BRIGNOLE-BAUDOUIN F, STAUBER J–Loos, Paris, Gif-sur-Yvette ophthalmic application Quantitative andqualitativelabelfreeimagingusingmassspectrometryinthecontextofan SCHMETTERER L–Vienna SCHMIDL D, BOLTZ A, KAYA S, PALKOVITS S, TOLD R, FUCHSJAEGER-MAYRL G, WERKMEISTER R, GARHOFERG, DAIEN V, KAWASAKI R, VILLAIN M, FESLERP–Montpellier, Melbourse hypertensive subjects Retinal vascular caliber isassociatedwithrenalfunctioninnormotensiveandnever-treated EKLUND A–Umeå JóHANNESSON G, AMBARKI K, HALLBERGP, LINDéNC, ZARRINKOOB L, WåHLIN A, BIRGANDERR, MALMJ, imaging technique Volumetric fl ow rate ofophthalmicarteryinhealthyindividualsusinganewmagneticresonance FUCHSJAGER-MAYRL G, PALKOVITS S, BOLTZ A, WERKMEISTER R, TOLD R, SCHMETTERERL–Vienna Choroidal bloodfl ow incentral serouschorioretinopathy(CSC) GRIFFITH M–Ottawa Biomimetic materialsforregenerating thecornea STORSBERG J, KOBUCH K, DUNCKERGIW, KNAKM, REHFELDTS, SCHMIDTC, NASSN, SELS–Potsdam, München, Halle Synthetic eyeprosthesis–phaseIresultsofasuccesfullydevelopedbiomaterial DANIELS JT Plastic compressedcollagenasabiomimeticsubstrate forhumanlimbalepithelialculture LLOYD A, AVADHANAM V, SANDEMANS, LIUC–Brighton Options fortheedentulouspatientwhorequireOOKPsurgery Is asyntheticlaminatheultimategoalforosteo-odonto-keratoprosthesis (OOKP)surgery? FUCHSLUGER T–Düsseldorf Where arethelimitsofcornealtransplantation -whyisthereaneedforbiomaterials? Eye motionincreasestemporal visualfi eld extent intraocular pressureinhealthyhumans Role ofnitricoxide inopticnerveheadbloodfl ow regulationduringexperimentalincreaseof SATURDAY Thalie Erato 117 EVER 2012 Programme book 118

EVER 2012 Programme book intermediate 62 75 SECOND AFTERNOONSESSION 16:20 -17:50 SATURDAY In addition, thepersonalviewfromanauthorsandeditorsperspectivewillbegiveninavividdiscussionwithparticipant What todowhenyourpaperisrejected? When canitbeappropiatetorequestareevaluation ofarejectedpaper? 72 4774 4773 17:26 4772 17:04 16:42 4753 17:26 4752 17:04 16:42 (4) Vitreo-retinal surgeryinuveitis. will focus on 4 topics: (1) Surgery of the infl ammatory cornea or sclera, (2) Cataract surgery in uveitis, (3) Glaucoma surgery useful.is experience and therapeuticdecisions observed.guide be to ThisHence,data instruct evidence-based scarce are there Entities that may result in intraocular infl ammation are heterogeneous and a broad range of situations requiring surgical inter is alsoakey-factor forthelong-termsuccessofprocedures. ocular of needs careful planning and preventive measures to avoid a higher-than-average complications rate of post-operative complications.infl secondary Adequate fo of However,management infl ammatory eyes. surgical intervention.The surgical in ammatory require often treatment and structures of ocular all infl fiinvolve line may the ammation rst always is therapy medical Adequate response:Delayed paper? manuscript? your good organize characteristicsa to the of How are journal? What a choose to When How The panelistswillraise thediscussiononissueslike: process inparticulartherevisionforeventualresubmission. decisions:basic including process editorial work,the submit to where manuscript,a prepare and organize to how th deal to how write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss maj Junior researchers often face the challenge of get their interesting work published. The goal of this session will be to provid 62 4751 16:20 appropriate to ask for the status of your manuscript? How to interpret the letter from the editor? How to write a good reply to 62 4771 16:20 OOG-Businessmeeting JM SHowtogetyourworkpublished? WS IM Course 15

9. ClosureofBusinessMeeting 8. Any OtherBusiness(AOB) 7. DetailsofnextOOGMeetings 6. Updateoncurrentcollaborative studies/newproposals 5. NominationsformembershiptoOOG 4. OOG Website update 3. Financialreport 2. OOG YIN elections 1. MinutesofpreviousBusinessMeeting(Paris, March2012) 4754 Uwe PLEYER Antoine BREZIN, DominiqueMONNET Surgery ofinfl BEHAR-COHEN F–Paris Vitreo-retinal surgeryinuveitis LACHKAR Y–Paris Glaucoma surgeryinuveitis MONNET D, BREZIN A–Paris Cataract surgeryinuveitis BOURGES JL–Paris Surgery oftheinfl ammatory corneaorsclera STEFANSSON E–Reykjavik How togetyourworkpublished? KIVELÄ T–Helsinki How togetyourworkpublished? DUA H–Nothingham How togetyourworkpublished? PLEYER U–Berlin How togetyourworkpublished? ammatory eyes Gallieni 1&2 or aspects of the the reviewers? e some keys to Gallieni 4 in uveitis and and uveitis in s. vention may ion course ion e review e llow-up Clio eyes is it is

VNN ESO 18:00 -19:30 EVENING SESSION . Presentationoftheboard2012-2013 7. Resultsoftheelections 6. Reportofthe Treasurer, Jean-Jacques GICQUEL 5. ReportoftheProgramme Secretary, Marcela VOTRUBA 4. ReportoftheSecretaryGeneral, Bahram BODAGHI 3. MinutesoftheGeneral Assembly 2011 2. President’s address, LeopoldSCHMETTERER 1. Agenda 14. Handover ofchainoffi14. ce Acknowledgments 13. Miscellanea 12. Prize giving 11. Future congresses 10. PresentationandreportoftheScientifi c Sectionsmeetings 9. PresidentElect, Vice PresidentElect 8. EVER General assemblyandprizegiving - dischargetothedirectors - approval oftheaccounts2011 - approval budgetfor2012 Uranie SATURDAY 119 EVER 2012 Programme book 120 EVER 2012 Programme book CONCORDIA

EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH EUPO European University Professors Professors University European of Ophthalmology EUPO Offi ce •Kapucijnenvoer 33•3000Leuven •Belgiumwww.eupo.eu Cornea, Conjunctiva and SEPTEMBER 18-21 COPENHAGEN Refractive Surgery EUPO 2013 Denmark June 7-8 SCIENCE FORSIGHT www.ever.be 2013 NICE EVER For information allfurther logonto www.ebo-online.org UNITED IN PROMOTING EDUCATION IN OPHTHALMOLOGY UNITED IN PROMOTING EDUCATION Paris, on10-11May2013 Le Palais des Congrès, EBO 2013 EBO will commence from from commence will will takewill in place Application period Autumn 2012 121 EVER 2012 Programme book Important Dates

G Abstract submission October 15 – December 7, 2012

G Hotel reservations Open now

G Early meeting registration Opens September 17, 2012

+1.240.221.2900 [email protected] www.arvo.org/am

Acta Ophthalmologica Edited by: Einar Stefánsson

Why should you be reading? s Impact – our impact factor continues to increase and now stands at 2.629*, placing us amongst the most highly–cited ophthalmology journals. s Coverage that’s relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye. sOf fi cial publication of EVER and all fi ve Nordic Ophthalmological Societies. Members of s EVER receive FREE online access to Visit www.actaophthalmologica.com Acta Ophthalmologica for more information as part of their *2011 JCR, Thomson Reuters membership. EVER www.ever-f.eu

NEW In 2012 two Research Fellowships f will be awarded European Association for Vision and Eye Research Foundation

ASCASO F: S029, S046, 3264 ARNDT C: S062, 3826 ARNAUD M: 4245 ARJAMAA O: F106 ARDAN T: T078 ARAIE M: 2855 ARA GABARREM: F047, 2454 APTEL F: F002, F044 ANSARI E: F007, F038, 2754 ANGI M: 2874 ANGERMANN W: 3881 ANDROUDI S: 1512 ANDRIANAKI A: F108 ANDJELIC S: S116 ANASTASAKIS A: 4714 AMIRYAN AG: S010, 3286 AMELOOT F: T015, 2465 AMBATI J: 4311 ALSHAMEKH S: T143, 4476 ALSHAGHTHRAH A: F069 ALLIKMETS R: 3311 ALJAMAL R: 4465 ALISSA R: F066 ALIO SANZJ: 2722 ALHARBI A: T005 ALEKSEEV O: T112 ALBERT R: 2235 AKNIN I: S105, 4616 AKHTAR S: T080, 1523, 3875 AGARD E: F008 ACLIMANDOS W: 2771 ACAR N: 4265 ABU EL ASRAR A: 1613, 2683 ABOUZEID H: S117 ABDEL-HAY A: 4724 MAIJ >Saturday, 09:50 >Friday, 15:55 AMBATI J > Thursday, 09:50 >Friday, 09:50 SPAETH GL > Wednesday, 18:10 ALLIKMETS R > Wednesday, 17:50 MILLER J > Wednesday, 17:15 HEIJL A ZEYEN T MARTIN L KEYNOTE LECTURES BATISTA A: T032, 4647 BASLI E: 2635 BARREAU G: 3483 BARRAQUER RI: 4433 BARRAQUER J: 3872 BARISANI-ASENBAUER T: F095, 2774, 2844 BARGARY G: 4283 BARBUR JL: F073, 3471 BARBAZETTO I: 3662 BANDLITZ S: 4641 BANDELLO F: 3212, 3812 BAMBO M: F020, S092, S099, 2616 BAKALIAN S: S011 BAÏZ H: T038 BAILLIF S: S012 BAIKOFF G: 1633 BAGNOLI P: 3232 BABCHIA N: S055 AZIZ A: F046 AYCHOUA N: 3486 AVADHANAM V: 4634 AUGUSTIN A: S104, 4615 ATCHISON DA: 3274 ASOKLIS R: S002 BENNAI D: 4244 BEN MHAMEDM: T067, 2636 BENBOUZID F: S132 BENAYOUN Y: 4445 BEK T: 2813 BEHAR-COHEN F: 2246, 3215, 3512, 4216, 4774 BECHRAKIS NE: 1671, 2212 BECCAT S: F093 BAZEWICZ M: S069 BAUDOT A: S086 BATTA B: T120 Four digitnumbersrefertooralpresentations Day | Timeslot |HallOrderinsession X PRESENTING FIRST AUTHORS PRESENTING FIRST BIKBOVA G: 4475 BI W: 3472 BEUERMAN R: 1623, 2762, 3832 BERROD JP: 1552, 3821 BERNARDES R: 2611 BERNARD A: T072, T073, 3871 BERENDSCHOT T: 3663 BENZERROUG M: S032 BENTALEB Z: S027 BRON A: 1651, 2451, 2752, 3253, 3414, 4252 BRISCOE D: 1564 BRETILLON L: 3661 BREMOND-GIGNAC D: 1643, 3671, 4275 BOYCHUK IRYNA: F056, T088 BOUTBOUL S: F060 BOURGES JL: 1632, 2831, 4771 BOURCIER T: T052 BOULADI M: S057, S067 BOUCHENAKI N: 2643, 3844 BOUABANE I: T063 BOSCHI A: 2734 BOSCHER C: S085 BORRUAT FX: 1661, 1663, 2732 BORDERIE V: 2262, 3431 BONNIN ARIAS C: F054 BONINI S: 3633 BOLTZ A: 3664 BOLDIN I: T035 BOGDANICI T: S016 BODAGHI B: 1532, 1615, 2274, 3643, 4214 BOCQUET B: 2782 BLATSIOS G: 2214 BLASETTI F: F100 BLACK GCM: 2662, 2882 BITOUN P: 4222 One letterandthreedigitnumbersrefertoposters Day |Orderinthepostersession X { 125 EVER 2012 Programme book 126 EVER 2012 Programme book CUNHA-VAZ J: 2824, 2825 CUCHERAT M: F031 CUBBIDGE R: F109, F113 CSUTAK A: S037 CRUZ N: S129, T138 CREUZOT C: 1555, 2414, 2773, 3823, 4211 COUPLAND SE: 1672, 2871 COSTAGLIOLA C: S013 COSCAS G: 3513 CORNUT PL: F090 CORDEIRO MF: 2854 CONRATH J: 3811 CONART JB: 3822 COLIN J: 4431 COLBY K: 4632 COLAS E: S124 COFFIN-PICHONNET S: S020, 3685 COCHENER B: 2436, 2522, 4673 CLOCHÉ V: T018 CHOI MJ: S075 CHOI HJ: T024 CHIQUET C: F091, F092, 2647, 3413 CHIN H: S073 CHEN Y: F014 CHEBIL A: S026, S056 CHAVES A: 3852 CHATEAU N: 2431 CHARLIER J: F063 CHAPELLIER B: 2631 CHAN C: 3241, 3644 CHAMORRO E: T050 CELLINI M: T079 CAUJOLLE JP: 4461 CASTRO NAVARRO J: S058, S088, 3824 CASTELO-BRANCO M: 3265 CASSOUX N: 2445, 4464 CAPOROSSI ALDO: 4435 CANADAS SUAREZ P: T089, T090, 4443 CAMPOLMI N: S074, 2264 CABEZON L: S128, T123 BUTEL N: S068 BUSUTTIL A: 4636 BUSHUYEVA N: F118 BURIAN G: 3223 BUIJSROGGE M: T142, 4477 PRESENTING FIRST AUTHORS PRESENTING FIRST DAMATO EM: 2275 DAMATO B: 1676, 2873 DALY MK: 3482 DAIEN V: 4743 DONOVAN K: S040 DOBROWOLSKI D: T068, T069, T116, 3877 DOAN S: T086, 3673 DO TN: S023 DJABAROUTI M: S083, T031, 4645 DICK A: 1511, 2743, 3846 DIAZ ALEMAN VT: S137 DE ZAEYTIJDJ: T121 DEWISPELAERE R: F077 DE SMETM: 3514 DESJARDINS L: 1675, 4467 DENOYER A: 4652 DENION E: F119, F121, 4746 DELMAS J: S101, T117, 4225 DELETTRE C: 4285 DEL BUEYMA: T092, T093 DELBARRE M: T091 DE LAPAZ M: T087, 3481 DE LANGEMJ: 3283 DE LAMATA G: S080, S130 DE KEIZERRJW: S021, 3686, 4243 DEKARIS I: 1534, 2261 DEISSLER H: 4411 DE GROEFL: F050, 4657 DEGOUMOIS A: T135 DEGLI ESPOSTIS: S028 DE FRANCESCOS: S017, 4663 DE FAYS A: F006 DAULL P: T036, T037, 4446 DANIELS JT: 4733 ESPINASSE M: T034, 2237 ENGIN K: 2253 EL MATRI L: T011, T012 ELENA P: F029, F107 EL CHEHABH: F010 EGEA ESTOPINAN C: S043 DUPONT L: T059 DUA H: 1541, 1644, 2523, 4752 DROUECHE Z: 3825 DOWNES S: 2664 DOT C: S119 FUCHSJAGER-MAYRL G: 4741 FSADNI MG: T132 FRUSCHELLI M: S110, 4727 FRANCOZ M: F016 FRANCOZ A: 2453 FOURNIE P: 4432 FORTOUL V: 4614 FOKINA DV: 4262 FLEITMAN J: F032 FISHER A: 2424 FIGUEIRA L: 2233 FIGUEIRA J: 2826 FERRANDEZ ARENAS B: 4246 FERNANDEZ-PEREZ S: S015, S019 FERAOUN N: 2841 FENOLLAND J: F018 FEL A:2642 FAVARD A: T128 ETXEBARRIA J: 4631 GIL ARRIBAS L: 4451 2835, 3675, 4441, 4646 GICQUEL JJ: T030, 1542, 1635, 1641, 2433, GIBSON J: 2816 GHOUBAY D: T111 GHERGHEL DOINA: 2853 GENEVOIS O: T131 GAVRILOVA I: F041 GAVARD-PERRET A: S003 GAUTHIER AS: F116 GAUDRIC A: 2415, 3211, 3464, 3466, 3612 GATZIOUFAS Z: 4235 GARHOFER G: 2862 GARCIA-MARTIN E: T126, T127 GARCIA FERNÁNDEZM: T008, 2787 GARCIA FERNANDEZM: S106, 4617 GARCIA FERNÁNDEZM: 2614 GANDORFER A: 2411 GAN N: S065 GALGAUSKAS S: T083 GAJECKA M: 2783 GAIN P: T096 GAGLIANO C: F028, 2457 GABISON E: T115 4731 FUCHSLUGER T: T033, 2263, 2637, 2745, 3631, HERRERO LATORRE R: S094, T139 HERRERO C: 3434 HERMEL M: 2269 HERGELDZHIEVA T: 1533 HERBORT CP: 1516, 2272, 2442, 3842, 4422 HEITMAR R: F111, F112 HEIMANN H: 2213 HE Z: T074, T075, T107, 3437 HAWLINA M: 3261 HA THI BM: T071, 2236, 3433 HARITOGLOU C: 2412 HARDARSON S: 2672, 2811 HÄNLER M: F079 HAN SJ: F067 HAMMER M: 2812, 2863 HAMM G: 4745 HAMED AZZAM S: 4444 HALL G: 2661, 2881 T133, 4471 HALFELD FURTADO DEMENDONCAR: S039, HALDAR S: S098, 2716 HADJISTILIANOU T: S006, 4661 HABAY T: T007 GUSHCHA S: F114, F117 GURNY R: 2242 GUINDOLET D: F098 GUIMARAES P: 2712 GUEUDRY J: T061 GUENOUN S: T102 GRZYBOWSKI A: 3263, 3451, 4242 GRUS F: 3235 GRUENERT A: 2741, 3435 GRIVET D: 4642 GRIOT O: T095 GRILLO-ANTONELLI S: S063 GRIGORIU D: 2776 GRIFFITH M: 4735 GRANGE JD: 4466 GOTZARIDIS S: 3611 GONZALEZ C: S051, S087, S097, 2717 GOCHO-NAKASHIMA K: 2715 GIZZI C: F015, 4453 GIRAUD JM: S120 GILLNER M: S134 GILLESPIE-GALLERY H: F072 HOFFART L: T056, 4284 HO J: S122 HICKEY J: F070 HERRERO-VANRELL R: 2243 JOUFFROY T: 4224 JONAS JB: S100, 1554, 2617, 2851, 3654, 4452 JÓHANNESSON G: 4742 JIRSOVA K: 2267 JIMENEZ DELRIOB: T094, T125 JIA Y: 4282 JEEVA I: F101, 2273 JAUHONEN HM: 2632 JANSONIUS NM: 2652 JANKOWSKA-LECH I: T129 JAKOB E: F078 JAGER MJ: 3281 JAE HOS: T027 IRION L: F087, T076, 3436 IBANEZ J: F039, F042 HYTTINEN J: 4485 HUSEVA YA: T019, 2686 HUMAYUN M: 2244 HUDSON C: 2815 HUBAULT B: S102, T026, 4226 HORWATH-WINTER J: 2474, 4274 HONG S: 2685 HOMMER A: 1652 HOLZER S: F023, 2455 HOLZAPFEL S: 3882 HOLZ F: 3221, 3226, 3227 HOLLANDERS K: 4653 HOLDER GE: 2224, 2423, 2753 HOLAN V: T042 HOFFMANN E: 2721 KANG HM: S052 KALITZEOS A: S107, 4618 KALESNYKAS G: 1621, 3834 KACHANOV ANDRE: T099 KABANAROU SA: S082, S090, 2422 KAARNIRANTA K: 4481 JURKUTE N: T081 JUNG SH: F103 JUN A: 4233 JUMELLE C: 3432 JULIENNE R: 2266 PRESENTING FIRST AUTHORS PRESENTING FIRST KIM HS: S041 KIM C: F049, F052 KHAWAJA A: 3851 KHAIRALLAH M: 1514 KEUKEN A: 3476 KESTELYN P: 1611 KERNT M: F011, 4722 KEILHOLZ U: 2876 KEANE PA: 3243 KAYA S: T064 KAWASAKI A: 1662, 2223, 2731, 3863 KAUPPINEN A: 2842 KATSIMPRIS J: 4716 KAROLAK JA: T004, 2786 KARDON RANDY: 3862, 3865 KANNENGIESSER M: S133 KANG SW: 4424 KANG MH: T028 KANG KD: F012 LACHKAR Y: 4773 LABETOULLE M: F084, 1642, 3412 LABALETTE P: F102 LAAKSO N: F080 KURUN S: F099, S077 KUDRYAVTSEVA Y: S113, S114 KRATZER T: 3275 KRASTEL H: F064, 3474 KOWALSKI R: 2644, 3444 KOVALIUNAS E: S126 KOTECHA AACHA: 3454 KOROBELNIK JF: 1551 KOOK K: T002 KONSTANTAKOPOULOU E: 3473 KOEV K: S053, T084 KOEHRER P: 4264 KOEFERL P: S045 KOCABORA S: 2252 KNOP N: 1521, 4272 KNOP E: 1522, 2471, 2681, 4271 KNOLL A: F083, F089, 2277 KNECHT P: 2845 KLETTNER A: 3284 KIVELÄ T: 1673, 2461, 2875, 3463, 4753 KIM S: F034 KIM N: F105 127 EVER 2012 Programme book 128 EVER 2012 Programme book MANTOVANI A: 2271 MANES G: 2781 MAMUNUR R: 4664 MALTMAN J: 2823 MALIK A: S035 MAKRI OE: S115 MAINDRON C: 3485 MADIGAN MC: S005, T039, 3682, 3683, 4447 MACKENSEN F: 2276 MACHALINSKA A: F075, 4286 LUSSATO M: T066 LUKASIK U: T013, T014, 2466 LUHMANN U: 3244 LUCAS R: 3861, 3864 LU F: T103 LOSONCZY G: 2462 LORENZ K: 2725 LORENZ B: 4241 LOPEZ DELAFUENTEC: F004, F005 LOEWENSTEIN A: 3515, 4215, 4513 LOEFFLER K: 1562 LOBATO RINCONLL: F057 LLOYD A: 4732 LIU C: 4633 LIM K: 3853 LIM FPM: T082 LIASKA A: F037, 4454, 4457 LERUEZ S: 2784 LEROY BP: 2222, 2425, 2884, 4213 LEONARDI A: 2521 LE MEURG: 4223 LEINO L: T104 LEE R: 2444, 4635 LEE MA: T045 LEE K: F009 LEE DW: S038, S118 LECUEN N: S127 LEAL C: 2633 LAZREG S: S059, T106 LAVILLE MA: S008 LASUDRY J: 1561 LARSEN A: 4667 LANGENBUCHER A: T085 LANCON A: S054 LAMBROU G: 2822 PRESENTING FIRST AUTHORS PRESENTING FIRST MARTY A: F045 MARTENS TF: 4261 MARSOVSZKY L: 2634 MARKOMICHELAKIS N: 1614 MOTTET B: F003 MORTEMOUSQUE B: 3672 MORGAN IAN: 2684 MONTEIRO M: S060, 4473 MONTEIRO K: 4472 MONTAN P: 3411 MONNET D: 4772 MOJON D: 3262 MOCKO L: F055, T105 MILLER JW: 2311 MILANO G: F019 MIDENA E: 1674 MICHELSON G: 2852 MICHALSKA-MALECKA K: S123 MICHAEL R: 3484 MGARRECH M: T049 MEZIANI L: S095 MESQUIDA M: S007, 4668 MENICACCI F: T097 MENEZO ROZALENJL: 4234 MENDRINOS E: 3615 MENDES-JORGE L: T029 MENCUCCI R: 1544 MCNAUGHT A: 4254 MCKENNA KC: 3642 MAY F: 2656 MATHYSEN D: 2775 MATEO J: S076, T122 MASSIN P: 3815 MASCHI C: 4462 NAPORA KJ: F110 NAOR J: 3225 MUSELIER A: T057, 2777 MURTA J: 1631, 2723 MUNIER F: 3462 MOZAFFARIEH M: 3453 MOURTZOUKOS S: 4712 MOURIAUX F: 1563 MOULIN A: 3681 MOUINGA ABAYI DA: S125 MOTULSKY E: 2682 OHLENDORF A: 3273 O’FLYNN L: 2232 OCHIAI H: S112 OBWALLER A: F086, 2646 NUBILE M: 1543, 2833 NONOMURA S: S036 NIKULIN SERGE: T098 NIELSEN K: T055 NICOLO M: 4423 NGUYEN E: S071 NGUYEN AM: F096, 2847 NERI P: 1513, 2446, 3845, 4421 NEPP J: 2472 NEMETH AH: 2663 NEMATI F: S014 NEFZAOUI C: T108 NAVARRO VALLS J: F053 NASR MB: 2654 NASINNYK I: T113 PFENNIGSDORF S: F025 PETROVSKI G: 4483 PETRASH M: 2761 PETO T: 3421 PESCE G: F048 PERIS-MARTINEZ C: S136, T101 PEREZ GARCIAD: T022, T023 PEREIRA I: F013 PEFKIANAKI M: S061, S081 PAVESIO C: 2441, 3841 PATTERSON EJ: 4281 PARROZZANI R: 4665 PARRAVANO M: 4426 PAREKH M: 2268 PAPPAS G: 4715 PAPADIA M: 2846, 3843 PAOLI V: 4463 PALKOVITS S: 4611 PAGOULATOS D: T025 OSTADIMOGHADDAM H: F071 OSHITARI T: S072 OSBORNE N: 3452 ORSSAUD C: T136, T137 ORSKI M: S070, T065 OLSEN T: 2245 OLDAK M: T003, 2785 ROUSSEAU A: T043, T058 ROULAND JF: F030 ROSSETTI L: 3252 ROSNER M: S022, 3687 ROMANOWSKI E: F082, 3442 RODRIGUEZ-CARMONA M: 3475 RODRIGUES P: 2713 ROCHA DESOUSA A: 4263 ROBERT PY: F115, T040, 2645, 3876 RITTER T: 2744 RICH C: 2724, 3224 REKIK R: S091 REINISALO M: F122, 4266 REHAK M: 4416 REHAK J: 4415 RECALDE S: S064, T009 RASMUSSEN P: 4666 RANCHON-COLE I: F104 RAMIRO P: F036, S121 RAMASAMY P: 3282 RAJU L: 3441 RAHMI A: S096 RAFAT M: 2231 RADUNOVIC M: F027 RADOI C: S084, S111, 4613, 4728 RABOT A: T100 RABENSTEINER DF: 2475 PURSLOW C: 4273 PRIETO CALVO E: F040 POURNARAS JA: 3813 POURNARAS CJ: 1553, 2817, 3213, 3614, 4414 POURJAVAN S: 3854, 4456 POPA CHERECHEANU A: F021, F022 POMMIER S: S042 POLI M: T041 PLEYER U: 1515, 2641, 2742, 3634, 3641, 4751 PISELLA PJ: 2435 PIPERNO-NEUMANN S: 2877, 4468 PINTO LA: 3653 PINNA A: S048 PINILLA I: S034, S093 PINELLO L: T118 PILECKI W: T141 PIERRU A: S109, T130, 4726 PHILIPPAKIS E: 3684 RUSSO A: S078 RUIZ MORENOJM: 3214 RUBERTE J: T021 ROZEMA J: 2726, 4672 SMEDOWSKI A: F001, F026, F051 SKOTTMAN H: 4484 SJÖSTRAND J: S024, S025 SIJNAVE D: 4654 SICARD F: T070, 4648 SHIN HJ: F123, 2452 SHENG-YAO HSU: F017 SHANKS RM: F094, 3443 SERGEEVA M: T046, T047, 4442 SEGURA CALVO F: F059, F061 SCORCIA V: 2834 SCHWEITZER D: 2671 SCHULZ S: F024, 2456 SCHMIDL D: F120, 4744 SCHMIDBAUER M: F058, S030 SCHMETTERER L: 2673, 2861, 2864, 3651 4723, 4725 SCHLINGEMANN RO: S108, T020, 2821, 4486, SCHALENBOURG A: 3461 SCHAEFFEL F: 2621, 3271 SAVARY P: S089 SAULE S: 2872 SAUER A: F085, T119, 2843 SATUE M: S004, S018, 4474 SANKARIDURG P: 3272 SALVADOR CULLAB: 3874 SAHEL JA: 3222 SAAKYAN S: 4662, 466a SAAB S: S103, 4227 RUSSO R: 3231 STEIN A: 2653 STEIBER Z: T001 STEFANSSON E: 2814, 3632, 4754 STECH S: F088 STAURENGHI G: 4212 STAPPLER T: 3613 STALMANS I: 3251, 3255, 3652, 3884 SPILEERS W: 2221 SPAETH G: 2655, 3711 SOLER V: T060, 4231 SOKOLAKIS TH: T010, 2467 PRESENTING FIRST AUTHORS PRESENTING FIRST TOBE A: F097 TILLEUL J: 2613 THURET G: 1524, 1634, 2265, 4643 THIERRY M: F076, 4287 THEOCHARIS IP: 2711, 4711 TEKELI OYA: 2251 TASSIGNON MJ: 2772, 4674 TARNAWSKA D: 4644 TARFAOUI N: S135 TADAYONI R: 2211, 2413, 3511, 3666, 4511 SZENTMARY N: T077 SUZUKI N: 4721 SUZANI M: 2615 SUTTIE A: 3885 SUNARIC MEGEVAND G: 1654, 3254, 4251 SULLIVAN DA: 2473 STROBBE E: S066 STORSBERG J: 3635, 4734 STEINMETZ P: S031, S033 VASSILEVA P: 1531 VARDARINOS A: S047 VAN KUIJKE: S050 VAN GINDERDEURENR: S009, 4669 VAN ESSEN TH: 2234 VANDEWALLE E: 4651 VAN DE VELDE S: 4656 VAN DE VEIRE S: F035, 2458, 4455 VANDERMEER G: 2432 VAN DENBERG TJTP: 2434, 4671 VAN BREEMCJ: 4675 VAN BERGEN T: 4655 VAGGE A: T134 UUSITALO-JÄRVINEN H: 1624, 2763 UUSITALO H: 3831 URTTI A: 2241 UDZIELA M: T006 TURCOTTE S: F033, 3285 TSERVAKIS I: 4713 TRONE M: T109 TRECHOT F: T044, T124 TRAN TL: 2651 TRAN THC: 4425 TOUBOUL D: 2832, 4232 TOMLINS PJ: T048 TOLD R: 3665 129 EVER 2012 Programme book 130 EVER 2012 Programme book ZUEVA M: F068, 2421 ZRENNER E: 4221 ZOGRAFOS L: 3465 ZIERHUT M: 3883 ZEYEN T: 1653, 2751, 4253 ZERBIB J: 2612 ZADOROZHNYY O: F043, S079 ZACK DJ: 1622, 3833 YONEYA S: 2714 YI JH: S049 YEUNG A: 1545, 3674 YEKTA AA: T016, T017 YANG FP: S131 YANDIEV Y: 4412 YAN X: T140, 2464 XU H: 3242 XU D: F062 WYLEGALA E: S001, 3873 WOWRA B: T062, T114 WOLFENSBERGER T: 3814 WOJCIK L: T051, T053 WILLERMAIN F: 1612 WIEDEMANN P: 4413 WEIGERT G: 4612 WEBER M: 4512 WATSON P: 2443 VOTTONEN P: F074 VOTRUBA M: 2883 VIIRI J: 4482 VIGHETTO A: 2733 VIDAL-SANZ M: 3233 VICENTE TEJEDOR J: F065 VERONESE RODRIGUESML: 2463 VEREB Z: T054 VELICHKO LN: F081 VEKRIA P: S044 VEGA-ESTRADA A: 4434 VAVVAS D: 3234 PRESENTING FIRST AUTHORS PRESENTING FIRST Belarus ...... 1 Austria ...... 21 Australia ...... 4 Algeria ...... 1 United States ...... 28 United Kingdom ...... 70 Ukraine ...... 6 Turkey ...... 3 Tunisia ...... 5 Switzerland ...... 20 Sweden ...... 6 Spain ...... 48 South Korea ...... 21 Slovenia ...... 2 Singapore ...... 4 Saudi Arabia ...... 1 Russia ...... 10 Romania ...... 3 Portugal ...... 12 Poland ...... 18 Netherlands ...... 10 Montenegro ...... 1 Lithuania ...... 5 Japan ...... 9 Italy ...... 37 Israel ...... 4 Ireland ...... 3 Iran ...... 2 Iceland ...... 2 Hungary ...... 7 Greece ...... 17 Germany ...... 50 France ...... 181 Finland...... 19 Denmark ...... 6 Czech Republic ...... 4 Croatia...... 1 China ...... 3 Canada ...... 4 Bulgaria ...... 3 Brazil ...... 2 Belgium ...... 39 AUTHORS BY COUNTRY 131 EVER 2012 Programme book URANIE EUTERPE ERATO THALIE CLIO GALLIENI 1&2 GALLIENI 4 GALLIENI 3 Wednesday October 10, 2012 12:00 - 14:15 IM: EBO course: Intraocular ACB: Morphological COS: Challenges of herpetic COS: Common corneal RV: EBO course: Retinal PO: Eyelid tumours infl ammation and Infection techniques in eye research eye disease procedures detachment: fi rst to describe (Part I) and then to treat Bahram BODAGHI Erich KNOP Jean-Jacques GICQUEL Catherine CREUZOT Frédéric MOURIAUX Carl P HERBORT Nadja KNOP Petja VASSILEVA Harminder S DUA Constantin POURNARAS Karin LOEFFLER 14:30 - 16:45 IM: EBO course: Intraocular ACB: Experimental models for COS: Endothelial keratoplasty: COS: Corneal infectious G: A glaucoma tool kit for NSPH: The ocular motility PO: Management of Infl ammation and Infection eye research the hidden face diseases update beginners examination and common pigmented fundus lesions (Part II) disorders of ocular motility Bahram BODAGHI Hannu UUSITALO Jean-Louis BOURGES Jean-Jacques GICQUEL Laurence DESJARDINS Carl P HERBORT Ulla AAPOLA Joaquim MURTA Harminder S DUA Alain BRON Aki KAWASAKI Bertil DAMATO 17:00 - 17:15 Welcome by the President EVER 2012 - Leo SCHMETTERER Uranie 17:15 - 17:50 EVER Lecture - Lene MARTIN Uranie 17:50 - 18:10 European Ophthalmology Heritage Lecture - Ophthalmology: a philatelic view - Thierry ZEYEN Uranie 18:10 - 18:50 EVER-Acta Lecture - Anders HEIJL Uranie 18:50 - 19:00 Welcome address by the city of Nice Uranie 19:00 - 21:00 EVER Welcome Reception in Acropolis Convention Center Thursday October 11, 2012 08:15 - 09:45 RV: Anterior segment EOVS: Doctor, I don’t like bright COS: Free papers COS: PBP: Ocular pharmacology and G: Glaucoma: Looking beyond COS: European Eye Bank IM: Free papers: FRO - Belgian Fund for complications in lights Ocular surface and corneal drug delivery an ocular disease Association Advances in diagnosis and Research in vitreoretinal surgery - bioengineering management of uveitis Ophthalmology 1 why they occur and how to deal with them Nikolaos E. BECHRAKIS Jean-Jacques GICQUEL Iva DEKARIS Piergiorgio NERI Marie - José TASSIGNON Heinrich HEIMANN Graham HOLDER Mario NUBILE Francine BEHAR-COHEN Kaya N ENGIN Vincent BORDERIE Carlos PAVESIO Philippe KESTELYN 09:50 - 10:35 Keynote Lecture: New treatments for age related macular degeneration, Joan MILLER Uranie 10:35 - 11:00 Break 11:00 - 12:30 RV: Peelings in macular surgery EOVS: ISCEV COS: Wavefront aberrometry IM: New advances in managing G: Free papers : Imaging 1 / MBGE: Free papers: ACB: Lid margin, FRO - Belgian Fund for and quality of vision scleritis and Treatment in glaucoma Genetics and epidemiology meibomian glands and dry eye Research in peripheral ulcerative keratitis Ophthalmology 2 Catherine CREUZOT Jean-Jacques GICQUEL Piergiorgio NERI Jost B JONAS Marzena GAJECKA Erich KNOP Philippe KESTELYN Ramin TADAYONI Graham HOLDER Pierre Jean PISELLA Carlos PAVESIO Anton HOMMER Graeme CM BLACK Nadja KNOP Marie - José TASSIGNON 12:35 - 13:35 Lunchtime CIS Théa: What’s new in ocular surface? Euterpe 13:35 - 15:05 RV: Free papers : Imaging 1 EVI Award Lectures COS: Free papers : IM: Free papers : New frontiers G: Free papers : Diagnosis in MBGE: Next-generation PBP: Proceedings in functional ACB: Free papers : Lessons from Infl ammatory ocular surface in ocular infectology glaucoma sequencing in retinal genetics and structural imaging human and animal studies Carl ARNDT Constantin POURNARAS Eric GABISON Uwe PLEYER Andrew MCNAUGHT Bart LEROY Gerhard GARHOFER Erich KNOP Catherine CREUZOT Gilles THURET Regis KOWALSKI Thierry ZEYEN Graeme CM BLACK Sveinn HARDARSON Giedrius KALESNYKAS 15:15 - 16:45 RV: Free papers : Imaging 2 EVICR.net: Clinical trials in NSPH: Optic neuropathies IM: Progress in corneal trans- G: Dealing with advanced ACB: Retinal barriers EBO: What can education MBGE: Free papers: Genetics, glaucoma, anterior segment mistaken for optic neuritis plantation: immunology and glaucoma organisations do for young Genotypes and Phenotypes and ocular surface infl ammation ophthalmologists? Esther HOFFMANN Michel PAQUES Jorge ALIO SANZ Antonella BOSCHI Thomas FUCHSLUGER Hannu UUSITALO Peter RINGERS Marcela VOTRUBA Heinrich HEIMANN Joaquim MURTA Aki KAWASAKI Uwe PLEYER Ejaz ANSARI Kai KAARNIRANTA Marko HAWLINA Bart LEROY 16:45 - 18:00 Poster session 1 : Molecular Biology / Genetics / Epidemiology - Anatomy / Cell Biology - Cornea / Ocular Surface - Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology Agora 18:00 - 19:30 RV: Retinal oximetry - EVICR.net: Clinical trials in COS: As lamellar as possible : IM: Free papers : Ocular G: Eye and brain in glaucoma PBP: Retinal vessel analysis - PO: Metastatic disease from MBGE: Educational case challenges, possibilities and diabetic retinopathy and retinal an update on pros and cons of immunology for 360° from biomarkers and new uveal melanoma: prediction, presentations in ophthalmic future outlook vascular disease corneal lamellar surgery basic science to clinical practice developments detection and treatment genetics Rebekka HEITMAR Jean-Jacques GICQUEL Talin BARISANI-ASENBAUER Georg MICHELSON Sarah COUPLAND Bart LEROY Einar STEFANSSON Jose CUNHA-VAZ Mario NUBILE Uwe PLEYER Doina GHERGHEL Leopold SCHMETTERER Bertil DAMATO Graeme CM BLACK URANIE EUTERPE ERATO THALIE CLIO GALLIENI 1&2 GALLIENI 4 GALLIENI 3 Friday October 12, 2012 07:15 - 08:15 Breakfast CIS Alcon: An innovative new approach to treating vitreomacular traction and macular hole Uranie 08:15 - 09:45 RV: Central serous chorio- EVICR.net: Clinical trials in PBP: Neuronal death processes IM: Beyond age related macular G: Structure and function in NSPH: Controversies in neuro- EOVS: Myopia – genesis, PO: Free papers : retinopathy: what’s new? AMD and rare diseases in retinal disease degeneration glaucoma management ophthalmology and paediatrics prevalence and control Uveal melanoma Francine BEHAR-COHEN Piergiorgio NERI Ingeborg STALMANS Andrzej GRZYBOWSKI Martine J JAGER Alain GAUDRIC Jose SAHEL Neville OSBORNE Andrew DICK Luca ROSSETTI Francisco ASCASO Franziska RAUSCHER Ann SCHALENBOURG 09:50 - 10:35 Keynote Lecture : Genetics and treatment of Stargardt disease, Rando ALLIKMETS Uranie 10:35 - 11:00 Break 11:00 - 12:30 RV: Endophthalmitis from the EVICR.net: Reading centres COS: Free papers: IM: Research challenges of G: Controversies in current PO: Vascular tumours of the EOVS: Free papers: LC: Free papers: ocular surface to the vitreous: From banking to grafting anti-microbial ocular therapy concepts of glaucoma retina and choroid Colour vision Cataract surgery prevention, diagnosis, treatment Christophe CHIQUET Vincent BORDERIE Sayeh POURJAVAN Tero KIVELÄ Werner SPILEERS Marie - José TASSIGNON Alain BRON Tunde PETO Christopher LIU Regis KOWALSKI Andrzej GRZYBOWSKI Ann SCHALENBOURG Miguel CASTELO-BRANCO Rafael I. BARRAQUER 12:35 - 13:35 Lunchtime CIS Allergan: Focus on Infl ammation in retinal disease Uranie 13:35 - 15:05 RV: Macular surgery EVICR.net: General Assembly COS: Therapeutics in the IM: ARVO@EVER : Translating G: Recent developments in RV: Free papers : AMD NSPH: Ocular surface disorders PO: Free papers : Basic pipeline for unmet needs in ocular immunology from the ocular blood fl ow and glaucoma in children mechanisms in ocular pathology ophthalmology laboratory to the clinic Efstratios MENDRINOS Thomas FUCHSLUGER Justine SMITH Ingeborg STALMANS Gisèle SOUBRANE Jean-Jacques GICQUEL Steffen HEEGAARD Constantin POURNARAS (members only) Einar STEFANSSON Sally ATHERTON Leopold SCHMETTERER Anita LEYS Dominique BREMOND-GIGNAC Karin LOEFFLER 15:10 - 15:50 RV Business meeting COS Business meeting IM / NSPH Business meeting G Business meeting PBP / MBGE Business meeting ACB / PO Business meeting EOVS / LC Business meeting 15:55 - 16:35 Ophthalmic Research Lecture: Priorities of Ophthalmic Research, George L. SPAETH Uranie 16:35 - 17:30 Poster session 2 : Glaucoma - Electrophysiology/ Physiological Optics/ Vision Sciences - Immunology / Microbiology - Physiology / Biochemistry / Pharmacology Agora 17:30 - 19:00 RV: New trends in the RV: Free papers: Surgery ACB: From ocular surface to IM: Killer cases in uveitis: G: Myopia and glaucoma NSPH: The blue light photo- COS: Free papers : Patients as stakeholders in treatment of diabetic macular ganglion cells challenges and controversies receptor and ipRGCs : From refractive surgery to European ophthalmology oedema Review and update of their corneal grafting role in human health Pascale MASSIN Jean-Paul BERROD Hannu UUSITALO Piergiorgio NERI Sayeh POURJAVAN Harminder S DUA Nadja KNOP Jean - Antoine C POURNARAS Jost B JONAS Giedrius KALESNYKAS Carl P HERBORT K. Sheng LIM Aki KAWASAKI Frederic CHIAMBARETTA Erich KNOP 20:30 - 23:00 EVER Congress Dinner in Negresco - Registration required Saturday October 13, 2012 07:15 - 08:15 Breakfast CIS Croma Uranie 08:15 - 09:45 RV: Unmet needs in treatment RV: Free papers : Dystrophy, COS: Update on keratoconus NSPH: Free papers : G: Cataract and glaucoma PBP: Free papers : Retinal ACB: MGD - Pathophysiology, EOVS: Free papers : Physiologi- of retinal diseases Infl ammation, Miscalleneous pathophysiology Neuro-ophthalmology 1 surgery, combined or staged? physiology and pharmacology diagnosis and clinical treatment cal optics and visual function Isabelle AUDO Eberhart ZRENNER François MALECAZE Aki KAWASAKI Leopold SCHMETTERER Erich KNOP John L. BARBUR Gisèle SOUBRANE Pierre BITOUN Joseph COLIN Antonella BOSCHI Thierry ZEYEN Amandio ROCHA DE SOUSA Nadja KNOP Graham HOLDER 09:50 - 10:35 Keynote Lecture : Diced Alu: Canning the blinding infl ammasome, Jayakrishna AMBATI Uranie 10:35 - 11:00 Break 11:00 - 12:30 RV: Pathogenesis of macular RV/IM: SOIE/CAC - Indocyanine COS: Current management of COS: Free papers : G: Free papers : Imaging 2 / OOG session 1 - NSPH: Free papers : ACB: Free papers : Functional oedema and neurodegenera- green angiography (ICGA) : is it keratoconus Ocular surface and dry eye Treatment in glaucoma Uveal melanoma Neuro-ophthalmology 2 studies of retinal cells tion in vascular retinal diseases still relevant today? Matus REHAK Carl P HERBORT Rafael I. BARRAQUER Dominique BREMOND-GIGNAC Gordana SUNARIC MEGEVAND Bertil DAMATO Andrzej GRZYBOWSKI Heli SKOTTMAN Peter WIEDEMANN Piergiorgio NERI Ralph MICHAEL Thomas FUCHSLUGER Anna-Maria STEVENS Nathalie CASSOUX Francisco ASCASO Goran PETROVSKI 12:35 - 13:35 Lunchtime CIS Bayer: The management of neovascular AMD in 2012 and beyond Uranie 13:35 - 15:05 RV: Free papers : RV: FAN Club COS: Keratoprostheses 1 COS: Free papers : Imaging G: Free papers : Translational OOG session 2 : LC: Ocular straylight: Vascular Diseas research in glaucoma Retinoblastoma and other new developments tumours Constantin POURNARAS Christopher LIU Leopold SCHMETTERER Neville OSBORNE Theodora HADJISTILIANOU Ralph MICHAEL Albert J. AUGUSTIN Anita LEYS Thomas FUCHSLUGER Pierre Jean PISELLA Alain BRON Steffen HEEGAARD Thomas JTP VAN DEN BERG 15:05 - 16:20 Poster session 3 : Pathology / Oncology - Retina / Vitreous - Lens and Cataract Agora 16:20 - 17:50 RV: Conventional surgery for RV: Free papers : Clinical COS: Keratoprotheses 2 – PBP: Free papers : Bloodfl ow How to get your work OOG - Business meeting IM: Surgery of retinal detachment diabetic eye desease Biomaterials and pharmacology published? infl ammatory eyes Pascale MASSIN Thomas FUCHSLUGER Gerhard GARHOFER Antoine BREZIN Elias FERETIS Catherine CREUZOT Christopher LIU Sveinn HARDARSON Uwe PLEYER Dominique MONNET 18:00 - 19:30 EVER General Assembly and Prize Giving Uranie THANK YOU SPONSORS

EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2012. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

MAIN SPONSORS

MAJOR SPONSOR

CIS SPONSORS

SPONSORS

Carl Zeiss Vision

SPONSORS IN EXHIBITION

EVER 2012 Programme Book - www.ever.be